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ABSTRACT 
 
  
                                                                                                                                                  
 
 
Colorrectal cancer (CRC) is the third most diagnosed cancer worldwide with nearly a million of deaths 
yearly. CRC does not present symptoms until advanced stages, leading to a reduction of the 
treatment efficacy. Therefore, new biomarkers for early detection need to be assayed. Alterations in 
different metabolic pathways such as carbohydrate have been broadly analyzed, but new elements 
of the metabolism have increased its importance in malignant progression, such as lipid metabolism. 
We first describe a metabolic acyl-CoA synthetase/ stearoyl- CoA desaturase ACSLs/SCD 
(ACSL1/ACSL4/SCD) signature leading to enhanced invasive and migratory capacities and stimulation 
of several survival pathways to CRC cells. This mesenchymal phenotype is restored upon reactivation 
of the master metabolic regulator, AMPK. Regarding the individual contribution of ACSL/SCD network 
enzymes, ACSL4 is related with increased proliferation and migration and a more glycolytic 
phenotype; while ACSL1 stimulates the presence of invasion and metastasis markers presenting a 
lower basal respiratory rate. ACSL1 is also characterized by an acylcarnitines elevation. 
Polyunsaturated fatty acids (PUFA) lower levels, probable due to a greater utilization, is the main 
feature for ACSL4 pro-proliferative cells; while monounsaturated fatty acids (MUFA) upregulation 
characterize the individual overexpression of SCD. The simultaneous overexpression of the network 
implies upregulated phospholipids and urea cycle derived metabolites showing that the global effect 
of the network is not performed by the sum of the individual overexpression effects. Besides, 
ACSL/SCD overexpressed cells present a better overall energetic status showed by lower basal 
respiration levels and upregulated creatine pathway. Other invasive CRC cell lines present these 
same features converting ACSL/SCD metabolic network in an example of metabolic adaptations for a 
more invasive phenotype. 
Thus, the development of new therapies targeting this metabolic network may be useful for the 
cancer progression blockade or as biomarkers of the disease. In this sense, ACSL/SCD overexpression 
correlates with poorer clinical outcome and increased risk of relapse of stage-II colon cancer patients. 
Moreover, ACSL/SCD chemical inhibition by a combined specific treatment decreases cancer cell 
viability without affecting normal colon cells. Post-transcriptional regulation by microRNAs (miRNAs) 
also represents a therapeutic opportunity for ACSL/SCD axis. We described miR-544a, miR-142 and 
miR-19b-1 as major overall regulators of the metabolic axis ACSL/SCD. Outstandingly, miR-19b-1 is 
able to inhibit invasion in several CRC cell lines, and lower miR-19b-1 expression is related with poor 
survival rate in CRC patients (stages II and III); according to ACSLs/SCD overexpression involvement in 
patient relapse. This miRNA, therefore, could be used both as therapeutic or prognostic miRNA with 
a potential noninvasive biomarker role for disease-free survival (DFS) in CRC patients. 
CRC-like organoids represent an excellent physiological tool modeling stages I to IV of intestinal 
tumors. We show that ACSL4 expression augmented with the stages in the organoids while miR-19b-
1 diminished its expression. Besides, since Metformin is able to rescue the invasive and migratory 
phenotype conferred to cancer cells upon ACSL/SCD axis overexpression; we checked the effect of 
                                                                                                                                                  
 
 
Metformin treatment in organoids, resulting in a viability decrease in first tumor phases and in a 
downregulation of the stem cell biomarker LGR5,  becoming an appealing chemotherapy drug  for 
intestinal cancers. According to ACSL/SCD metabolic switch, Metformin action in CRC organoids is not 
related to a Warburg-effect impairment. This research contributes to the current issue of the use of 
Metformin as an anticancer drug in colorectal cancer (CRC), and reveals organoids as a 
representative tool platform to assay tumor stage-dependent drugs and a model for specific and 
personalized treatment.  
 
  
                                                                                                                                                  
 
 
 
 
 
RESUMEN 
 
  
                                                                                                                                                  
 
 
El cáncer colorrectal (CCR) es el tercer cáncer más diagnosticado a nivel mundial, con casi un 
millón de muertes al año. Este tipo de cáncer no presenta síntomas hasta las etapas más 
avanzadas, lo que conlleva una reducción en la eficacia del tratamiento y, por lo tanto, nuevos 
biomarcadores para su detección precoz deben ser analizados. Las alteraciones en diferentes 
vías metabólicas, como los carbohidratos, han sido ampliamente estudiadas. Sin embargo, 
nuevas rutas del metabolismo han ido aumentado su importancia en la progresión maligna, 
como es el metabolismo de los lípidos.  
En primer lugar, hemos descrito una firma metabólica Acil-CoA sintetasa / Estearoil-CoA 
desaturasa (ACSLs / SCD (ACSL1 / ACSL4 / SCD)) capaz de aumentar sus capacidades invasivas y 
migratorias a la vez que  estimula varias vías de supervivencia. Este fenotipo mesenquimático se 
restaura tras la reactivación del principal regulador metabólico, AMPK. Nuestro objetivo es 
comprender las diferencias funcionales y la contribución individual de la red metabólica de 
ACSLs/SCD. ACSL4, por su parte,  está relacionado con una mayor proliferación y migración; de 
acuerdo con un fenotipo más glicolítico; mientras que ACSL1 estimula los marcadores de 
invasión y metástasis que presentan una tasa respiratoria basal más baja. ACSL1 también se 
caracteriza por un aumento de acilcarnitinas. Los niveles más bajos de ácidos grasos 
poliinsaturados, probablemente debido a una mayor utilización, es la característica principal de 
las células pro-proliferativas que sobreexpresan ACSL4; mientras que la sobre regulación de los 
ácidos grasos monoinsaturados caracteriza la sobreexpresión individual de SCD. La 
sobreexpresión simultánea de la red implica un aumento de fosfolípidos y metabolitos derivados 
del ciclo de la urea, lo que demuestra que el efecto global de la red no es la suma de la 
contribución individual. Además, las células que sobreexpresan ACSL/SCD presentan un mejor 
estado energético general mostrado por unos niveles de respiración basal más bajos y un 
aumento de la vía de creatina. Otras líneas celulares de CCR invasivas presentan estas mismas 
características que convierten a la red metabólica ACSL/SCD en un ejemplo de adaptaciones 
metabólicas de un fenotipo más invasivo. Por lo tanto, el desarrollo de nuevas terapias dirigidas 
a esta red metabólica puede ser útil para el bloqueo de la progresión del cáncer así como el 
estudio de nuevos biomarcadores de la enfermedad. En este sentido, la sobreexpresión de 
ACSL/SCD se correlaciona con un peor pronóstico clínico y un mayor riesgo de recaída en 
pacientes con cáncer de colon en estadio II. Desde un punto de vista terapéutico, la inhibición 
química de ACSL/SCD mediante tratamiento específico combinado disminuye la viabilidad de las 
células cancerosas sin afectar a las células de colon normales. Los microRNAs (miRNA) emergen 
como potentes reguladores post-transcripcionales y, por lo tanto, como una oportunidad 
terapéutica convincente para el eje ACSL/SCD. A partir de una base de datos de treinta y un 
                                                                                                                                                  
 
 
supuestos miRNAs comunes que se predice que actúan simultáneamente en la red ACSL/SCD; las 
validaciones in vitro señalan a miR-544a, miR-142 y miR-19b-1 como los principales reguladores 
globales del eje metabólico. Cabe destacar que una reducción en la expresión del miR-19b-1 está 
relacionada con una menor tasa de supervivencia en pacientes de CCR (estadios II y III); de 
acuerdo con los datos de sobreexpresión de ACSL/SCD en la recaída del paciente. Además, el 
miR-19b-1 es capaz de inhibir la invasión en varias líneas celulares de CCR, de nuevo 
evidenciando la capacidad del eje ACSL /SCD de conferir propiedades invasivas a dichas células. 
Este miRNA, por lo tanto, podría usarse como miRNA terapéutico o pronóstico en un posible 
papel biomarcador no invasivo para la supervivencia libre de enfermedad  en pacientes con CCR.  
Para un análisis más profundo del eje metabólico, los organoides de tipo CCR implican una 
herramienta más fisiológica que representa las etapas I a IV del tumor. Se muestra como ACSL4 
aumentó mientras que miR-19b-1 disminuyó su expresión, progresivamente a lo largo de la serie 
de organoides. Además, dado que el eje ACSL/SCD estimula la progresión del cáncer de colon, y 
la Metformina es capaz de revertir el fenotipo invasivo y migratorio conferido por dicho eje; 
verificamos el efecto del tratamiento con Metformina en los organoides como modelo para el 
tratamiento específico y personalizado, convirtiéndose en un fármaco quimioterapéutico 
plausible en las primeras fases del tumor. La Metformina también es capaz de disminuir la 
expresión del biomarcador de células madre LGR5 +, reafirmando su uso potencial en los 
cánceres intestinales. A su vez se muestra que la acción de la Metformina en los organoides tipo 
CCR no está relacionada con el efecto de Warburg. Esta investigación contribuye a la 
investigación actual del uso de la Metformina como fármaco anticanceroso en el cáncer 
colorrectal, así como  revela a  los organoides como una plataforma ventajosa para analizar 
fármacos dependientes de la etapa tumoral, acercándonos a una medicina más personalizada. 
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1. Colorectal cancer 
 
1.1. Statistics  
 
According to the International Agency for Research on Cancer (IACR), colorectal cancer (CRC) is 
the third most common cancer in men (746,000 cases, 10% of the total), after lung and prostate 
cancer, and the second in women (614,000 cases, 9.2% of the total), after breast cancer 1,2.  
 
Latest Spanish statistics from REDECAN (Red Española de Registros de Cáncer)3, claim that 
almost 250.000 new patients were diagnosed with invasive cancer: 149,000 in men (60.0%) and 
99,000 in women (40. 0 %). In Spain, CRC raises to the second position of the most common 
cancers both in men (16.6%), after prostate cancer; and in women (16.9%). 
 
Curiously, statistics highlight the stabilization of cancer incidence in men due to a decrease in 
tobacco-related cancers compensated by the increase in other types of tumors like CRC and 
prostate cancer. However, in women, the stabilization of breast cancer incidence has been 
overcome by the escalation of colorectal and tobacco-related cancers incidence. 
 
For the next years, the main efforts will be to intensify smoking control policies and CRC early 
diagnosis to reduce the incidence of lung cancer and CRC, respectively. For all these facts, CRC 
has become one of the greatest priorities in worldwide Healthcare Institutions. 
  
1.2. Risk factors 
 
CRC risk factors can be divided into the ones that can be avoided and the ones that cannot be 
avoided. Generally, CRC rates are found to be higher in developed countries such as in Europe, 
North America, Japan and Oceania and are increasing rapidly in less developed countries such as 
Latin America, Asia and Eastern Europe 4, which reflects the influence of western lifestyles 
implementation and therefore, the existence of avoidable risk factors.  
Among these modifiable risk factors, being obese or overweight give a greater chance of 
developing CRC, especially in men 5; through plausible biological mechanisms such as insulin 
resistance, hyperinsulinemia, chronic inflammation, altered levels of growth factors, 
adipocytokines and steroid hormones 6,7. Furthermore, diet has been extensively correlated with 
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cancer; concretely, high red-meat diets (such as beef, pork, lamb, or liver), processed meats 
(such as bacon, sausages, hot dogs, salami, corned beef, beef jerky and ham) or over-cooked 
meats (frying, broiling, or grilling), which creates risky chemicals8–10. Even though the fats` role it 
is not completely clear, diets enriched in fibers such as vegetables, fruits or whole-grain foods 
have been linked to a lower risk of CRC 11.  
Physical inactivity has been also related to CRC risk. Albeit mechanisms are not entirely clear, the 
hypotheses for the benefits of having an active lifestyle are abundant, such as increasing gut 
motility and reducing gastrointestinal material transit time, enhanced immune function as well 
as decreasing insulin and insulin-like growth factor levels, decreasing obesity, enhancing free 
radical scavenger systems and influencing prostaglandin levels 12,13. Smoking, which is the main 
risk for developing lung cancer, has been also linked to CRC 14. Alcohol consumption has been 
also reported to represent a strong risk; particularly in cancers of the upper aerodigestive tract, 
CRC, liver and breast cancer through aberrant patterns of DNA methylation 15. 
Regarding the CRC risk factors that are not susceptible to be changed, we can find age, with a 
higher risk above 50; and gender, with a slightly higher risk in man than in woman. Medical 
histories predisposing to CRC are colorectal polyps and inflammatory bowel disease (IBD), 
including either ulcerative colitis or Crohn’s disease. Finally, genetics is determinant for CRC risk 
such as having a family history of CRC or adenomatous polyps or having an inherited syndrome 
like familial adenomatous polyposis (FAP) and Lynch syndrome (hereditary non-polyposis 
colorectal cancer, or HNPCC) 16–20. 
Taking into account the above-mentioned data, changes in diet and lifestyle could prevent the 
avoidable risk factors improving the quality of life for people. This, together with early diagnosis 
routines could derive into potent prevention tools for CRC. 
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1.3. Histopathological characteristics  
 
The intestinal wall includes three layers: mucosa (which includes epithelial cells, basement 
membrane, lamina propria [connective tissue] and muscularis mucosae), submucosa (with three 
levels of depth) and muscularis propria (the muscle layer) (Figure 1). 
 
 
Figure 1: Human large intestine division. (Source: Encyclopædia Britannica, Inc. 21)  
 
The intestinal epithelium is in constant flux of cell renewal to maintain homeostasis processes 22. 
The epithelial cells keep attached to the basement membrane, which is part of the extracellular 
matrix. The assembly is performed by different proteins secreted by both epithelial and stromal 
cells, mainly fibroblast which lie below the membrane. Other cell types in this stromal cell layer 
include endothelial cells, which form the walls of capillaries, lymphatic vessels and immune cells. 
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Beneath this layer, there is a thick layer of smooth muscles responsible for intestinal peristalsis 
through periodic contractions. 
The earliest phases of colorectal tumorigenesis initiate in the normal mucosa, in the epithelial 
layer; which could undergo a generalized disorder of cell replication with the appearance of 
clusters of enlarged crypts (aberrant crypts) showing proliferative, biochemical and biomolecular 
abnormalities. It is possible to observe a variety of tissue states with different degrees of 
abnormality, to mildly divergent tissues and high malignancy state, and finally into multiple 
metastatic growths. The majority of colorectal malignancies develop from adenomatous polyps. 
These can be defined as well determined masses of epithelial dysplasia, with uncontrolled crypt 
cell division. All these forms are considered benign until neoplastic cells pass through the 
muscularis mucosae and infiltrate the submucosa 23 (Figure 2).  
 
  
  
Figure 2: Colorectal cancer development from lesions in the colon and polyps. (Source: Adapted from 
Johns Hopkins Colon Cancer Center 24). 
 
Among colorectal carcinomas, more than 90% are adenocarcinomas, originated from epithelial 
cells of the colorectal mucosa. Other rare types of colorectal carcinomas include 
neuroendocrine, squamous cell, adenosquamous, spindle cell and undifferentiated carcinomas. 
The glandular formation is the main characteristic of adenocarcinoma, which is also the basis for 
histologic tumor grading. Besides, in well-differentiated adenocarcinoma, more than 95% of the 
tumor is gland forming 25. 
The reasons why the incidence of CRC is so high could be determined by the histopathological 
characteristics of the tissue. Large intestine owns a high rate of cell division required to maintain 
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the rapid turnover of cells within the intestinal epithelia, which causes a high incidence of DNA 
replication errors and therefore the accumulation of DNA mutations in these cells. Also, the 
direct exposure of intestinal cells to potential carcinogens via ingested food further increases the 
mutation rate.  
1.4. Staging 
 
Since 1959, The American Joint Committee on Cancer (AJCC) established a universal staging 
model named Tumor-Node-Metastasis (TNM), which has been developed and improved over the 
years. 
The TNM (Tumor, Nodes, and Metastasis) system is based on tumor infiltration degree and 
divides it regarding the intestinal wall layer in which it has spread. Thus, it codes the extent of 
the primary tumor (T), whether it arrives at regional lymph nodes (N), or invades other organs 
causing distant metastases (M) 26,27. 
 
Tis represents the carcinoma in situ or intramucosal carcinoma (involvement of lamina propria 
with no extension through muscularis mucosae). When the tumor invades submucosa it is 
entitled T1. If the tumor moves through the muscularis propria it is called T2. In T3, the tumor is 
able to invade the pericolorectal tissues. Finally, in T4a, the tumor invades through the visceral 
peritoneum, and in T4b, the tumor directly invades or adheres to other adjacent organs or 
structures. Lymph node detection is also remarkably important to predict the outcome of 
patients. To this aim, the number of regional lymph nodes must be examined. The N0 
classification means lymph nodes are metastases free. When 1-3 lymph nodes are detected it 
changes to N1. In N2, metastases in 4 or more regional lymph nodes can be counted. The M0 
and M1 values for cancer patients, indicates the presence or absence of metastases respectively.  
The TNM categories are combined in stage groups, ranging from 0 (in situ tumor) to IV (distant 
metastasis). The higher the stage is, the less the probability of survival. In fact, the survival rate 
at 5 years of people with stage I colon cancer is about 92%, while stage IV colon cancer patients 
have a 5-year relative survival rate of about 11% 28–30. 
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Table 1: TNM staging. (Source: Based on American Joint Committee on Cancer data (AJCC)) 
Stage 0: Tis N0 M0 
Stage I: T1 - T2 N0 M0 
Stage IIA: T3 N0 M0 
Stage IIB: T4a N0 M0 
Stage IIC: T4b N0 M0 
Stage IIIA: T1 - T2 N1 / N1c M0 
  T1 N2a M0 
Stage IIIB: T3 - T4a N1 / N1c M0 
  T2 - T3 N2a M0 
  T1 - T2 N2b M0 
Stage IIIC: T4a N2a M0 
  T3 - T4a N2b M0 
  T4b N1 - N2 M0 
Stage IVA: any T any N M1a 
Stage IVB: any T any N M1b 
Stage IVC: any T any N M1c 
 
 
1.5. Genetics 
 
In recent times it has been demonstrated with increasing evidence the heterogeneity of CRC and 
that these molecular or genetic differences in the tumor, determine the prognosis and response 
to treatment 31. 
Traditionally, CRC has been divided as following described. Most of the CRC cases are sporadic 
(70-80%), which consists of the acquisition of somatic mutations and in which there is no family 
history or genetic predisposition. The remaining cases (20-30%) are divided into: inherited (less 
than 10%), in which germline mutations are present and can be transmitted between 
generations, and familial (or non-syndromic), among close-degree relatives 32. They have a 
higher risk of developing CRC in comparison with the general population, although not as high as 
in the inherited syndromes 33. A small subgroup of around 1–2 % of CRC cases is the 
consequence of IBD 34. 
 
Among the CRCs which present a hereditary origin (inherited), we can mention the two most 
common types: Familial adenomatous polyposis (FAP) and the Hereditary Non-Polyposis CRC 
(HNPCC, also named Lynch syndrome). 
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As it is above mentioned, CRC occurs sporadically in the majority of cases, mainly in patients 
who have a median age of 70–75 years, and approximately 70% of these tumors develop in the 
distal colon. Genetically, their development is due to the accumulation of abnormalities in tumor 
suppressor genes and oncogenes 35. Sporadic CRC follows different genetic pathways such as: 
chromosomal instability (CIN) (70% of sporadic CRC) 36, microsatellite instability (MSI) pathway 
caused by dysfunction of DNA MMR genes, mostly MLH1 37 and CpG island methylation 38. 
 
Previous research postulated the adenoma-carcinoma transition theory proposed by Fearon and 
Vogelstein 39 in which specific somatic mutations promoting tumorigenesis were acquired. Their 
multistep cancer progression model is popularly called the Vogelgram and suggests that the 
adenoma to carcinoma sequence is initiated by alterations in the APC gene, followed by 
mutations in KRAS or BRAF genes, PI3KCA or PTEN, mutations or loss of TTP53 gene and of SMAD 
family member 4 (SMAD4) (Figure 3). The Vogelgram is based on the CIN pathway for sporadic 
CRC. 
 
 
Figure 3 Adenoma–carcinoma sequence model for chromosomal instability in colorectal cancer (Source: 
Adapted from Walther, A. et al. 40) 
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1.5.1 The Molecular Consensus Subtypes of CRC 
 
Although different efforts have been made to stratify CRC through gene expression profiling in 
different groups 41–45,no one of them lead to a useful, consistent and universal classification 
system making traditional classifications sometimes insufficient to determine the scope of the 
prognosis and the accuracy to treatment 31. 
The Cancer Genome Atlas (TCGA) is an ambitious project which applies high-throughput genome 
analysis techniques together with bioinformatics to catalogue genetic mutations in different 
types of cancer 46. CRC results were released in 2012 47. To date, though, the most compelling 
CRC classification was performed by an international expert consortium 48  that describes four 
consensus molecular subtypes (CMS) after analysis of 18 different CRC gene expression datasets, 
including data from TCGA in conjunction with molecular data on mutations and somatic copy 
number alterations (SCNA) for a subset of samples (Figure 4). 
This CMS classification has been suggested as the basis for upcoming clinical stratification in 
terms of subtype-based targeted interventions, although further research is needed to fully 
complete this classification 32. The first subtype is CMS1 (microsatellite instability-immune) or 
MSI-like. It represents the 14 % of CRC and is characterized by a hypermutated status due to 
defective DNA mismatch repair. This group, evidence a strong immune activation and poor 
survival rates. The CMS2 subtype (canonical, 37 %) shows epithelial features and are activated 
by the Wnt-β-catenin pathway. CMS2 patients have a better survival rate after relapse 
compared with the other subtypes. The CMS3 (metabolic, 13 %) subtype, more 
hypermutated/MSI than CMS2 and CMS4, still, presents fewer SCNA. It is frequently KRAS 
mutated, displays epithelial markers and present a general metabolic dysregulation. The CMS4 
subtype (mesenchymal, 23 %) shows epithelial-mesenchymal transition (EMT) genes expression 
increased, TGF-β over activation, and overexpression of genes involved in angiogenesis, matrix 
remodeling and stromal invasion. CMS4 patients have the poorest overall and relapse-free 
survival among all the subtypes. The final 13% is grouped in a mixed subtype which represents a 
transition phenotype or intratumor heterogeneity 48. 
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Figure 4: Consensus Molecular Subtypes classification (Source: Adapted from Guinney, J. et al. 48) 
 
 
 
 
 
2. Metabolic abnormalities in cancer 
 
 
2.1. Metabolic reprogramming as a hallmark of cancer 
 
In a landmark article 49 the development of a human tumor is characterized by six different 
biological capabilities comprising sustaining proliferative signaling, evading growth suppressors, 
resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating 
invasion and metastasis. Genome instability and inflammation were not initially incorporated 
but both of them underlie these hallmarks. Over the last decade, the understanding of the 
dimension and complexity of a tumor lead to the incorporation of the two last hallmarks 50: 
reprogramming of energy metabolism and evading immune destruction (Figure 5). 
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Figure 5: The Hallmarks of cancer. The next generation (Source: Adapted from Hanahan, D. & Weinberg, 
R. A.50) 
Over the last decade, the interest in metabolic research with respect to cancer has been 
expansively increased. Since 1990 the scientific production linking cancer and metabolism has 
increased more than 10-fold (Table 2).  
 
Table 2: Number of publications since 1990 regarding cancer and metabolism- (Source: Based on Web of 
Science, Clarivate statistics content) 
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2.2. Glucose and glutamine abnormalities in cancer development. 
 
Cancer is mainly considered a cell growth and proliferation disorder. Cellular building blocks, 
such as nucleic acids, proteins, carbohydrates and lipids are required to this effect 51. Tumor cells 
alter their metabolism to accumulate intermediates as sources of these building blocks; which 
will efficiently generate energy and biomass components for their expansion and later 
dissemination. Despite the high diversity in type and etiology, cancer cells frequently share this 
metabolic reprogramming feature. 
The first and most characterized tumor metabolism event to be described is an exacerbated 
glucose uptake and glycolysis utilization leading to increased lactate production, so that 
carbohydrates from glucose even in normoxic condition are not used for maximal ATP 
generation via mitochondrial respiration, but to make up other molecules instead of oxidizing 
them to carbon dioxide 51. This phenomenon is often denoted as the “Warburg effect” due to Dr. 
Otto Warburg discovery between 1930 and 1956 52, which could be understood as an 
energetically wasteful alteration.  
Another metabolic alteration in which cancer cells depend on is the glutamine consumption. 
Glutamine serves as an important source of reduced nitrogen and carbon for amino-acids, 
nucleotides and lipids biosynthesis 53. Glutamine is the major substrate to produce α-
ketoglutarate, which enters in the Krebs cycle and it is responsible also for the production of 
pyruvate 54. Glutamine metabolism also leads by reversal enzymes reactions to citrate, essential 
for the production of acetyl-groups for fatty acid  synthesis (FAS) 55. 
Even though lipid- and cholesterol-associated pathways are functionally dependent on glucose 
and glutamine catabolic pathways, these metabolic pathways are now recognized as relevant 
metabolic features with a key role in tumorigenesis (Figure 6). 
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 Figure 6: Main metabolic pathways in cancer cells. 
 
2.3. Lipid metabolism alterations during cancer development: FA 
metabolism significance 
 
Lipids comprehend a vast group of molecules in terms of their chemical structure: fatty acids 
(FA) chain length, position and number of double bonds and backbone structure (glycerol and 
sphingoid bases). Lipids perform multiple biochemical functions during cancer development 
including cell membrane composition (phosphatidylcholine (PC) and phosphatidylethanolamine 
(PE), sterols, sphingolipids, and lyso-phospholipids (lyso-PLs)), lipid rafts formation for signaling, 
protein recruitment and thus protein-protein interactions leading to signal transduction involved 
in cell survival, angiogenesis, and metastatic processes; as well as energy sources 51,56,57.  
The majority of these lipids contain FA in their backbones. FA are made up of a terminal carboxyl 
group and a hydrocarbon chain that can be either saturated or unsaturated. As a lipid category, 
FA are also essential for energy storage, membrane biogenesis, and the creation of signaling 
molecules. FA as building block could be provided by both, exogenous sources or being 
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synthesized de novo. As the main source of lipids, proliferating tumor cells prefer to synthesize 
FA de novo, rather than utilizing exogenous sources like the majority of non-transformed human 
cells 58,59. The point of departure for de novo FA synthesis is acetyl-CoA which connects this route 
with major core metabolic pathways. 
Lipid metabolism abnormalities have recently become a remarkable feature of cancer 
metabolism. Despite initially not been paid too much attention, FA metabolism abnormalities in 
cancer progression have been increasingly recognized over the last years, in fact, there has been 
a 10-fold increment in the scientific production on the topic (Table 3) in the last years. One of 
these first reports, in 1950, suggested the tumor cells rewiring in the glucose and lipid 
metabolism scenario to sustain their growth and survival 58,60. Since then, several reports 
claimed the importance of FA availability in the progression of cancer 51, devoting special 
attention to the reprogramming of FA metabolism that suggests novel therapeutic approaches 
to fight cancer 51,61–64. Of importance are the recent reports of FA metabolism in cancer stem 
cells  65,66. 
Table 3: Number of publications since 1990 regarding cancer and lipid metabolism - (Source: Based on 
Web of Science, Clarivate statistics content). 
 
 
2.3.1. Restricting fatty acid availability  
Nowadays, there is plenty of evidence suggesting that enzymes involved in lipid synthesis 
pathways, and especially in FA synthesis and availability, could be appealing therapeutic targets 
in cancer.  To this aim, five ways to target FA availability can be considered (Cruz-Gil et al, 
“review submitted for publication”), such as targeting lipid storage formation, their hydrolysis, 
FA synthesis, FA oxidation, and finally, avoiding FA activation. 
17
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Figure 7: Fatty acid pathways involvement in cancer progression (Source: 
Cruz-Gil, et al., submitted for publication) 
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2.3.1.1. Increasing lipids storage  
 
Lipid droplets (LD) represent the main site of energy storage 67 in nearly every eukaryotic cell 68. 
Tumor cells prefer endogenous sources, accumulating these LD 69 and being considered as 
hallmarks of cancer aggressiveness 70,71. The goal could probably be to avoid lipotoxicity  of lipids 
in the cytoplasm or to have a readily available source of them 69. Glycerol-3-phosphate 
acyltransferase (GPAT), acylglycerolphosphate acyltransferase (AGPAT), phosphatidic acid 
phosphohydrolase (Lipin or PAP), and diacylglycerol acyltransferase (DGAT) are part of this route 
converting FA-CoA into diacylglyceride (DG) (Figure 7, A, lipids storage). The pathway 
intermediates could lead to the synthesis of biological membranes components, or act as lipid 
signaling molecules for cancer progression 72. Hence, these enzymes overexpression, except for 
the last one, lead to cancer events 51,73–76, suggesting that efforts should be focused on their 
blockade 77. Increasing storage through DGAT activation could be a potential strategy for cancer 
prevention 78,79, since endogenous FA availability represents also an oncogenic stimulus per se 
that could lead to tumor malignant progression 80. This strategy should be accompanied by lipids 
hydrolysis obstruction. All in all, LDs storage role in cancer cells is still not well understood 81 and 
need further study to be considered as a potential target for cancer treatment. 
2.3.1.2. Avoiding lipid droplets hydrolysis 
 
During LD hydrolysis and release of their molecules (Figure 7, A, lipids release), the triglyceride 
(TG) molecule is hydrolyzed consequentially by three enzymes: triglyceride lipase (ATGL), 
hormone-sensitive lipase (HSL), and monoacylglycerol lipase (MAGL). Preventing the release of 
FAs from TG can be a strategy to reduce their availability. 
ATGL is the rate-limiting enzyme hydrolyzing TG into DG and FA. Elevated ATGL (and HSL to an 
extent) activity may be a general feature of many cancer types as a strategy to obtain an extra 
FAs input 82. However, other studies report the downregulation of ATGL linked with several 
malignant tumors 83–85. In these cases, though, the overexpression of ATGL or HSL could be 
detrimental for the patient due to its association with cachexia 86. Upregulated expression of 
MAGL was observed in several human cancers and primary tumors 87,88. In conclusion, there are 
again scarce data concerning lipids storage and release role in cancer progression. Moreover, 
certain enzymes display dual roles dependent on the tumor type as well as lipids droplets that 
show a controversial role in cancer. Further analysis is needed before considering them as 
potential targets for therapeutic strategies, claiming that other routes could be more suitable 
when confronting cancer.  
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2.3.1.3. Unraveling fatty acid oxidation  
 
Fatty acid oxidation (FAO) is mainly a repeated cycling for FA shortening producing in each cycle 
NADH, FADH, and acetyl-CoA. NADH and FADH besides representing redox power, could enter 
the electron transport chain (ETC), therefore producing ATP 56. It has long been thought that 
cancer cells prevail in the utilization of metabolic intermediates for anabolic processes which 
aim is to construct cell building blocks. Therefore, enhancing catabolic routes such as FAs β-
oxidation to limit their concentration levels could, in theory, be beneficial. Nevertheless, data 
from experiments testing this idea are contradictory. Cancer cells could require increased ATP 
production in different situations. In fact, greater evidence has been reported in the last years 
linking elevated levels of different enzymes related to oxidation processes in cancer 56. 
For FAO it is essential the carnitine palmitoyltransferase system that is in charge of transporting 
FA, previously activated as FA-CoA, from the cytoplasm into the mitochondria to enter the β-
oxidation route (Figure 7, B). This transport system is composed by carnitine 
palmitoyltransferase I (CPTI), the carnitine-acylcarnitine translocase (CACT), carnitine 
palmitoyltransferase II (CPTII) and the carnitine acetyltransferase (CrAT), which closes the 
carnitine cycle. The connection of this transport system with cancer has been extensively 
described by Melone et al. 89. 
The reported overexpression of the previous enzymes in different cancer types 89 suggests that 
FA could serve as energy sources and metabolic fuel for tumor growth and proliferation through 
the mitochondrial oxidation pathway. But controversial results exist, especially for CPTII 90,91, 
which difficult the establishment of therapeutic strategies based on these enzymes. 
Nevertheless, further studies over the entire system could open a new avenue of cancer 
therapies. 
 
      2.3.1.4.         Avoiding extra fatty acids input 
Fatty-acid-binding proteins (FABPs) are a small intracellular lipid transporters family with an 
affinity for long-chain free fatty acids and other ligands. These enzymes transfer FA from 
extracellular compartments besides being involved in intracellular transport 92. Despite FABPs do 
not take part in de novo FA synthesis pathways (Figure 7, C), this family blockade needs to be 
taken into consideration since some tumors gather lipids from their surroundings to potentiate 
de novo FA synthesis for their own benefit 61. Though distinct isoforms of these enzymes have 
been found upregulated in several tumors 93,94, controversial results are also found, such as 
those indicating a negative correlation between FABP4 overexpression and cancer progression in 
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(HER2)-positive breast tumors 95. It is noteworthy that these enzymes perform not only 
intracellular but also extracellular actions. New studies point out their critical role as mediators 
of metabolic and inflammatory processes 96,97; and some specific isoforms are also involved in 
hormone control 98. Hence, these enzymes arise as interesting candidates for the development 
of therapeutic strategies, which justify further and deeper studies. 
 
   2.3.1. 5.           Blocking Fatty Acid Synthesis enzymes 
 
Finally, the main and most effective way to reduce FA availability is to inhibit the enzymes 
responsible for their synthesis (Figure 7, D).  The linking point between glucose metabolism and 
de novo lipogenesis is the citrate. The citrate enters the Krebs cycle when is located in 
mitochondria, but its translocation to the cytoplasm by mitochondrial citrate carrier (CIC) or 
SLC25A1, feeds de novo FA synthesis 99. Limiting this translocation by inhibiting this carrier has 
been performed resulting in anti-tumor activity 100. However, CIC inhibition could lead to citrate 
accumulation inside the mitochondria, feeding the TCA cycle and therefore exacerbating the 
Warburg effect, which could represent a handicap for its potential use as a therapy.  
 
Blocking the next enzyme in the route, ATP citrate lyase (ACLY, ACL, or ATPCL), has stronger 
effects than CIC 101. ACLY converts citrate to acetyl CoA and its levels have been found to be 
fairly increased in tumors compared to normal cells, including CRC, broadly reviewed by 
Khwairakpam et al. 102. Nevertheless, inhibiting this enzyme would affect other pathways since 
its product acetyl-CoA is a core central molecule not only to FA synthesis but also to glucose, 
glutamine and mevalonate pathways 103, as well as to protein acetylation reactions, controlling 
major cellular processes such as autophagy, energy metabolism, mitosis, etc. 104,105.  
 
Acetyl-CoA carboxylase (ACC) is a rate-limiting enzyme in de novo fatty acid synthesis converting 
acetyl-CoA in Malonyl-CoA. Malonyl-CoA synthesized by ACC isoform  1 (ACC1) is the substrate 
for FA synthesis, but if synthesized by ACC2 is a CPT inhibitor, thus preventing FA degradation via 
β-oxidation 106. ACC has been extensively documented in cancer development and progression 
106,107. In the majority of studies, the overexpression of FA synthesis enzymes such as ACC along 
with its immediate downstream group of enzymes known as FASN, indicates tumor progression 
and cell malignancy 106,108,109. 
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Fatty acid synthase (FASN) is possibly the most studied enzyme related to FA metabolism and 
cancer. FASN catalyzes consecutive condensation reactions to form long-chain fatty acids from a 
molecule of acetyl-CoA and malonyl-CoA, mostly generating 16-carbon palmitate. FASN is 
associated with poor clinical outcomes, presents a universal upregulation and is involved in the 
progression, maintenance and enhancement of the malignant phenotype in most human 
cancers 110–115. Despite the more than proved evidence for FASN involvement in tumor metabolic 
reprogramming, the clinical scenario has remained uncompleted with first generation inhibitors, 
though it is getting improved with next-generation FASN inhibitors 116. 
 
Finally, it is worthy to briefly mention the role of sterol regulatory element-binding protein 
(SREBP) in cancer metabolism, able to modify metabolic genes expression. SREBP  is conceived 
as the master transcriptional regulator of FA synthesis 117, and represents gene expression 
control of the main lipid metabolism enzymes. In non-transformed cells it maintains lipid 
homeostasis 118, regulating genes from the routes previously mentioned (ACLY, ACC, FAS, as well 
as SCD-1, and GPAT). In addition, a growing number of reports suggest SREBP implication in 
uncontrolled cancer cells proliferation such in prostate cancer patients 119 or breast cancer 
patients 120. Hence, SREBP inhibition in cancer cells leading to FA synthesis genes downregulation 
could represent a therapeutic window to prevent cancer cell proliferation. 
 
2.3.1.6.        Fatty acid activation: strategic core in metabolism obstruction 
 
Acyl-CoA Synthetases  
 
Before a FA enters any metabolic pathway it needs to be activated by the addition of a molecule 
of coenzyme A (CoA). These free FA are converted to acyl-CoA (FA-CoA) by acyl coenzyme A 
synthetase (ACS) (Figure 7, E) in an ATP-dependent manner in the presence of CoA and Mg2+ 121. 
This allows the FA to enter multiple physiological and metabolic routes such as TG synthesis and 
cholesterol esters, retinal esters and phospholipids, β-oxidation (peroxisomes, mitochondria), ω-
oxidation (ER), elongation and/or desaturation, signaling molecules and protein acylation among 
others 122. The largest family of mammalian ACS is the long-chain acyl-CoA synthetases (ACSL) 
family, which catalyze the formation of acyl-CoA from FA with 12-20 carbon atoms chain lengths 
123. To date, five isoforms of the ACSL mammalian family have been identified: ACSL1, -3, -4, -5 
and -6, which present different preferences regarding the chain length of their FAs substrates. 
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The expression of ACSL family members varies in different tissues and also in its subcellular 
location 122. 
ACSL1 is expressed in multiple subcellular locations such as mitochondria, peroxisomes, plasma 
membrane, ER and lipid droplets nucleus; but also in GLUT4 vesicles, reviewed by Grevengoed et 
al. 122. It has been associated with the elevated levels of the unsaturated FA oleate and linoleate 
124,125. ACSL3 is abundantly expressed in lipid droplets and ER and is mainly required for FA 
uptake. Importantly, its N-terminus is able to translocate FAs from the ER to LD 126. ACSL4 is 
most commonly located in the ER, mitochondrial-associated membrane, and peroxisomes 127 
and has a clear substrate preference for arachidonate with respect to linoleic acid 128. ACSL4 has 
also been reported to increase the conversion of free arachidonic acid (AA) into prostaglandins 
and into PE, PI and TG 129,130. ACSL5 is also located on mitochondria, supporting FA synthesis and 
β-oxidation 131 with a marked preference for palmitic acid, palmitoleic acid, oleic acid and linoleic 
acid 132. Finally, ACSL6 is found in the plasma membrane and has a clear preference for C16-C20 
saturated and polyunsaturated FAs 133,134. Together with ACSL3, it is predominant in the brain 135. 
 
Acyl-CoA Synthetases and cancer 
 
Previous reports associated patients with inflammatory bowel disease (IBD) with the over-
expression of ACSL1 and ACSL5 in the terminal ileum and colon 136. IBD represents a risk feature 
for developing CRC 137, suggesting the possible role of these isoforms in CRC initiation. A 
systematic analysis of the ACSL family members gene expression in various kinds of cancers has 
also been made 132 . This analysis concluded that ACSL1 was upregulated in CRC but diminished 
in lung and breast cancer as well as in the brain, cervical, esophageal, head and neck, leukemia, 
liver, and sarcoma cancers. Chen et al. also analyzed the prognostic value of ACSL1 in cancer 
progression, relating breast cancer and CRC patients’ poorer survival rates with increased ACSL1 
expression.  
ACSL3 has been reported to be overexpressed in lung cancer 138 and melanoma 132, but in 
contrast lower levels were found in prostate cancer tissues 139 or ovarian cancer 132. Besides, 
from the systematic analysis previously mentioned, ACSL3 was overexpressed in head-neck and 
liver cancer, but it was under expressed in CRC. 
ACSL4 was previously associated with the colon carcinogenesis 132,140,141; with tumor cell growth 
in liver cancer 142, and described as an independent prognostic factor in patient tissue analysis 
143. Similarly, it has been implicated in cell growth, invasion and hormonal resistance in prostate 
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cancer cell lines 144, positively correlated with a specific subtype of breast cancer and frequently 
downregulated in gastric cancer tissues 145. ACSL4 was downregulated in tumor bladder, brain, 
leukemia, and lung cancer 132.  
On the contrary, ACSL5 lower expression was observed in the CRC tissue, leading to longer 
disease free-survival (DFS) 146. High expression of ACSL5 predicted good prognosis in glioma 147, 
breast, ovarian, and lung tumors, predicting good prognosis 137. 
ACSL6 was decreased in most forms of cancers, except for CRC; according to Chen Oncomine 
analysis 132. In addition, the expression of ACSL6 was downregulated in leukemia with good 
prognosis, emerging as a potential tumor suppressor gene in leukemia 132. 
 
Stearoyl-CoA desaturase 1 
 
Stearoyl-CoA desaturase (SCD) is a rapidly-degraded ER membrane protein which catalyzes the 
first desaturation in delta 9-cis carbon of acyl-CoA (Figure 7, E), downstream ACSLs action. It 
presents a clear preference for palmitoyl-CoA (C16:0) and stearoyl-CoA (C18:0) producing 
palmitoleoyl-CoA (C16:1) and oleoyl-CoA (C18:0), respectively. The products of SCD desaturation 
also act as substrates for the synthesis of different lipids such as phospholipids, diacylglycerols, 
triglycerides, cholesterol and wax esters. There are two isoforms of SCD in human cells (SCD1 
and SCD5). SCD1 gene is ubiquitously expressed while SCD5 expression is limited in certain adult 
human tissues  148–150.  
 
Stearoyl-CoA desaturase 1 and cancer 
 
SCD represents the biosynthetic source of components for a plethora of lipids, such as the 
precursors oleic and palmitoleic acids, the most abundant MUFAs with central roles in tumor 
progression allowing cellular membrane biogenesis, energy storage and cell signaling 151.  
The ratio between saturated versus unsaturated fatty acids (SFA / MUFA) is crucial for cancer 
cells since its alterations affect fluidity and protein dynamics. Several studies point to elevated 
MUFAs in blood cancer patients causing an increase of cancer episodes, poorer prognosis and 
higher death rate in patients 152,153 (for review see 154). Likewise, along the years SCD has been 
reported to have a determinant role in various types of tumor including lung, breast, prostate, 
colon, kidney, thyroid and lymphoma, and its inhibition has shown effectiveness for suppressing 
different tumor aspects (reviewed in 151,154). For instance, SCD regulates apoptosis in 
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hepatocarcinoma 155 and prostate cells 156, increases hepatoma cells proliferation 157, and its 
inhibition reduces tumor cells survival in breast and prostate cancer 158.  
Regarding CRC, SCD is able to promote tumor cell proliferation and apoptosis inhibition 159, 
besides augmenting metastasis through MUFA increased production 160. In addition, SCD is 
involved in several gene signatures, evidencing that de novo fatty acid synthesis is increased in 
these tumors 161,162.  
SCD1 is key in the control of the overall scenario of lipid synthesis in cancer cells 154 by mainly 
three processes. Firstly, SCD1 channels FA to the different lipid metabolic routes, on one hand by 
augmenting MUFA ratio for the biosynthesis of phospholipids needed for the membrane 
biogenesis process in rapidly replicating cells; and on the other hand by reducing the toxic 
accumulation of extra SFA in cell membranes, which generates ER stress, lipid-mediated 
cytotoxicity and, eventually, cell death 163,164. Secondly, SCD is able to modulate the catalytic 
activity of ACC through the saturated acyl-CoA molecules which act as allosteric inhibitors of ACC 
165,166. Finally, SCD1 could enhance the lipogenesis induced by SREBP 154 . Additional SCD1 
overexpression known effects in cancer include increased cell proliferation, survival, cell cycle 
progression, colony formation and invasiveness, which leads to tumor formation and metastasis 
154.  
 
3. Posttranscriptional regulation: miRNAs 
 
Post-transcriptional regulatory mechanisms might represent new therapeutic opportunities for 
cancer treatment. Among them, microRNAs (miRNAs), have emerged as potent epigenetic 
modulators 167. 
miRNAs are endogenous non-coding small RNAs which were first discovered in 1993 in the 
nematode C.elegans 168. MiRNAs play key roles in the regulation of gene expression at the post-
transcriptional level, fine-tuning the expression of almost 30% of all mammalian protein-
encoding genes. A mature microRNA is constituted by approximately 18-22 nucleotides in length 
in single-stranded RNA molecules 169. To date, over 38500 miRNAs have been identified and 
cataloged in the public database miRbase (www.mirbase.org). MiRNAs have been identified in 
animals, plants and viruses 170. 
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3.1. MicroRNAs transcription, processing and gene expression regulation  
 
Genes encoding for microRNAs are transcribed by RNA polymerase II as long primary transcripts 
(pri-microRNA). Also in the nucleus, a pri-microRNA is processed by a protein complex containing 
the RNase III enzyme Drosha, to form a hairpin-like of approximately 70 nucleotide precursor 
microRNA (pre-microRNA). This precursor is subsequently exported to the cytoplasm by Exportin 
5 where it is processed again by a second RNase III enzyme, DICER, producing the mature 
microRNA. The mature microRNA is then incorporated into a ribonuclear particle to form the 
RNA-induced silencing complex, RISC, which mediates gene silencing, bind to complementary 
regions within messenger RNAs to promote their degradation through precisely complementary 
pairing and/or to inhibit translation through non-precisely complementary pairing 167,169,171,172. 
Gene silencing is usually performed upon the binding of the miRNA to the 3’UTR of the targeted 
mRNA, leading to the suppression of the protein synthesis and/or by initiating mRNA 
degradation (Figure 8).  
Figure 8: Canonical pathway of microRNA synthesis. 
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3.2. MicroRNAs biological functions 
 
MicroRNAs have been reported in a wide range of biological processes. They are involved in the 
development and physiology of animals and plants. Regarding animals, miRNAs are key 
regulatory elements in cell differentiation and development. Still, viruses take advantage of 
miRNAs to take control of their host cell; as well as host cells use miRNAs to target vital viral 
functions for example in HIV-1 or hepatitis C virus (HCV) replication 173,174.  
They are involved in neurogenesis and also in the maintenance of the survival of mature neurons 
and their function. Several miRNAs regulate the maturation and function in synaptic plasticity 175 
or midbrain dopaminergic neurons 176. 
miRNAs have also emerged as critical regulatory features in the mammalian immune system, 
which controls the generation and activation of granulocytes 177, and their deregulation is 
related to psoriasis-affected skin, contributing to the dysfunction of the cross-talk between 
resident and infiltrating cells 178, among others. 
Furthermore, they also take part in developmental angiogenesis, blood stem cell formation, and 
plays a role in the pathology of vascular disease 179. Among other processes of miRNAs 
regulatory role we can find cardiac 180 and skeletal muscle development 181, in the response to 
stress, insulin secretion, cholesterol metabolism, aging ,cell proliferation and apoptosis 182,183. 
 
3.3. MicroRNAs in cancer development and other diseases  
 
Since miRNAs contribute in most aspects of cellular differentiation and homeostasis, they 
subsequently play key roles in many pathologies, including cancer. More than 50% of miRNA 
genes are located in cancer-associated genomic regions forming central nodal points in cancer 
progression 184, where they can act as both oncogenes (oncomiRs) or tumor suppressors (TS) 
depending on their targets. Previous studies point to different miRNAs roles involving cancer 
development and maintenance 185, stemness 186,187, metastasis, EMT or angiogenesis 188,189, and 
drug resistance 187. 
In the majority of the tumors, it has been reported the dysregulation of miRNA expression 
profiles depicting any of the abovementioned functions 190,191. Though, it is a challenge to make 
an accurate miRNA classification as oncomiRs or TS since they differ from specific tissues and 
differentiation stages 192–194. Another complication is that a single mature miRNA can be 
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implicated in multiple targets 195. This together with tissue-specific expression could implicate a 
miRNA as a TS in one context and as an oncogene in another. Yet it is also necessary to clarify 
whether these altered expression patterns are the cause of cancer progression or it is an indirect 
effect of previous phenotypic changes 169. 
Several oncomiRs have been observed in a wide range of tumor cell lines (miR-21 in breast, 
colon, lung liver; miR-155 in Lymphoma, leukemia, breast, colon, lung; miR-222 in osteosarcoma, 
glioma, breast cancer,, miR-378 in breast carcinoma, etc.) as well as the expression of TS miRs 
were reported diminished in many cancer cell lines (miR-1 in prostate cancer, head and neck, 
miR-7 in breast, ovarian cancer and miR-18a in CRC, miR-34a in breast, lung, colon, kidney, 
prostate, bladder, etc.), examples synthesized in 196. 
At times, miRNAs are situated in polycistronic miRNA “clusters”, where a single primary 
transcript generates multiple miRNA genes. The miR-17-92 miRNA cluster is the most complex 
and is highly conserved among all vertebrates. Among humans, the cluster is composed of six 
mature miRNAs (miR-17, miR-18a, miR-19a, miR-19b-1, miR-20a and miR-92-1). 197,198. Although 
the mainstream supports miR-17-92 as an oncogene there is strong evidence that it also acts as 
a TS. In the following thesis, miR-19b-1, a miRNA of this cluster, will be discussed as a TS miRNA. 
Some other emerging roles of miRNAs in disease include type 2 diabetes 199 and several diseases 
of the central nervous system including Alzheimer’s, Parkinson's disease, Huntington's disease, 
schizophrenia and autism 200.  
 
3.4. MicroRNAs as biomarkers or therapeutic targets 
 
Different strategies in order to change the expression of a particular cancer-associated miRNA 
have been reported. The inhibition of tumor-promoting miRNA activity can be achieved by 
different miRNA inhibitors and oligomers, among others. On the contrary, to keep and augment 
TS miRNA expression it can be achieved by miRNA mimetics 196. All these therapies development 
endorse that miRNAs may be used as therapeutic targets and tools in cancer treatment.  
As well, miRNAs could also be used as potential biomarkers. Specific miRNA expression 
signatures have been identified in different cancer pathologies 201,202 to predict clinical 
outcomes, and also among different cancer stages during its development. Besides, the 
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possibility to detect miRNAs in body fluids such as serum plasma, saliva or urine makes them 
ideal tools for an early cancer detection, significantly contributing to the treatment success 203. 
4. ORGANOIDS: 3D cultures  
 
For a better understanding of CRC progression; more personalized and physiological tools are 
needed since most of the available data rely on traditional studies using cancer cell lines 
cultures. In this way, the organoid culture system opens a new methodological door for ex vivo 
studies. 
 
4.1. Intestinal anatomy and function: The birth of organoids 
 
Adult tissue-derived epithelial organoids, also called “miniguts” 204 are stereotypic tissue-like 
structures derived from digestive healthy tissues or tumors which mimics in vitro the tissue 
composition and morphology of their in vivo counterparts 205. This methodology was first 
established in long-term primary culture from mouse small intestinal crypts to generate 
epithelial organoids with crypt- and villus-like epithelial domains representing both progenitor 
and differentiated cells 206. 
The epithelium of the adult small intestine forms a contiguous two-dimensional sheet: crypts 
and villus. New cells are added in the crypts and removed by apoptosis upon reaching the villus 
tips a few days later. Stem cells and Paneth cells at the crypt bottom escape this flow  
Figure 9: The anatomy of the small intestinal epithelium (Source: Radtke, F. & Clevers, H.207) 
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The organoids technology takes advantage of the intestinal epithelium self-renewing capacity. 
Organoids starts from Lgr5+ gut or duct epithelial stem cells forming symmetric cyst structures, 
which finally will form budding structures resembling intestinal crypts (Figure 10). These budding 
structures are formed by these Lgr5+ stem cells flanked by differentiated daughter cells 204. In 
small intestinal organoids, Lgr5+ stem cells receive niche signals from the neighboring 
differentiated Paneth cells for their self-renewal 208. This process takes from 7-10 days; later 
splitting of organoids leads to single cells dissociation and the formation of new organoids that 
could be indefinitely propagated through such passaging.  
  
 
                       Figure 10: Intestinal organoid morphology. (Source: STEM CELL Technology 209) 
 
One of the critical steps of organoids is their culture conditions, which should recapitulate each 
tissue stem cell microenvironments from where they come. Organoids can also be employed for 
in vitro generation of digestive tissue from embryonic, pluripotent and induced pluripotent stem 
cells 205, to phenocopy diseases such as cystic fibrosis 210  and can be easily manipulated by 
genetic engineering tools such as transfection, viral transduction and CRISPR/Cas9 technique 211–
214. Along with small intestinal organoids, similar epithelial organoids culture conditions for other 
mouse and human digestive epithelial tissues were also adapted 208,215–217 including tumor-
derived organoids from cancer patients. Importantly, organoids grow as pure epithelial cultures 
without any contamination of vessels, immune cells or non-transformed mesenchymal which 
leads to an accurate sequencing or expression profiling 205 
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4.2. Organoids uses and benefits of the 3D system 
 
Modeling cancer by the organoids 3D culture has raised to an undisputedly and invaluable 
research tool. The fact that organoids own all the epithelial cell type hierarchy provides a 
functionally, physiologically relevant and similar model to in vivo response than conventional 2D 
culture methods. Human CRC organoids present varied requirements in terms of niche factors 
dependent on the pathways mutated, making them harder to culture. Besides, CRC is one of the 
most heterogeneous cancers, mostly in its last stages. However, murine organoids allow an 
accurate monitoring of the mutations and the cancer stage, together with the ease of 
manipulation, exploiting new lines of research using CRISPR and siRNA techniques. 
In the past five-year period, translational research in regards to organoids has experimented a 
great growth with the establishment of human organoid biobanks 218 or by the possibility to 
correct mutations in ex vivo tumors using gene-editing techniques and further implantation of 
the genetically engineered organoids 213. Organoids models suppose this “missing gap” among in 
vivo and in vitro studies, which in precise situations would allow continuing the research with 
the ethical advantage of reducing the animals suffering and for the obvious economic reasons. In 
summary, the utility of 3D organoid culture as a model for personalized medicine is in great 
expansion. 
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Hypothesis & Objectives 
 
 
HYPOTHESIS  
Metabolic reprogramming is essential for tumor aggressiveness, and more precisely, lipid 
metabolism becomes crucial for energy supplies and a building blocks source for the tumor 
progression. Nonetheless, deeper analysis of lipid metabolism enzymes role in cancer is still 
necessary. We postulate that the metabolic enzyme family, ACSL, which represents a key point 
in the departure of FAs into different catabolic or anabolic routes, together with the 
immediately downstream enzyme, SCD, also key in the partition of desaturated active FAs, 
would be essential in cancer progression. Therefore, targeting these enzymes would also inhibit 
the progression of the tumor. Since some metabolic drugs such as Metformin have 
demonstrated a therapeutic role in cancer, knowing the status of this pathway in CRC patients 
could be relevant for the potential targeted use of these metabolic drugs in CRC patients. 
 
OBJECTIVES 
1.  To unravel the role of the lipid metabolic enzymes ACSL and SCD on CRC tumor progression. 
1.1.  In vitro analysis of the metabolic enzymes, individually and in combination, using CRC-
derived cell lines.  
1.2.  Analysis of the specific metabolomic profiles associated to the enzymes dysregulation. 
 
2. To describe the possible association of the enzymes with clinical prognosis in CRC to be used 
as therapeutic targets and biomarkers of the progression of the disease.   
2.1. Analysis of the expression of ACSL and SCD genes in CRC patient’s cohorts to be used as a 
biomarker in the clinics. 
2.2. In vitro analysis of the pharmacological specific inhibition effect over ACSL and SCD enzymes. 
2.3. Identification and analysis of the best regulatory microRNAs for ACSL and SCD enzymes, 
searching their possible use as noninvasive biomarkers. 
 
3. To develop a model of intestinal organoids to validate the relevance of this pathway as an in 
vitro approach for personalized medicine. 
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Results 
OVERALL RESULTS SUMMARY 
 
This Doctoral Thesis aims to describe the reprogramming metabolic pathways involved in FA 
activation that a colorectal cell could suffer for its malignant transformation to CRC. ACSL 
represent a key point in the departure of FAs into different catabolic or anabolic routes, and we 
postulated that this family is essential in tumor progression, together with the immediately 
downstream enzyme, SCD, also key in the desaturation of active FAs. Both enzymes where 
previously described in CRC progression independently, and previous studies from the group 
highlighted their overexpression in a genetic fingerprint involved in CRC patients prognosis 162. 
Thus, we first aimed to unravel the role of these enzymes in tumor progression (Objective 1).  
To that end, we first followed an in vitro approach in which we overexpressed ACSL and SCD 
metabolic enzymes in human CRC cell lines individually and in combination (Objective 1.1.). This 
work suggested that there was a synergistic effect in tumor progression when ACSL and SCD 
were expressed together. Results demonstrated that the simultaneous overexpression of two 
isoforms of the ACSL family, ACSL1 and ACSL4 plus the desaturase SCD, promoted the 
adquisition of mesenchymal characteristics,  conferring cancer stem cells properties to cells, 
increasing cellular migration and invasion and stimulating several survival pathways, 
(PUBLICATION I, Oncotarget 2015).  
To further verify these results, we analyzed the metabolomic profile of the individual 
contribution of these enzymes in comparison to their simultaneous overexpression (Objective 
1.2.). As it is shown in PUBLICATION II (Scientific reports 2017), acylcarnitines upregulation, 
polyunsaturated or monounsaturated FA dysregulation characterizes the individual 
overexpression of ACSL1, ACSL4 OR SCD, respectively. However, higher phospholipid levels, urea 
cycle upregulation and upregulated creatine pathway characterize the complete ACSL/SCD 
network metabolic action evidencing that the complete axis phenotype is not the sum of 
individual enzymes effects. Indeed, only the complete ACSL/SCD network -driven cells present 
metabolic features that also characterize other invasive and metastatic cells. 
Once determined the ACSL/SCD network importance in CRC progression, new therapeutic 
opportunities for CRC treatment might be considered. We aimed to describe the potential role 
of these enzymes as therapeutic targets and biomarkers of the progression of the disease 
(Objective 2). To clarify the prognostic value of the axis to be used as a biomarker in the clinics, 
cohorts of CRC patients were analyzed for gene expression (Objective 2.1.). Results showed that 
patients with simultaneous overexpression of ACSL1, ACLS4 and SCD, displayed significant 
increased risk of relapse than other patients within the same clinicopathological stage 
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(PUBLICATION I, Oncotarget 2015). Once established the potential relevance of this pathway as a 
biomarker of the disease, its role as a therapeutic target was also analyzed.  Through in vitro 
analyses, the combination of low doses of pharmacological inhibitors targeting specifically ACSL 
and SCD were used (Objective 2.2.), and we observed a dramatic inhibition of cell viability in a 
synergistic manner without having any effect in normal colonocytes, representing a new 
therapeutic possibility and concluding with the objective (reported in PUBLICATION I, 
Oncotarget 2015).  
Regarding the inhibition of these enzymes expression, the reported existence of the epigenetic 
modulators such as miRNAs with great impact on metabolic homeostasis could represent a 
source for regulating these metabolic enzymes as well as being used as clinical biomarkers due 
to its capacity to be detectable in body fluids such as urine or plasma. Thus, the possibility to 
detect miRNAs in body fluids as noninvasive biomarkers, together with their potential regulating 
role of this pathway, made us to focus on finding regulatory miRNAs of the axis (Objective 2.3.). 
A screen of miRNAs simultaneously targeting ACSL1, ACSL4 and SCD evidences three miRNAs as 
regulators of the ACSL/SCD protumorigenic network. Importantly, one of these candidate 
miRNAs, miR-19b-1, correlates with a better prognosis in CRC patients, designating it as a 
promising noninvasive biomarker in CRC, fulfilling the objective 2.3. (PUBLICATION III, JLR 2017)  
Finally, when referring to targeted and personalized approaches for cancer patients, new 
approaches would be necessary to explore the potential use of a specific therapeutic approach 
in a concrete patient. To date, platforms such as ex vivo explants cultures to test drugs were 
currently used. However, they do not allow an accurate analysis of the molecular characteristics 
of the tumor, and therefore they are still susceptible for improvement. In this sense, organoids 
technology embodies a more physiological tool to check the status of ACSL/SCD axis as well as its 
regulatory miRNAs. Thus, our last objective has been to establish organoids models of intestinal 
tumors to evaluate their potential as a more adequate tool to analyze the effect of ACSL/SCD 
pathway in CRC (Objective 3). In this way, as a first approach to develop human organoids, a 
model of murine CRC-like organoids following the different stages of the disease were 
established.  As it is shown in PUBLICATION IV (Submitted for publication), ACSL4 is progressively 
overexpressed throughout the CRC-like organoids stages; while miR-19b-1 expression behaves in 
an opposite fashion. In the search of new drugs targeting the axis, we demonstrate that 
organoids also represent a great tool to study stage-dependent drugs. In this way, Metformin 
arises as an efficient treatment in CRC organoids first stages, completing the third block of 
objectives and extensively explained in PUBLICATION IV.  
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A link between lipid metabolism and epithelial-mesenchymal transition provides a target 
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PUBLICATION I SUMMARY  
 
A link between lipid metabolism and epithelial-mesenchymal transition provides a target for 
colon cancer therapy 
The unusual metabolic reprogramming in a cell is considered a critical hallmark of cancer. In 
addition to the well-studied tumor carbohydrate metabolism, other metabolic pathways 
involved in malignant progression, such as lipid metabolism, demand further attention. 
Throughout this publication, we set up the basis of the present Doctoral Thesis. Here we 
described a metabolic ACSL/SCD network, capable of triggering invasive and mesenchymal 
features in CRC cells. The enzymes at issue were two members of the long-chain acyl-CoA 
synthetases (ACSL) family, isoform 1 and 4. ACSL family activates FAs from free FAs to fatty acyl-
CoA (FA-CoA). This bioactive pool of FA-CoA can henceforth enter multiple physiological and 
metabolic routes. The third enzyme is the Stearoyl-CoA desaturase (SCD) which catalyzes the 
desaturation of FA-CoA. The products of SCD desaturation also serve as substrates for the 
synthesis of different complex lipids. 
We performed the ACSL1, ACSL4 and SCD simultaneous overexpression (x3 cells) through 
specific lentiviruses in CRC cell lines (DLD-1) and we observed a phenotypic change characterized 
by a spindle-like shape and a scattered distribution, consistent with an EMT phenotype. To 
confirm this EMT phenotype, characterized also by cell-to-cell adhesion lost, E-cadherin marker 
was measured by immunofluorescence technique, confirming that it was mislocalized in x3 cells. 
Besides, β-catenin, a transcriptional coactivator, switched from the membrane to the nucleus. 
Furthermore, GSK3β inhibitory phosphorylation was shown highly increased in x3 cells by 
western blot technique (WB), allowing β-Catenin nuclear translocation to promote the 
transcription of mesenchymal-promoting genes. Different markers were also checked by qPCR, 
in x3 cells, whereas different mesenchymal markers were found overexpressed, the epithelial ones 
appeared downregulated. Since EMT processes are known to present cancer stem cells features, 
we measured CRC stem cells markers where we found x3 cells positively enriched on these 
proteins. In accordance, x3 cells were able to form tridimensional colonies in a “grape-like” or 
even “stellate” shape highlighting the mesenchymal behavior of these cells and suggesting 
invasive capacities. 
Using wound-healing assays, we confirmed the migratory enhanced capacities of x3 cells. 
Moreover, we observed the gain of invasiveness upon the three enzymes overexpression in the 
poorly invasive DLD-1 cells, using Matrigel chambers experiments. Even though some enzymes 
individually promoted those effects, none of these effects was as prominent as the three 
45
Results 
enzymes simultaneous overexpression effect. Colony formation experiments, used to analyze 
long-term growth and survival, showed x3 cells with a more than twice efficiency in colony 
formation compared to control cells. To accurately assay proliferation, we performed EdU assays 
with no substantial differences in proliferation in any of the cell lines. We next analyzed Erk and 
Akt activation, two well-known pathways for cell survival involved in mesenchymal features 
induction mainly through GSK3β regulation, finding a significant activation of both cascades in x3 
cells. Again, we observed partial effects in single overexpression cases, such as SCD 
overexpressing cells, but far from the three enzymes overexpression full effect. Hence, ACSL1, 
ACSL4 and SCD act as a network specifically promoting invasion and survival but not 
proliferation, unlike Warburg driven tumors. In agreement with that, x3 cells did not show 
increased glycolytic activity analyzed by L-lactate measurements when compared with DLD-1 
control cells. Furthermore, we proved the implication of the master metabolic regulator, AMPK, 
upon treatment with three different AMPK activators; Metformin, phenformin and AICAR that 
resulted in the DLD-1 epithelial phenotype rescue. As well, ACC, an AMPK downstream target, 
turns inactive by phosphorylation when induced by AMPK activators in x3 cells. Furthermore, 
Metformin treatment stimulated the expression of epithelial markers and decreased 
mesenchymal gene expression levels. AMPK is considered a tumor suppressor, inhibiting tumor 
metabolism through Akt-MDM2-Foxo3 signaling axis. This is in agreement with the increased Akt 
signaling observed in x3 cells. However, Akt inhibitor IV does not revert EMT suggesting 
additional pathways affected by AMPK signaling that are also needed for a complete rescue.  
We further analyzed 77 samples from stage-II CRC patient’s series and a further 119 stage-II CRC 
patients validation series, finding that the combined overexpression of ACSL1, ACSL4 and SCD in 
patients results in a poorer outcome and higher risk of relapse compared with the upregulation 
of each of the genes alone. This suggests an increased aggressiveness of tumors overexpressing 
ACSL/SCD network. 
We wanted to assay the therapeutic potential of targeting the ACSL/SCD axis using chemical 
inhibitors. For this, we assayed the combination of Triacsin C, an ACSL inhibitor, and A939572 an 
SCD inhibitor. This combination synergistically reduces CRC cells viability without affecting 
normal colon cells. Importantly, this combination was also operative in CRC cells resistant to 
current chemotherapy (5-FU) and able to reverse the mesenchymal phenotype of x3 cells to the 
initial situation resembling control cells. Together with these results, we observed an increase in 
epithelial markers expression and a reduced expression of mesenchymal-promoting -genes in 
treated x3 cells. Hence, the pharmacological inhibition of ACSL/SCD network is able to 
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counteract the x3 cells invasive features and may designate the ACSL/SCD axis interference as a 
promising opportunity for cancer therapy development. 
PUBLICATION I CONCLUSIONS  
 
 A cooperative metabolic network comprising ACSL1, ACSL4 and SCD is involved in 
colorectal cancer progression. 
 Simultaneous overexpression of ACSL1, ACSL4 and SCD induces mesenchymal features, 
confers the cells cancer stem cells properties, increases cellular migration and invasion 
and stimulates several survival pathways. 
 The combination of low doses of pharmacological inhibitors targeting both ACSL and SCD 
dramatically affects cancer cell viability in a synergistic manner without having any effect 
in normal colonocytes. 
 CRC patients with tumors displaying simultaneous overexpression of ACSL1, ACLS4 and 
SCD show an increased risk of relapse than other patients within the same 
clinicopathological stage. 
 ACSL/SCD network might be relevant for colon cancer progression through conferring 
increased energetic capacity and invasive and migratory properties to cancer cells and 
might represent a new therapeutic opportunity for colon cancer treatment 
 
My concrete contribution to this part of the research was first learning and improve the 
techniques above-mentioned. The principal author, Ruth Sanchez and I worked together on the 
whole project.  
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ABSTRACT
The alterations in carbohydrate metabolism that fuel tumor growth have been 
extensively studied. However, other metabolic pathways involved in malignant progression, 
demand further understanding. Here we describe a metabolic acyl-CoA synthetase/ stearoyl-
CoA desaturase ACSL/SCD network causing an epithelial-mesenchymal transition (EMT) 
program that promotes migration and invasion of colon cancer cells. The mesenchymal 
phenotype produced upon overexpression of these enzymes is reverted through reactivation 
of AMPK signaling. Furthermore, this network expression correlates with poorer clinical 
outcome of stage-II colon cancer patients. Finally, combined treatment with chemical 
inhibitors of ACSL/SCD selectively decreases cancer cell viability without reducing normal 
cells viability. Thus, ACSL/SCD network stimulates colon cancer progression through 
conferring increased energetic capacity and invasive and migratory properties to cancer 
cells, and might represent a new therapeutic opportunity for colon cancer treatment.
INTRODUCTION
Colorectal cancer (CRC) is one of the most deathly 
tumors worldwide. In addition to genetic modifications, 
factors causing metabolic alterations such as obesity, 
sedentarism and westernized diet, are risk factors for the 
disease [1]. Metabolic reprogramming is a distinguished 
cancer hallmark [2]. It is well known the Warburg effect by 
which cancer cells preferentially drive glucose metabolism 
to lactate production under aerobic conditions [3]. In 
addition to carbohydrate metabolism, other metabolic 
pathways have been found to be altered in cancer [4]. 
Lipid metabolism, represents an extremely relevant source 
of energy and structural and biosynthetic resources [5, 6].
De novo fatty acid synthesis is required for 
membrane production, essential for cell growth and 
proliferation. In addition, an appropriate ratio between 
saturated and monounsaturated fatty acids (SFA and 
MUFA, respectively) is needed for proper membrane 
fluidity and cell function. An increased content of MUFA 
has been observed in several cancers [7] and it has been 
proposed as a predictive marker [8]. The rate-limiting 
enzyme converting SFA into MUFA is steraroyl-CoA 
desaturase-1 (SCD), which introduces a double bound into 
palmitic acid and stearic acid giving rise to palmitoleic 
and oleic acid, respectively [9]. SCD have been 
described upregulated in several types of human tumors 
and its expression has been correlated with malignant 
transformation, proliferation and survival [10–14].
Acyl-CoA synthetases (ACSL) catalyze the 
conversion of long chain fatty acids to acyl-CoA, which 
is critical for phospholipid and triglyceride synthesis, 
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lipid modification of proteins as well as for fatty acid 
β-oxidation [15]. These enzymes have been related to 
carcinogenesis [16, 17]. Although involved in the same 
reaction, enzymes of ACSL family differ in substrate 
specificity, subcellular localization, and tissue distribution. 
In fact, these enzymes use saturated and unsaturated fatty 
acids of 8–22 carbons as substrates with the exception 
of ACSL4 that shows a clear preference for arachidonic 
acid as a substrate [6]. ACSL4 increases proliferation, 
tumor growth and survival in breast, prostate, colon 
and liver malignancies [18–21]. Remarkably, ACSL4 
overexpression channels fatty acids preferentially 
towards phosphatidylinositol, an effect not observed 
for ACSL1 [22]. ACSL1 has been recently involved in 
lipid metabolism alterations in cancer [23], including in 
a screening in colon cancer of lipid metabolism-related 
genes recently conducted in our research group [24, 25].
Epithelial-mesenchymal transition (EMT) is a conserved 
morphogenetic program characterized by the loss of epithelial 
phenotype and the gain of mesenchymal features [26]. 
Epithelial cells discard their cell polarity and cell-cell adhesion 
and acquire a mesenchymal morphology with migration and 
invasion capability. These properties promote metastasis and 
the development of several neoplasias [27]. Loss of E-Cadherin 
and nuclear translocation of β-Catenin constitute known EMT 
biomarkers. β-Catenin trans location to the nucleus leads to 
invasion genes transcription [28]. This requires avoiding 
β-Catenin rapid cytosolic degradation by the proteasome, 
achieved upon GSK3β phosphorylation [29]. An implication of 
carbohydrates metabolism in the EMT phenotype acquisition 
and maintenance has been reported [30, 31] although no 
connection has been yet described with fatty acid metabolism.
Here we identify a cooperative metabolic network 
comprising ACSL1, ACSL4 and SCD, involved in CRC 
progression. The simultaneous overexpression of ACSL1, 
ACSL4 and SCD induces EMT, increases cellular migration 
and invasion and stimulates several survival pathways. 
Besides, the combination of low doses of pharmacological 
inhibitors for ACSL and SCD, dramatically decreases 
cancer cell viability in a synergistic manner. Moreover, such 
combination also reduces cell viability of chemotherapy 
resistant colon cancer cells without having any effect in normal 
colonocytes. Finally, the clinical relevance of these findings is 
underscored in CRC patients with tumors displaying ACSL1/
ACSL4/SCD simultaneous overexpression that show an 
increased risk of relapse compared to other patients within 
the same clinicopathological stage.
RESULTS
Lipid metabolism enzymes overexpression 
confers EMT properties to colon cancer cells
The aim of this study was to perform a comparative 
analysis of the potential involvement of ACSL1 and ACSL4 
in CRC, in addition to analyzing whether their combination 
with the related enzyme SCD might increase tumorigenesis 
due to the probable role of SCD in preventing lipotoxic 
effects that could result from ACSL overexpression. For 
this purpose we generated human colon cancer stable 
cell lines overexpressing either ACSL1, ACSL4 or SCD 
(ACSL1 cells, ACSL4 cells, and SCD cells, respectively) 
or the three genes simultaneously (x3 cells), transducing 
the DLD-1 CRC cell line with specific lentiviruses. An 
equivalent control vector which does not express any ORF 
was also used to generate the No ORF cell line. Transcript 
levels of ACSL1, ACSL4 and SCD were measured to 
ensure that stable expression of the constructs was achieved 
(Figure 1A), which was further confirmed by Western Blot 
analysis of the proteins levels (Figure 1B).
Unlike No ORF controls, nor any of the cell lines 
overexpressing any of these genes individually, x3 cells 
displayed a more spindle-like shape with a more scattered 
distribution, resembling mesenchymal or fibroblast-like 
phenotype (Figure 1C). Since this morphological change 
resembled an EMT phenotype characterized by loss of 
cell-cell adhesion, we next analyzed the expression of the 
epithelial marker E-Cadherin. As shown in Figure 1D, 
the membrane-associated pattern of expression of 
E-Cadherin was disrupted upon ACSL1, ACSL4 and 
SCD simultaneous overexpression. Mislocalization of 
E-cadherin was more evident in the areas where the more 
fusiform and rounded x3 cells were present (Figure 1D, 
bottom panel, arrow). Moreover, loss of β-Catenin from 
the membrane and a clear increase in nuclear localization 
was also found in x3 cells when compared with No ORF 
control cells (Figure 1E). This is also in agreement with 
a loss of epithelial characteristics and gain of an EMT 
phenotype, since its translocation to the nucleus would 
lead to the transcription of invasion genes [28]. Figure 1F 
shows how GSK3β inhibitory phosphorylation is 
highly increased in x3 cells, allowing β-Catenin nuclear 
translocation. β-Catenin acts as a transcriptional 
coactivator at the nucleus promoting the transcription of 
EMT genes [32]. Accordingly, together with a decrease in 
the expression of the epithelial markers E-Cadherin, K18 
and Na+/K+ATPase β1, x3 cells increased the expression 
levels of EMT associated genes N-cadherin, Slug and 
Vimentin (Figure 1G) which are normally not expressed in 
the markedly epithelial DLD-1 cells.
Accordingly with the lack of any morphological 
change, no mislocalization of E-cadherin nor changes 
in epithelial markers were observed in cell lines singly 
overexpressing any of these genes (Supplementary 
Figure S1A–S1B). Interestingly, an increase in GSK3β 
phosphorylation was also observed in SCD cells 
(Supplementary Figure S1C). In contrast, only cells 
overexpressing ACSL1, but not ACSL4 or SCD (data not 
shown) displayed an up-regulation of N-cadherin and Slug 
expression (Supplementary Figure S1D). These results 
suggest that each gene might be contributing in different 
aspects of EMT, though the cooperation of the three genes 
is needed to trigger the EMT program.
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Cells undergoing EMT have been described to 
present cancer stem cells features [33]. Accordingly, x3 
cells were significantly enriched in the well-established 
markers of CRC stem cells CD44, LGR5, ALDH1A1, 
EpCAM and CD29 when compared with No ORF cells 
(Figure 1H). Moreover, x3 cells form tridimensional 
colonies with differential morphologies when grown 
in matrigel. While No ORF cells displayed the normal 
DLD-1 spheroid round morphology termed as “mass” 
[34, 35] (Figure 1I, left panel), x3 cells whether presented 
“grape-like” spheroids with loose cell-cell contacts 
(Figure 1I, central panel) or even “stellate” colonies 
with invasive projections able to bridge several cell 
colonies (Figure 1I, right panel). This again highlights 
the more mesenchymal behavior of x3 cells and suggests 
an invasive capacity for these cells.
Figure 1: ACSL1, ACSL4 and SCD overexpression induces EMT in CRC cells. A. Stable cell lines overexpressing ACSL1, 
ACSL4 and SCD, alone or in combination (x3) were generated using lentiviral transduction and expression levels of every gene were 
measured by RT-QPCR. B. Protein expression levels of ACSL1(upper band), ACSL4 and SCD for each cell line were detected by Western 
Blot with specific antibodies. β-Actin detection was used as a loading control. C. Representative phase contrast images showing atypical 
morphology of x3 cells compared to control No ORF cells. Scale bars, 100 μm. D–E. Representative immunofluorescence images of 
E-Cadherin (green) (D) or β-Catenin (green) (E) cellular distribution of No ORF and x3 cells. Arrows indicate the different expression 
patterns in the cellular distribution of E-Cadherin (D) or β-Catenin (E) in both types of cells. Nuclei were stained with DAPI (blue) and 
equivalent phase contrast images were taken. Scale bars, 50 μm. F. Levels of GSK3 phosphorylation detected by Western Blot using a 
phospho-specific antibody (Ser21/9). Total GSK3β levels detection and Ponceau-stained band served as loading controls. Bottom panel: 
Quantification of bands intensity showing the ratio of phosphorylated to total protein. (Continued )
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ACSL/SCD metabolic network fuels migration, 
invasion and cell survival
The acquisition of migratory and invasive properties 
is a general feature of cells undergoing EMT, crucial for 
metastasis formation and cancer progression. In order to 
check if the combination of ACSL and SCD overexpression 
could confer cancer cells a gain of migratory capacity, we 
performed wound healing assays. Figure 2A shows how x3 
cells present an increased migration ability compared to 
No ORF cells. As illustrated in the magnification, x3 cells 
close the wound upon random migration, characteristic 
of a mesenchymal behavior. In contrast, No ORF control 
cells, ACSL1, SCD, and more markedly ACSL4, display 
the collective unidirectional migration of cohesive epithelial 
sheets. Furthermore, poorly invasive DLD-1 cells gain 
the ability to invade through Matrigel (Figure 2B) upon 
ACSL1, ACSL4 and SCD simultaneous overexpression 
(x3). The invasion capacity was also increased upon 
individual overexpression, especially in the case of ACSL1 
cells. However, any of these individual effects was less 
prominent that the one observed in x3 cells. These results 
highlight the cooperative effect in promoting migration and 
invasion achieved when these three metabolic genes act in 
a combined manner.
Cancer cells often use metabolic strategies to 
promote cell survival and proliferation. To analyze 
whether an increased lipid metabolism caused by ACSL1, 
ACSL4 and SCD overexpression could be implicated in 
these processes, we first performed clonogenic assays to 
monitor long-term growth and survival. Figure 2C shows 
that x3 cells present more than twice efficiency in colony 
formation compared to control cells. In contrast, none of 
the individual overexpression caused this increase in the 
number of colonies formed indicating again that it is the 
combination of the three genes that confers the cells the 
more aggressive characteristics.
To directly assay cell proliferation we analyzed the 
incorporation of EdU as a measure of DNA synthesis rate. 
No significant changes in proliferation were found in any 
of the stable cell lines (Figure 2D). Since colony formation 
needs cell proliferation, we also performed those EdU 
assays in conditions of confluence to make these assays 
more comparable to the growth conditions in the colonies 
produced during clonogenic assays. Again, we do not find 
substantial differences in proliferation in any of the cell lines 
(Supplementary Figure S2). A number of EMT regulators 
have been reported not to increase proliferation, and invasive 
cells associated to decreased cell cycle progression [36, 37]. 
We next analyzed Erk and Akt activation, two well-known 
Figure 1: (Continued ) ACSL1, ACSL4 and SCD overexpression induces EMT in CRC cells. G. RT-QPCR analysis of 
epithelial (E-Cadherin, K18 and Na+/K+ATPase β1) and mesenchymal genes (N-Cadherin, Slug and Vimentin) for x3 cells compared to 
levels in No ORF control cells. H. The expression levels of the colon cancer stem cell markers CD44, Lgr5, ALDH1A1, EpCAM and CD29 
were measured by RT-QPCR in x3 cells and compared to the levels in No ORF control cells. I. Phase contrast pictures showing the different 
morphology of spheroids formed by No ORF and x3 cells cultured under 3D on-top assay conditions. Scale bars, 100 μm. Experiments in 
A, G and H were performed in triplicates (n = 3). Results represent the mean ±SD (n = 3). *, p < 0.05, **, p < 0.01, ***, p < 0.001.
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pathways for cell survival involved in EMT induction mainly 
through GSK3β regulation [38]. We found a significant 
activation of both cascades in x3 cells (Figure 2E). Besides, 
a clear increase in Erk and Akt phosphorylation was found 
in SCD cells, as well as in ACSL4 cells in the case of Akt 
phosphorylation. These partial activations per se may 
be insufficient but may contribute to the full effect and 
phenotype observed in x3 cells.
All these data suggest that unlike other tumor 
metabolic pathways such as the Warburg effect, the 
ACSL/SCD network acts specifically promoting invasive 
and pro-survival properties without major effects on cell 
proliferation. In agreement with that, x3 cells did not show 
increased glycolytic activity when compared with No ORF 
control cells (Figure 2F). This reveals that EMT promotion 
might require particular metabolic advantages other than 
pro-proliferative aerobic glycolysis.
AMPK signaling counteracts the EMT 
phenotype triggered by the ACSL/SCD 
signaling network
In addition to classical oncogenic pathways [38], 
nutrient sensing and inflammation regulators have 
been more recently added to the list of EMT-inducers 
[39, 40]. Since ACSL/SCD overexpression may represent 
Figure 2: Combination of ACSL with SCD overexpression stimulates migration, invasion and colony formation 
without major effects on proliferation. A. Phase contrast pictures of wound healing assay comparing migratory capacities of No 
ORF, ACSL1, ACSL4, SCD and x3 cells. Magnification (right panels) shows the different behavior of control and x3 cells at 36 hours of 
wound closure. Scale bars, 100 μm. B. Boyden chamber transwell assay of invasion through Matrigel. After 48 hours, cells were fixed and 
stained with crystal violet (bottom panels) and counted under an optical microscope. Migratory cells were quantified as the average number 
of cells found in five random microscope fields in three independent inserts. Scale bars, 50 μm. (Continued)
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an energetic advantage, we wondered if the master 
regulator of energy balance, AMPK, was involved. 
This kinase, considered to act as a tumor suppressor by 
inhibiting tumor metabolism and associated cell growth 
signaling pathways [41] has been described to suppress 
EMT by regulating the Akt-MDM2-Foxo3 signaling axis 
[42]. Accordingly, treatment with three different AMPK 
activators; metformin, phenformin and AICAR, was able 
to rescue the DLD-1 epithelial phenotype (Figure 3A).
Besides sharing arachidonic acid as a substrate, 
ACSL4 regulates COX-2 expression and thus 
prostaglandin production [19], also implicated in cell 
malignancy and EMT promotion [43]. Since x3 cells, but 
not any of individually overexpressing cell lines, show 
increased levels of COX-2 expression (Figure 3B); we 
surmised that x3 EMT might be mediated by a COX-2 
dependent mechanism. Conversely, treatment with the 
COX-2 inhibitor NS-398 had no effect on the x3 cells 
phenotype reversion (Figure 3C, central panel). Moreover, 
despite the strong Akt activation in x3 cells (Figure 2E), 
the treatment with Akt inhibitor IV (Figure 3C, right 
panel) was also inefficient to revert x3 mesenchymal 
features. This drug only inhibited cell viability of both 
cell lines without altering their morphological features. 
These data pointed towards AMPK signaling as key for 
maintaining the DLD-1 cells epithelial phenotype. This 
was further demonstrated by analysis of the downstream 
AMPK target, Acetyl-CoA Carboxylase (ACC), which 
is inactivated upon phosphorylation at Ser79 (P-ACC). 
The ACC inhibitory phosphorylation was induced upon 
metformin or phenformin treatment in x3 cells (Figure 
3D). Furthermore, metformin treatment stimulated the 
expression of the epithelial markers E-Cadherin, K18 and 
Na+/K+ATPase β1 and decreased the expression levels of 
the EMT-induced genes N-Cadherin and Slug in x3 cells 
without increasing those levels in control No ORF cells 
(Figure 3E).
Stage-II CRC patients with simultaneous 
overexpression of ACSL1, ACSL4 and SCD 
have worse clinical outcome
In order to determine the clinical relevance of ACSL/
SCD network activation in CRC, we analyzed the putative 
association between the simultaneous overexpression of 
ACSL1, ACLS4 and SCD with clinical outcome in a 
set of 77 samples from stage-II CRC patients. Towards 
this aim we have recently developed a global analysis of 
lipid metabolism-related genes [25]. Median follow-up 
of these patients was 71.5 months. The 3-year disease 
Figure 2: (Continued) Combination of ACSL with SCD overexpression stimulates migration, invasion and colony 
formation without major effects on proliferation. C. Clonogenic assay quantification. Individual cells were plated and colonies 
formed were grown during 2 weeks. Data are presented as the average number of colonies resultant for each cell line. D. Quantification 
using fluorescence microscopy of EdU incorporation as a measure of cell proliferation. E. Erk1/2 and Akt phosphorylation were detected 
by Western Blot with phospho-specific antibodies (Tyr204 Erk and Thr308 Akt). Total Erk and Akt were used as their respective controls. 
Bottom panels: Quantification of bands intensity showing the ratio of phosphorylated to total protein. F. Quantification of extracellular 
L- Lactate produced by No ORF and x3 cells. Experiments in B, C, D and F were performed in triplicates (n = 3). Results represent the 
mean ±SD (n = 3). *, p < 0.05, **, p < 0.01.
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free survival (DFS) was 72.3%, 22 patients (28.57%) 
relapsed. Clinico-histopathological characteristics of 
these patients are detailed in Supplementary Table S1. An 
initial screening performed showed that 16 out of 70 lipid 
metabolism-related genes analyzed, including ACSL1, 
ACLS4 and SCD, might have a putative association 
with tumor aggressiveness [25]. Thus, we performed 
a comparative analysis of the relationship between the 
individual expression of these genes and their combined 
overexpression in these patients. As expected from the 
screening, Kaplan-Meier plots for disease free-survival of 
ACLS1, ACSL4 or SCD showed an association between 
high expression of each of these genes and poorer 
clinical outcome (Figure 4A, 4B and 4C). Moreover, 
the multivariable model x3 (combined expression of 
ACSL1, ACSL4 and SCD) showed that the simultaneous 
overexpression of the ACSL/SCD network resulted in a 
stronger and more potent association with patient relapse 
(Figure 4D and Table 1), confirming the acquisition of 
increased aggressive properties of CRC tumors with these 
characteristics.
We validated these results in an independent 
and bigger cohort of 119 stage II CRC patients with a 
median follow-up of 43 months and 3-year DFS of 86.1% 
respectively, from which 18 patients relapsed (15.3%) 
(Clinico-pathological characteristics summarized in 
Supplementary Table S1). The univariate cox regression 
analysis in this validation group also showed a statistical 
association between overexpression of each gene and 
clinical outcome (Figure 4, Table 1). The multivariate 
analysis in this validation group further demonstrated 
that the combined overexpression of these genes was 
associated with a higher increased risk of relapse of 
stage-II CRC patients, with higher power and statistical 
strengthening than any of these genes individually (x3: 
HR (95% CI) = 8.68 (1.9–39.66); p = 6e-04), which is 
more than 2-fold higher than any of these genes separately, 
results that were confirmed after adjusting for clinical 
confusing factors (Table 1).
These results, not only show the clinical relevance 
of the overexpression of these genes in CRC, but also 
demonstrate that their combination is associated with an 
Figure 3: AMPK activation rescues normal DLD-1 epithelial phenotype. A. Representative phase contrast pictures of No ORF 
and x3 cells treated either with 5 mM metformin, 1 mM phenformin, 1 mM AICAR or vehicle (water) for 48 hours. Scale bars, 100 μm. 
B. COX-2 expression levels of x3 cells compared to control No ORF cells, measured by RT-QPCR. C. Pictures represent cells treated for 
48 hours either with the COX-2 inhibitor NS-398 (10 μM), the Akt inhibitor IV (Akt-inIV, 2 μM), or with an equivalent amount of DMSO 
as control. Scale bars, 100 μm. (Continued)
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increased aggressiveness of CRC tumors in a clinical setting. 
Collectively, these results imply that ACSL1, ACSL4 and 
SCD increased expression might act as a marker of poor 
prognosis which contributes to reduced disease free survival 
of colon cancer patients. Very likely, the EMT program 
triggered by the ACSL1/ACSL4/SCD axis would be 
implicated in facilitating the spread of the disease.
Combined pharmacological inhibition of the 
ACSL/SCD network synergy to selectively inhibit 
cancer cells viability and mesenchymal features
The robust protumor action of ACSL1/ACSL4/
SCD network, together with the fact that all three of them 
are lipid metabolism enzymes, makes these druggable 
proteins attractive targets for cancer therapy. For this 
reason, we evaluated the combined effect on colon cancer 
cell viability of Triacsin C, a specific inhibitor of ACSL, 
and the SCD inhibitor A939572, both previously reported 
to reduce tumor growth both in vitro and in vivo [14, 17]. 
Triacsin C was able to decrease cell viability in DLD-1 
and SW620 cell lines in a dose-dependent manner (Figure 
5A). A similar effect was achieved upon treatment with 
A939572 (Figure 5B). Since the use of high concentrations 
of pharmacological inhibitors may cause side effects and act 
on other pathways, the combination of the two compounds 
might inhibit ACSL/SCD network and exert a similar action 
using much lower concentrations of both compounds .
Lower concentrations of Triacsin C and A939572 
alone or in combination were used in a panel of colon 
cancer cell lines (Figure 5C). As expected, treatment with 
1 μM Triacsin C or with 0.5 μM A939572 moderately 
decreased DLD-1 and SW620 cells viability, but 
importantly, the combined action of both inhibitors caused 
a strong cancer cell viability reduction. Furthermore, 
Triacsin C and A939572 individually had no effect on the 
viability of the more resistant HT-29 and LS174T cells; 
however, a potent inhibition was observed when those low 
doses of both compounds were used (Figure 5C).
In addition, to analyze the effect of these compounds 
on CRC cells resistant to conventional chemotherapy, we 
used a subclone of SW620 cells previously described [44], 
Figure 3: (Continued) AMPK activation rescues normal DLD-1 epithelial phenotype. D. Western blotting of ACC phosphorylation 
upon 48 hours of metformin (5 and 10 mM) or phenformin (0.5 and 2 mM) treatment in No ORF and x3 cells. Total protein extracts were blotted 
using a phospho-specific antibody (Ser79) and a total ACC antibody. β-Actin detection was used as a loading control. E. RT-QPCR analysis 
shows mRNA levels of epithelial markers (E-Cadherin, K18 and Na+/K+ATPase β1) upon 48 hours of metformin treatment (5 and 10 mM) 
in No ORF and x3 cells (left panel). Similarly, right panel presents the levels of the mesenchymal markers N-Cadherin and Slug in these cell 
lines under similar treatments. The values for every gene are presented as fold change referenced to their respective control (0 mM metformin) 
within each cell line. Results in C and E were performed in triplicates, and represent the mean ±SD. *, p < 0.05, **, p < 0.01, ***, p < 0.001.
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Figure 4: Prognostic value of ACSL1/ACSL4/SCD individual or simultaneous (x3) overexpression in early-stage CRC 
patients. Kaplan-Meier plots representing DFS for ACSL1 A. ACSL4 B. SCD C. and x3 D. overexpressing early-stage CRC patients and 
p Log Rank value in the training and validation groups are shown.
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which is resistant to 5-Fluorouracil. The drugs had little 
(Triacsin C), or no effect (A939572) on SW620–5FU-R 
when applied separately. Nonetheless, a strong cooperative 
effect was found upon simultaneous treatment with ACSL 
and SCD inhibitors (Figure 5D).
Since the EMT program observed in x3 cells is 
triggered by the combined action of ACSL with SCD, 
we wanted to assay the effect on EMT of their inhibitors. 
Combined treatment with low doses of these drugs was 
able to reverse the mesenchymal phenotype of x3 cells 
to a situation resembling No ORF cells (Figure 5E). 
Furthermore, this was accompanied by an increase 
in the expression of epithelial markers and a reduced 
expression of EMT-genes in x3 cells (Figure 5F). Hence, 
the pharmacological inhibition of ACSL/SCD network is 
able to counteract the x3 cells EMT features.
Finally, the ability of a compound to discriminate 
cancer cells from their normal counterparts is the basis for 
successful cancer treatment. For this reason, we assayed 
the effect of Triacsin C and A939572 on the viability of 
normal colonocytes. Very importantly, the same inhibitors 
concentrations that caused a massive loss of viability of 
colon cancer cell lines (Figure 5C and 5D) were completely 
ineffective when applied to normal colonocytes CCD18Co 
(Figure 5G). This was further confirmed using another 
normal colon cell line, CCD841 (Figure 5H) resulting in 
a similar behavior. Thus, the inhibition of ACSL1/ACSL4/
SCD axis by means of the selective effect of these drugs on 
cancer cells arises as a promising therapeutic strategy.
DISCUSSION
We show for the first time how the overexpression 
of lipid metabolism genes can lead to EMT induction and 
increased migratory and invasive properties. ACSL1/
ACSL4/SCD overexpression in CRC cells causes a 
phenotypic switch to a mesenchymal-like condition 
characterized by rounded cell morphology and E-Cadherin 
and β-Catenin mislocalization (Figure 1D and 1E). 
This phenotypic change, which leads to an increased 
migration and invasion (Figure 2) is only achieved upon 
overexpression of the three proteins, presumably having 
each of them more partial but differential functions. ACSL1 
may be an initiator of the process since its overexpression 
stimulates EMT genes expression (Supplementary 
Figure S1D). ACSL1 seems also to be fundamental for 
invasive abilities (Figure 2B) which could be caused by 
an increased expression of invasive genes such as matrix 
degrading enzymes. For its part, SCD overexpression 
strongly increases inhibitory phosphorylation of GSK3β 
(Supplementary Figure S1C). This may be a consequence 
of SCD overexpression-induced Akt activation (Figure 2E) 
which phosphorylates and inactivates GSK3β [38, 45, 46], 
avoiding β-catenin degradation and allowing further EMT 
signaling . Indeed, SCD knock-down impairs β-catenin 
signaling and inhibits EMT-like behavior of metastatic 
breast cancer cells [47]. SCD may maintain the network 
signaling through Erk and Akt stimulation (Figure 2E) 
Table 1: Univariate and Multivariate Cox regression analyses for Disease-free survival of the 
ACSL1, ACSL4 and SCD genes, the multivariable model x3 (combined expression of ACSL1, 
ACSL4 and SCD) in stage II CRC samples from the training group and the validation group
Variable Training group (n = 77) Validation group (n = 119)
Low Risk High Risk Unadjusted Adjusted# Low Risk High Risk Unadjusted Adjusted#
R N R N HR (95% 
CI)
P HR (95% 
CI)
P R N R N HR (95% 
CI)
P HR (95% 
CI)
P
ACSL1 10 51 12 26
2.93 
(1.26–
6.81)
0.013
2.34 
(0.91–
6.02)
0.082 5 61 13 58 3.12 
(1.11–8.76)
0.021
3.86 
(1.16–
12.79)
0.017
ACSL4 9 54 13 23
4.92 
(2.09–
11.62)
0
5.6 (2.19–
14.32)
0 8 78 10 41 2.59 (1.02–
6.57)
0.045
2.31 
(0.85–
6.27)
0.1
SCD 3 26 19 51
3.57 
(1.06–
12.08)
0.018
3.13 (0.9–
10.93)
0.046 3 57 15 62 5.32 (1.54–
18.38)
0.002
4.08 
(1.12–
14.9)
0.017
x3 6 46 16 31
5.36 
(2.09–
13.74)
0.000
4.99 
(1.81–
13.77)
0.001 2 58 16 61
9 (2.07–
39.21)
0.0002
8.68 (1.9–
39.66)
6E-04
Abbreviations: HR (95% CI), hazard ratio and corresponding 95% confidence interval from adjusted or unadjusted Cox 
regression analyses; P, p value from adjusted or unadjusted Cox regression analyses; N, N° of patients in each risk group; R, 
N° of patients with relapse.
#Cox regression analyses were adjusted for T stage, Vascular invassion, Perineural invassion, Bowel Obstruction/
Perforation and Age > 70.
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which are key for EMT programs [48]. In fact, oleic acid, 
the main product of SCD, activates Akt pathway while 
palmitic acid has the opposite effect [49]. Very likely, SCD 
maintenance of the cancer preferred MUFA/SFA ratio, is 
the driving force of Erk and Akt signaling as observed in 
lung and prostate cancers [10, 50]. Hence, the SCD-induced 
increase in MUFA content seems crucial to maintain 
EMT and tumor dissemination. We found no evidence 
highlighting any specific role of ACSL4 overexpression 
in EMT onset. However, due to its substrate preference for 
arachidonic acid, and the reported crosstalk with COX-2 
[18, 19], ACSL4 could favor prostaglandin production and 
other inflammatory mediators of EMT [40, 43]. Conversely, 
ACSL4-overexpressing cells display a more epithelial-like 
behavior in wound healing assays (Figure 2A). It could be 
possible that upon feeding EMT, ACSL4 could provide the 
necessary plasticity to revert to the epithelial phenotype 
through a mesenchymal–epithelial transition (MET) [26], 
crucial for the growth and establishment of metastasis.
Even though Warburg-like metabolism seems 
to be present in most malignancies, alternative energy 
sources can be used depending on the tumor context 
Figure 5: Synergistic effect of ACSL and SCD inhibitors on CRC cells. A–B. Dose–response curves of the MTT cell viability 
assays after 48 hours treatment of SW620 and DLD-1 colon cancer cells with increasing concentrations of ACSL inhibitor Triacsin C (A) or 
SCD inhibitor A939572 (B). C. MTT cell viability assays in DLD-1, SW620, HT-29 and LS174T colon cancer cell lines show synergistic action 
on cell viability of low doses of Triacsin C (1 μM) and A939572 (0.5 μM) upon 48 hours treatment. D. Response of SW620–5FU-R cells in 
MTT assays to the 48 hours treatment with different concentrations of Triacsin C and/or A939572. E. Representative phase contrast pictures of 
No ORF and x3 cells treated with vehicle (DMSO), Triacsin C (1 μM) and/or A939572 (0.1 μM) for 48 hours. Scale bars, 100 μm. (Continued )
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[4], suggesting an intrinsic metabolic flexibility for 
cancer cells. ACSL/SCD network promotes migration 
and invasion without main effects on cell proliferation 
(Figure 2). Hence, it is reasonable to think that an 
enhanced lipid metabolism has more implications other 
than support proliferation like pro-proliferative aerobic 
glycolysis. In fact, x3 cells show no increase, but a 
slight decrease in lactate production (Figure 2F). Altered 
lipid metabolism may be more directed to provide 
EMT and invasion. Interestingly, it has been reported a 
monoacylglycerol lipase-governed fatty acid network 
which drives invasion and cancer pathogenesis [51]. This 
could be initially driven by an EMT mechanism as the one 
generated by the ACSL1/ACSL4/SCD axis. On the other 
hand, lipids are important signaling molecules triggering 
a number of protumor pathways. SCD inhibition decreases 
the synthesis of PIP3, crucial for Pi3K/Akt signaling 
[10]. Furthermore, arachidonic acid, the main ACSL4 
substrate, is one of the most common fatty acids of PIP3. 
ACSL, especially ACSL4, also stimulate fatty acid entry 
into β-oxidation [15] which generates not only ATP but 
also redox power necessary to counteract tumor oxidative 
stress [5]. Lipid anabolism and catabolism alterations have 
been proposed to coexist in tumor cells [52]. Therefore, 
an increased fatty acid catabolism caused by ACSL 
overexpression, along with increased de novo fatty acid 
synthesis and advantageous MUFA content upon SCD 
upregulation could generate an array of protumorigenic 
signals capable of supporting malignancies through an 
initial EMT program.
The abnormal metabolism of x3 cells provides 
an energetic advantage crucial to EMT promotion and 
invasiveness. Such is the case, that if energy homeostasis 
is disrupted either upon AMPK signaling reactivation 
(Figure 3) or upon simultaneous chemical inhibition of 
ACSL and SCD (Figure 5E and 5F), epithelial features 
are rescued. Defective AMPK signaling seems to be 
the main mechanism to drive EMT by the ACSL/SCD 
network since interference with other pathways already 
described to cause EMT such as Pi3K/Akt or COX-2 
[43, 48] had no effect on the original phenotype recovery 
(Figure 3C). AMPK could be suppressing EMT through 
the regulation of the Akt-MDM2-Foxo3 signaling axis 
as recently proposed [42]. This is in agreement with the 
increased Akt signaling observed in x3 cells (Figure 2E). 
However, Akt inhibitor IV fails to revert EMT suggesting 
additional pathways affected by AMPK signaling that are 
also needed for a complete rescue. On the other hand, 
SCD downregulation activates AMPK [10, 53] but no link 
has been established between AMPK and ACSL. Since 
free fatty acids are able to activate AMPK [54] ACSL 
overexpression could prevent this activation through the 
conversion of fatty acids into Acyl-CoAs.
ACSL1 implication in triglyceride synthesis [55] 
together with the function of ACSL4 in phospholipids 
channeling [22] suggests an increased lipid synthesis upon 
Figure 5: (Continued ) Synergistic effect of ACSL and SCD inhibitors on CRC cells. F. RT-QPCR analysis showing the x3 cells 
mRNA levels of the epithelial markers E-Cadherin, K18 and Na+/K+ATPase β1 and the mesenchymal markers N-Cadherin and Slug upon 
48 hours of treatment with Triacsin C (1 μM) and/or A939572 (0.1 μM). G–H. MTT cell viability assays in normal colonocytes. CCD18Co 
(G), or CCD841 cells (H), were treated for 48 hours with different concentrations of Triacsin C and/or A939572. Data are represented as 
the mean ±SD (n = 3) in all the plots. C = Vehicle, T = Triacsin C, A = A939572, A+T = A939572+Triacsin C. *, p < 0.05, ***, p < 0.001.
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ACSL overexpression. Its associated lipotoxicity would 
be counteracted by SCD overexpression. Accordingly, x3 
cells have 20% less fat content than No ORF cells (data not 
shown). Thus, either a more efficient energetic use of lipids 
or an abnormally increased metabolism allows malignant 
features of x3 cells. Their advantage does not rely on 
exogenous lipid supply as no variations were found when 
experiments were performed upon serum lipid depletion or 
serum content reduction (data not shown). Besides, there 
was no increase in lipid incorporation neither of oleic acid 
nor palmitic acid into lipid vesicles upon ACSL1, ACSL4 
or SCD overexpression (data not shown). In agreement 
with that, the described monoacylglycerol-lipase invasive 
signature also shows independence from extrinsic fatty 
acids supply [51].
The combined overexpression of ACSL1/ACSL4/
SCD shows a poorer outcome and higher risk of relapse 
when compared to the upregulation of each of the genes 
separately in stage II-CRC patients (Figure 4 and Table 1). 
This suggests an increased aggressiveness of tumors 
overexpressing ACSL/SCD network. This fatty acid 
metabolism switch that acts through an EMT program 
is thus an example of how different types of metabolic 
reprogramming can be used by tumors to increase their 
malignity depending on the needs and the environment 
(Figure 6). The combination of ACSL/SCD inhibitors 
synergistically reduces cancer cells viability without 
decreasing normal cells viability (Figure 5C, 5G and 5H). 
Furthermore, this is also effective in CRC cells resistant 
to conventional chemotherapy (Figure 5D). Therefore, 
this sort of “synthetic lethality” caused by the combined 
action of ACSL and SCD inhibitors represents a new way 
of addressing tumor metabolism and may designate the 
ACSL/SCD axis interference as a promising opportunity 
for cancer treatment.
MATERIALS AND METHODS
Cell culture
Colon cancer cell lines, normal colon cell lines, 
and HEK-293T cells, were obtained from American Type 
Culture Collection (ATCC, Manassas, VA, USA), cultured 
in DMEM supplemented with 10% FBS and maintained 
under standard conditions. SW620–5FU-R cells were 
generated by exposing parental cells to increasing 
concentrations of the drug for 15 months as previously 
described [44]. All cell lines were authenticated by 
microsatellite genotyping. The 3D on top assays were 
performed as previously described [56]. Cells were plated 
in Matrigel (BD Biosciences, Franklin Lakes, NJ. USA) 
at a density of 10000 cells per well in 24-well plates 
and cultured for up to a week. Images were captured 
using a Leica DM IL microscope (Leica Microsystems, 
Wetzlar, Germany), with a 10X Plan Fluotar objective and 
registered using Leica Application Suite (LAS, Leica).
Reagents
Commercial antibodies used are listed in 
Supplementary Table S2. Antibody against SCD-1 [57] 
was a kind gift from Dr. Jean-Baptiste Demoulin, Université 
Catholique de Louvain, Brussels, Belgium. Anti-human 
ACSL4 was generously provided by Dr. Stephen Prescott, 
University of Utah, Salt Lake, USA and Dr. Diana Stafforini, 
Huntsman Cancer Institute, University of Utah, USA, and 
used as indicated in [58]. Triacsin C was purchased from 
Santa Cruz (Santa Cruz, CA, USA); A939572 was from 
Biofine International (Biofine International Inc, Vancouver, 
Canada); Metformin, Phenformin, AICAR, NS-398 and Akt 
Inhibitor IV were from Sigma-Aldrich, (Sigma-Aldrich, St. 
Louis, MO, USA).
Lentivirus-mediated stable overexpression  
of ACSL1, ACSL4 and SCD
HEK 293T cells were transfected using Lipofectamine 
2000 (Life Technologies, Carlsbad CA, USA) with 
lentiviral vectors expressing ACSL1, ACSL4, SCD or No 
ORF empty vector (DNA 2.0, Menlo Park CA, USA) along 
with a set of packaging plasmids (Addgene, Cambridge 
MA, USA). DLD-1 cells were infected with supernatant 
produced upon 48 hours transfection in HEK293T 
cells and 4 μg/μl polybrene (Millipore) as coadjutant. 
Selection was performed during 1 week by adding 
2 μg/ml puromycin, 3 μg/ml blasticidin, and 150 μg/
ml hygromycin, (Sigma) for SCD, ACSL4, and ACSL1 
constructs respectively.
Western blot
Cells were lysed in Laemmli buffer, proteins were 
separated by SDS–polyacrylamide gel electrophoresis 
and transferred onto a nitrocellulose membrane (Bio-Rad 
Laboratories, Hercules, CA, USA). The membranes 
were blocked using 5% nonfat dry milk in TBS 0.05% 
Tween-20. Primary antibodies were incubated overnight at 
4°C and upon 1 hour incubation with secondary antibodies 
signal detection was performed using the Clarity Western 
ECL Substrate (Bio-Rad). β-actin determination or 
Ponceau stain were used as loading controls.
Cell viability assay
Cell viability was determined by seeding 25000 
cells per well in 24-well plates and treated with the 
corresponding compounds for 48 hours. Upon treatment, 
cells were incubated 3 hours with 3-(4,5-dimethyl-thyazol-
2-yl)-2,5-diphenyl-tetrazolium (MTT, Sigma). The 
resultant formazan was dissolved in DMSO and its quantity 
determined by measuring absorbance at 560 nm. Data were 
expressed as the ratio of viable cells (%) which represents 
the percentage of viable cells upon treatment compared with 
the non-treated cells (100% ratio of viable cells).
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L-Lactate quantification
Cells were seeded at a density of 5000 cells per well 
in a 96-well plate. At 12 hours, medium was changed to 2% 
FBS and kept for 24 hours at 37°C before quantification. 
Using Cayman’s Glycolysis cell-based assay (Cayman, 
Ann Arbor, MI, USA, 600450) extracellular L-Lactate was 
measured by determining absorbance at 490 nm.
Quantitative real-time PCR
Total RNA was extracted using Tri Reagent 
(Sigma). 400 ng of RNA were reverse-transcribed using 
the High Capacity RNA-to-cDNA Master Mix system 
(Life Technologies). qPCR was performed in the 7900HT 
Real-Time PCR System (Life Technologies) using 
VeriQuest SYBR Green qPCR Master Mix (Affymetrix, 
Santa Clara, CA, USA) and gene specific primers listed 
in Supplementary Table S3. Values were corrected by 
GAPDH expression. The 2−∆∆Ct method was applied to 
calculate the relative gene expression.
Immunofluorescence
Cells were fixed with 4% paraformaldehyde for 
10 minutes at room temperature, then permeabilized 20 
minutes with 0.5% triton X-100, and stained with the 
primary antibody (1:100) followed with incubation with 
Alexa 488-conjugated anti-mouse secondary antibody 
(1:1000) and/or with DAPI (Prolong Gold antifade, Life 
Technologies) to visualize nuclei. Images were captured 
using a Leica DM IL microscope, with a 20X Plan Fluotar 
objective and registered using Leica Application Suite 
(LAS).
EdU incorporation assay
Cells were plated on coverslips and incubated 
24 hours before treatment with 10 μM EdU for 3 hours. 
In the case of the EdU assays in confluent conditions, 
EdU treatment was added once cells reached 
confluence. Cells were fixed with paraformaldehyde 
(4%) for 8 minutes and incorporation of EdU was 
Figure 6: ACSL/SCD-mediated tumor metabolic reprogramming. The combined action of ACSL1, ACSL4 and SCD confers an 
energetic advantage to tumor cells that stimulates several EMT-promoting and survival pathways. Lipid metabolism switches Warburg-like 
tumor metabolism into EMT-like tumor metabolism leading to a gain of mesenchymal and stem cell properties as well as migratory and 
invasive capabilities. This process can be reversed upon re-activation of AMPK signaling.
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assayed using Click-iT® EdU Alexa Fluor® 488 
Imaging Kit (Life Technologies). Coverslips were 
mounted on slides and nuclear DNA stained with 
DAPI. Images were captured using a Leica DM IL 
microscope, with a 40X Plan Fluotar objective and 
registered using LAS software.
Invasion assays
A density of 50000 cells was seeded into the inserts 
of a BD MatrigelTM invasion chamber (BD Biosciences) 
in serum-free DMEM. Medium containing 10% FBS 
was placed in the lower chamber as a chemoattractant. 
After 48 hours, inserts were fixed and stained with crystal 
violet, non-migrated cells removed using cotton swabs and 
images captured using an Olympus CKX41 microscope 
(Olympus, Tokyo, Japan), with a 20X LCAch objective 
and registered using analysis getIT software (Olympus)
Clonogenic assay
Single cell suspensions were seeded in 6-well plates 
at a density of 300 cells per well in 10% FBS DMEM. 
After 2 weeks, colonies were fixed and stained with crystal 
violet. Wells were photographed and colonies counted.
Wound healing assays
Cell migration was assayed using 24-well plates 
with IBIDI Culture-Inserts (IBIDI GmbH, München, 
Germany), where no cell damage occurs. 40000 cells were 
seeded into the two reservoirs of the same culture insert 
and incubated until confluence was reached. Inserts were 
removed and migration was monitored by taking pictures 
every 12 hours using a Leica DM IL microscope, with a 
10X Plan Fluotar objective.
Patients and samples
80 patients as training and 120 as validation set of 
stage II CRC patients undergoing surgery between 2000–
2004 and 2004–2008 respectively in La Paz University 
Hospital, were enrolled in the study. Formalin-Fixed, 
Paraffin-Embedded (FFPE) samples were obtained with 
the patient's authorization and with the approval of the 
human research Ethics review Committee of La Paz 
University Hospital (HULP-PI-1452). Inclusion criteria: 
Age ≥18, completely resected rectal cancer or colon 
adenocarcinoma located at ≥15 cm of the anal verge as 
determined by endoscopy or above the peritoneal reflection 
in the surgical resection, confirmed Stage II AJCC/
UICC primary CRC and follow-up of at least 36 months. 
Exclusion criteria: death within 30 days after surgery, 
other cancers in previous 5 years and inflammatory bowel 
disease or specific gene-related cancer.
Statistical analysis
Significance between groups was determined by 
t-test analyses. Data with P < 0.05 were considered 
statistically significant (*, P < 0.05; **, P < 0.01; ***, P 
< 0.001). Disease free survival (DFS) was estimated using 
Kaplan-Meier method. Log-rank test and Univariate Cox 
regression analysis was performed to test the association 
between DFS and gene expression. Hazard ratios (HR) 
and 95% CI were calculated from the Cox regression 
model, adjusted for potential confounding factors. All 
reported p values were two-sided. Statistical significance 
was defined as p < 0.05. The statistical analyses were 
performed using the R statistical software version 2.15 
(http://www.r-project.org).
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SUPPLEMENTARY FIGURES AND TABLES
Supplementary Figure S1: Individual overexpression of ACSL1, ACSL4 and SCD is not sufficient to promote complete 
EMT morphological program. A. Fluorescence microscopy showing normal distribution of E-Cadherin (green) in No ORF, ACSL1, 
ACSL4, SCD and x3 cells. Arrows indicate the differential cellular distribution of E-Cadherin in control and x3 cells. No morphological 
changes are observed in phase contrast images (bottom panels) except for x3 cells. Scale bars, 50 μm. B. RT-QPCR analysis of epithelial 
genes E-Cadherin (left panel), Keratin 18 (central panel) an Na+/K+ATPase β1 (right panel). A decrease in mRNA levels is only found in the 
case of x3 cells compared to control No ORF and ACSL1, ACSL4 and SCD cells. C. Levels of GSK3 phosphorylation detected by Western 
Blot using a phospho-specific antibody (Ser21/9). Total GSK3β levels detection and Ponceau-stained band served as loading controls. 
Bottom panel: Quantification of bands intensity showing the ratio of phosphorylated to total protein. D. ACSL1 stable overexpression alone 
increases EMT genes expression levels but this is insufficient to drive a complete phenotypical change. Mesenchymal genes (N-Cadherin, 
Slug and Vimentin) expression levels were measured by RT-QPCR. Experiments in B and D were performed in triplicates (n = 3). Results 
represent the mean ±SD (n = 3). *, p < 0.05, **, p < 0.01, ***, p < 0.001.
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Supplementary Figure S2: Absence of major changes in proliferation upon ACSL1, ACSL4 and SCD overexpression 
in confluent conditions. Quantification using fluorescence microscopy of EdU incorporation in confluent cells as a measure of cell 
proliferation. Experiment was performed in triplicates (n = 3). Results represent the mean ±SD (n = 3).
Supplementary Table S1: Clinical and histopathological characteristics of patients
Characteristics Stage II CRC
Training group Validation group
n° of 
Patients
(%) n° of 
Patients
(%)
Total sample size (n) 77 (100) 119 (100)
Age at Diagnosis (years)
Mean 68.22 66.08
Median 69 66
Age Range 32–86 26–91
<70 42 (54.55) 73 (61.34)
≥70 35 (45.45) 46 (38.66)
Gender
Female 33 (42.86) 54 (45.38)
Male 44 (57.14) 65 (54.62)
Stage
IIA (T3 N0 M0) 56 (72.73) 70 (58.82)
IIB (T4 N0 M0) 21 (27.27) 49 (41.18)
Total Lymph Nodes Resected
Mean Lymph nodes resected 12.09 14.20
Range of Lymph nodes examined 1–29 0–43
≤12 46 (59.7) 54 (45.4)
>12 30 -39 62 (52.1)
Unknown 1 (1.3) 3 (2.5)
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Characteristics Stage II CRC
Training group Validation group
n° of 
Patients
(%) n° of 
Patients
(%)
Location of Primary
Cecum and Ileocecal Valve 2 (2.6) 13 (10.92)
Acending colon and Hepatic flexure 29 (37.66) 29 (24.37)
Transverse colon 6 (7.79) 6 (5.04)
Splenic flexure and Descending colon 5 (6.49) 17 (14.29)
Sigmoid colon and rectosigmoid junction 34 (44.16) 54 (45.38)
Rectum 1 (1.3) 0
Grade/Differentiation
Well 5 (6.49) 10 (8.4)
Moderately 66 (85.71) 95 (79.8)
Poor 5 (6.49) 10 (8.4)
Unknown 1 (1.3) 4 (3.4)
Bowel Obstruction/Perforation
Yes 10 (12.99) 45 (37.82)
No 67 (87.01) 74 (62.18)
Other Histological Features
Perineural invasion 12 (15.58) 25 (21)
Vascular invasion 22 (28.57) 31 (26.05)
Adjuvant treatment
Yes 47 (61.04) 76 (63.87)
No 30 (38.96) 43 (36.13)
Disease-free survival
Patients with recurrence 22 (28.57) 18 (15.13)
Overall survival
n° of Exitus 13 (16.88) 11 (9.24)
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Supplementary Table S2: Commercial antibodies used in this study
Name Company Cat No
Anti-E Cadherin antibody [HECD-1] Abcam ab1416
Purified Mouse Anti-β-Catenin BD Transduction 610154
ACSL1 Rabbit Polyclonal Antibody Cell Signaling 4047
Phospho-Acetyl-CoA Carboxylase (Ser79) Antibody Cell Signaling 3661
Acetyl-CoA Carboxylase (C83B10) Rabbit mAb Cell Signaling 3676
Phospho-Akt (Ser473) Polyclonal Antibody Cell Signaling 9271
Akt (pan) (C67E7) Rabbit mAb Cell Signaling 4691
Phospho-GSK-3α/β (Ser21/9) Rabbit Polyclonal Antibody Cell Signaling 9331
GSK-3β (27C10) Rabbit mAb Cell Signaling 9315
p-ERK (E4) Mouse mAb Santa Cruz sc-7383
ERK2 (C-24) Rabbit Polyclonal Antibody Santa Cruz sc-154
Monoclonal Anti-β-Actin, mouse antibody Sigma A1978
Horseradish peroxidase conjugated antibody anti-mouse Millipore AP308P
Horseradish peroxidase conjugated antibody anti-rabbit Millipore AP307P
Alexa 488-conjugated anti-mouse antibody Invitrogen A-11001
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Supplementary Table S3: Primers used for quantitative real-time PCR
Gene name forward primer reverse primer
ACSL1 ACATTATGTTCCTGGGCCCA AGTCAGAAGGCCATTGTCGA
ACSL4 GGCACAACAGAAAGGGGTAG GGTTCCTCAGCTCCTTCCTT
SCD-1 TGCCCACCACAAGTTTTCAG CATCAGCAAGCCAGGTTTGT
E-CADHERIN (CDH1) GAACGCATTGCCACATACAC GAATTCGGGCTTGTTGTCAT
KERATIN 18 (KRT18) GAGTATGAGGCCCTGCTGAA CAGACACCACTTTGCCATCC
NA+/K+ATPASE B1(ATP1B1) GCCTCCCAAGAATGAGTCCT ATTTGGGCTGCAGGAGTTTG
N-CADHERIN (CDH2) CGGTTTCATTTGAGGGCACA TTGGAGCCTGAGACACGATT
SLUG (SNAI2) CGTTTTCCAGACCCTGGTT CTGCAGATGAGCCCTCAGA
VIMENTIN GAGTCCACTGAGTACCGGAG ACGAGCCATTTCCTCCTTCA
COX-2 ATCACAGGCTTCCATTGACC CAGGATACAGCTCCACAGCA
CD44 AGCAGCGGCTCCTCCAGTGA CCCACTGGGGTGGAATGTGTCT
LGR5 TCCAACCTCAGCGTCTTCAC CGCAAGACGTAACTCCTCCA
ALDH1A1 TGTTAGCTGATGCCGACTTG TTCTTAGCCCGCTCAACACT
EPCAM CGCAGCTCAGGAAGAATGTG TGAAGTACACTGGCATTGACG
CD29(ITGB1) CATCTGCGAGTGTGGTGTCT GGGGTAATTTGTCCCGACTT
GAPDH TGGTATCGTGGAAGGACTCATGAC ATGCCAGTGAGCTTCCCGTTCAGC
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PUBLICATION II SUMMARY  
 
Complementary ACSL isoforms contribute to a non-Warburg advantageous energetic status 
characterizing invasive colon cancer cells 
In this work we aimed to clarify the individual contribution and functional differences of the 
participating enzymes in the context of the whole network action. Here we show how 
deregulation of metabolic enzymes leads to global metabolic editing to fuel tumour 
transformation associated with the invasive features of cancer cells. Using the XCelligence 
technology to assay real-time cell proliferation in DLD-1 CRC cells stably overexpressing either 
ACSL1, ACSL4 or SCD, a clear increase in proliferation was only found upon ACSL4 overexpression 
when compared to control cells. However, proliferation rates were similar to the control in the 
case of ACSL1 cells and reversed in SCD proliferating cells. In addition, wound healing assays 
showed that ACSL4 cells presented a faster unidirectional migration of cohesive epithelial sheets 
that could be related to proliferation stimulation. Conversely, significantly more ACSL1 cells 
were able to invade through matrigel when compared to ACSL4 or control cells. ACSL1 
overexpression, but not ACSL4, stimulated N-cadherin or Slug expression, well-known 
mesenchymal markers related to invasion and metastasis. 
Through the extracellular acidification rate (ECAR) analysis using a Seahorse bioanalyzer, we 
observed that ACSL4 cells displayed the highest glycolytic function; according to their 
proliferative potential. In turn, ACSL4 presented an oxygen consumption rate (OCR) similar to 
control cells, indicating no altered performance of the mitochondria; while ACSL1 basal OCR was 
significantly lower, reflecting the mitochondria diminished workflow and probably an enhanced 
energetic status. All these data highlighted the different contributions to cancer cell features of 
each isoform with distinctive tumorigenic features in cancer cells. To gain insight into individual 
metabolic differences the axis enzymes, we performed metabolomics analysis using the 
Metabolon ® platform. ACSL1 overexpressing cells were mostly characterized by an increase in 
acylcarnitine levels that could be due to fatty acid oxidation reduction in mitochondria 
corresponding with the lower OCR previously found for ACSL1 cells. However, polyunsaturated 
fatty acids (PUFA) were the most remarkable feature of ACSL4 cells, probably reflecting the 
greatest utilization for membrane biogenesis. In SCD cells, mono-unsaturated fatty acids 
(MUFA), SCD natural products were elevated in a predictable fashion. The most outstanding 
results were obtained in x3 cells (494 differential biochemicals) where we found increased 
phospholipids levels of different classes; basic components of cell membranes, cell proliferation 
and cancer signaling 51,56,57. Furthermore, x3 cells showed an elevation of some urea cycle 
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derived metabolites, such as polyamines, extensively related to cell proliferation and growth 
219,220. Creatine and creatine phosphate, also found elevated, were in line with a more favourable 
energy status. Curiously, this altered metabolism in x3 cells is not associated with an increased 
proliferation, as demonstrated by real-time cell proliferation assays. Thus, x3 cells altered 
metabolic profile should be fuelling malignant characteristics other than proliferation, as 
invasiveness or a more favoured energetic balance.  Creatine levels in x3 cells was also assayed, 
as well as in several CRC invasive/metastatic cell lines. These cell lines presented increased 
creatine levels compared with less invasive and primary tumor-derived cells, suggesting that the 
creatine levels can be a common feature of CRC cells invasiveness and metastatic capacity. On 
the other hand, OCR analysis was performed in x3 cells and their control counterpart as well as 
in the well-known metastatic CRC cell line sw620 and its control primary tumor-derived cell line 
SW480. Invasive/Metastatic cell lines, x3 and SW620, presented a decreased basal rate of 
mitochondria oxidation when compared with their corresponding control non-invasive cells 
without major changes in glycolysis (ECAR). This reduced basal oxidative metabolism was in 
accordance with less oxidative stress in x3 cells, as was revealed by increased reduced 
glutathione (GSH) levels in x3 and sw620 cells.  
 
PUBLICATION II CONCLUSIONS  
 ACSL isoforms show functional and metabolic differences. ACSL4 fuels proliferation and 
migration accompanied by a more glycolytic phenotype. ACSL1 stimulates invasion 
displaying a lower basal respiration. 
 The elevation of acylcarnitines, lower levels of PUFA, and the upregulation of MUFA are 
the most remarkable metabolic features of the individual overexpression of ACSL1, 
ACSL4 and SCD. 
 Higher phospholipid levels and urea cycle upregulation characterize ACSL/SCD action as 
a network, a differential phenotype that cannot be explained by additive functions of 
each enzyme separately. 
 ACSL/SCD network produce more energetically efficient cells which present lower basal 
respiration levels and upregulated creatine pathway. These features also characterize 
other invasive and metastatic cells. 
 ACSL/SCD network exemplifies specific metabolic adaptations for invasive cancer cells. 
I contributed to the whole experimental part, with special emphasis in Metabolon analysis and in 
Seahorse experiments. I also contributed to the manuscript elaboration and response to 
reviewers.  
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Complementary ACSL isoforms 
contribute to a non-Warburg 
advantageous energetic status 
characterizing invasive colon cancer 
cells
Ruth Sánchez-Martínez, Silvia Cruz-Gil, María Soledad García-Álvarez, Guillermo Reglero & 
Ana Ramírez de Molina
Metabolic reprogramming is one of cancer hallmarks. Here, we focus on functional differences 
and individual contribution of acyl coA synthetases (ACSL) isoforms to the previously described 
ACSL/stearoyl-CoA desaturase (ACSL1/ACSL4/SCD) metabolic network causing invasion and poor 
prognosis in colorectal cancer (CRC). ACSL4 fuels proliferation and migration accompanied by a more 
glycolytic phenotype. Conversely, ACSL1 stimulates invasion displaying a lower basal respiratory 
rate. Acylcarnitines elevation, polyunsaturated fatty acids (PUFA) lower levels, and monounsaturated 
fatty acids (MUFA) upregulation characterize the individual overexpression of ACSL1, ACSL4 and 
SCD, respectively. However, the three enzymes simultaneous overexpression results in upregulated 
phospholipids and urea cycle derived metabolites. Thus, the metabolic effects caused by the network 
are far from being caused by the individual contributions of each enzyme. Furthermore, ACSL/SCD 
network produces more energetically efficient cells with lower basal respiration levels and upregulated 
creatine pathway. These features characterize other invasive CRC cells, thus, ACSL/SCD network 
exemplifies specific metabolic adaptations for invasive cancer cells.
Cancer energy relies on metabolic editing to fuel malignant transformation1. A great deal of effort has been done 
to characterize tumours metabolic phenotypes and new oncometabolites are constantly being described as mark-
ers of the disease2. Besides well-known carbohydrate metabolism alterations, it is becoming clear that there is an 
increasing range of metabolic adaptations that tumours can use to sustain their growth3–9.
Metabolic changes in cancer cells are often linked to growth and survival pathways driving different aspects of 
tumorigenesis. For instance, glycolytic behaviour associates with Akt and Erk pathways10–13, while Myc oncogene 
could govern glutamine addiction14. Alterations in lipid metabolism, both catabolic and anabolic, are part of the 
metabolic reprogramming that occurs in tumour cells in response to gene mutations, loss of tumour suppressors 
and epigenetic modifications15,16. Fatty acid (FA) metabolism enzymes have been found to be essential for neo-
plastic growth17–20 as well as lipid signalling triggers key tumorigenic pathways21–23.
Interconnection of metabolic pathways allows that metabolic enzymes deregulation in cancer exert unex-
pected effects on non-directly related routes24. Besides, cross-talk with tumorigenic pathways can cause activation 
of further metabolic routes triggered by core cancer signalling. This way, metabolic enzymes deregulation not 
only affect the proportion of their expected substrates and products as well as their immediate pathways. In some 
cases, substantial changes in unexpected parallel metabolic routes can be observed, allowing the connection with 
cell cycle regulation, redox management and other changes favouring different tumour cells characteristics25,26.
We have previously described a lipid network able to trigger epithelial-mesenchymal transition (EMT) and 
invasion, which is overexpressed in colorectal cancer (CRC) patients with poorer outcomes19. This network com-
prises ACSL1 and ACSL4, members of the fatty acid activating enzymes acyl coA synthetases (ACSL), critical for 
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lipid synthesis, modification and β-oxidation27; and the stearoyl-CoA desaturase (SCD), the main enzyme con-
trolling the rate of saturated (SFA) vs unsaturated fatty acids (MUFA)28, crucial for cancer cells29. These enzymes 
have been related to the prognosis and progression of several malignancies30–36. Despite ACSL isoforms can cat-
alyse the same reaction, to bind a molecule of Acetyl–CoA to a fatty acid giving rise to an Acyl-CoA, there is 
increasing evidence for a specialization in the substrates, functions and cellular localizations. ACSL1 has been 
reported to be more inclined to triglyceride synthesis37,38. In contrast, ACSL4, that prefers longer polyunsaturated 
fatty acids (PUFA) as substrates such as arachidonic acid, has been proposed to channel FA towards phospho-
lipids39. Here we further analyse the individual contributions of each enzyme to the ACSL/SCD network and the 
metabolic characteristics accompanying ACSL/SCD invasive cells. We present an example on how deregulation 
of metabolic enzymes gives rise to global metabolic changes that derive into specific ways of tumour fuelling 
associated with the invasive features of cancer cells.
Results
Metabolic differences correspond to diverse protumorigenic features conferred by ACSL1 and 
ACSL4 isoforms. In an earlier report, we described an ACSL1/ACSL4/SCD network causing EMT and inva-
sion in CRC cells19. To address more in detail the individual contributions of each enzyme integrating the ACSL/
SCD axis we started investigating the differences among ACSL1 and ACSL4 isoforms. First, using DLD-1 CRC 
cells stably overexpressing ACSL1 or ACSL4 proteins (ACSL1 or ACSL4 cells)19 we assayed cell proliferation. We 
used XCelligence technology to monitor real-time cell proliferation of these cell lines. ACSL4 overexpression 
caused the highest increase in proliferation when compared to control No ORF cells (Fig. 1A). Accordingly, the 
use of shRNAs against ACSLs (Supplementary Figure 1) caused the opposite effect, being again ACSL4 the iso-
form whose depletion caused the strongest effect on proliferation (Fig. 1B). The same tendency was observed in 
ACSL1 overexpressing or depleted cells, however, the effect was less marked. Specially, ACSL1 cells almost prolif-
erated at a similar rate to the No ORF control cells. Curiously, SCD caused a reverse effect, decreasing prolifera-
tion rate upon overexpression (SCD cells19) and a proliferation increase in the case of shSCD cells (Fig. 1A,B and 
Supplementary Figure 1). Wound healing assays are normally performed to assay migratory capacity. However, 
wounds can be closed by unidirectional migration of cohesive epithelial sheets that can be related to proliferation 
abilities. Would healing assays show that ACSL4 cells were able to close the wound faster than the ones overex-
pressing ACSL1 (Fig. 1C), displaying this collective unidirectional migration of cohesive epithelial sheets that 
could be related to the stimulatory effect of ACSL4 on proliferation (Fig. 1A). Conversely, significantly more 
ACSL1 cells were able to invade through matrigel when compared to ACSL4 or poorly invasive DLD-1 No ORF 
control cells (Fig. 1D). Correspondingly, ACSL1 overexpression but not ACSL4 stimulated N-cadherin or Slug 
expression (Fig. 1E), well-known EMT markers involved in cancer invasion and metastasis40,41. This mesenchy-
mal tendency of ACSL1 cells could lead them to close the wound more efficiently than No ORF control cells as 
can be inferred from the wound closure morphology (Fig. 1C). Taken together, these results highlight the differ-
ent contributions to cancer cell features of both isoforms.
It is well know the relation between metabolic alterations fuelling different malignant aspects of tumour cells, 
such as the pro-proliferative Warburg effect42. For this reason, we wanted to check the glycolytic potential, as the 
aerobic glycolysis is one of the most remarkable features of proliferative cancer cells. Extracellular acidification 
rate was measured to assay glycolytic function of ACSL1, ACSL4 and No ORF control DLD-1 cells. In accordance 
with their proliferative potential, the highest basal glycolysis, glycolytic capacity and reserve was found for ACSL4 
cells when compared to No ORF cells, finding an intermediate glycolytic phenotype for ACSL1 cells (Fig. 2A,B). 
We further wanted to check the oxidative metabolism reflecting the mitochondrial activity of these cell lines 
(Fig. 2C). Differently, ACSL4 presented both, a basal and maximal oxygen consumption rate (OCR) similar to 
No ORF cells, however, ACSL1 basal OCR was significantly lower than the other cell clones, highlighting again 
the metabolic differences among ACSL isoforms. Consequently, knocking down of ACSLs by shRNA means pre-
sented the opposite effect. In this case, shACSL1 cells presented the highest basal and maximal OCR, and again, 
ACSL4 and control (shCtrl) cells presented a parallel behaviour (Fig. 2D). All these data suggest that different 
metabolic performances are associated with distinctive tumorigenic features in cancer cells.
Metabolic profiling segregates ACSL isoforms and malignant features of CRC cells. To gain 
further insight into the functional differences between ACSL1 and ACSL4, and to elucidate the metabolic fea-
tures corresponding to the ACSL/SCD network enzymes, we performed metabolomics analysis using ACSL1 and 
ACSL4 cells together with the corresponding DLD-1 cells overexpressing SCD (SCD cells) and the three enzymes 
at the same time (x3 cells)19. A total of 494 differential biochemicals were identified. Figure 3A shows a summary 
of the numbers of metabolites that achieved statistical significance (p ≤ 0.05), as well as those with approaching 
significance (0.05 < p < 0.10). A principal component analysis, (PCA), was done to visualize how samples, within 
a group, cluster with respect to their data-compressed “principle components”. Figure 3B shows how all sample 
groups were well segregated from each other based on differences in their overall metabolic signature. According 
to this analysis, ACSL1 samples were the ones that were less separated from No ORF control ones, and, thus, more 
similar regarding their metabolic profiles. In contrast, the combination of overexpressed enzymes (x3) generated 
an overall metabolite profile most significantly diverged from the control.
Regarding the individual metabolic characteristics for each enzyme overexpression, ACSL1 cells were mostly 
characterized by an increase in acylcarnitine levels (Fig. 3C, Supplementary File 1). While ACSL4 and SCD 
cells also displayed some increases in acylcarnitines relative to control, ACSL1 was consistently the highest. 
Acylcarnitines are generated through the transfer of carnitine for CoA on acyl-CoA derivatives of long-chain FA 
by carnitine palmityoltransferase (CPT), to transport them through the mitochondrial membrane. Thus, elevated 
acylcarnitine levels can be due to increased CPT activity resulting from an increase in the cytoplasmic acyl-CoA 
substrate levels, such as the ACSL1 products.
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Figure 1. Comparison of protumorigenic capabilities conferred by ACSL isoforms to CRC cells. (A) Real-
time monitoring of cell proliferation for cells overexpressing ACSL1, ACSL4, SCD, both individually or 
simultaneously (x3). (B) Real-time monitoring of cell proliferation for cells stably expressing shRNAs for ACSL1 
(shACSL1), ACSL4 (shACSL4), SCD (shSCD) or scramble (shCtrl). Representative experiments are shown. Bar 
chart indicates the curves slope (proliferation rate) as the average of 3 independent experiments (n = 3). (C) 
Phase contrast pictures of wound healing assay comparing migratory capacities of No ORF, ACSL1 and ACSL4 
cells. Quantification (right panel) shows the different behaviour of control, ACSL1 and ACSL4 cells at 24 hours 
of wound closure. Scale bars, 100 μm. (D) Boyden chamber transwell assay of 48 hours of invasion through 
Matrigel. Migratory cells were quantified as the average number of cells found in five random microscope fields 
in three independent inserts. Scale bars, 50 μm. (E) RT-QPCR analysis of mesenchymal genes (N-Cadherin and 
Slug) for ACSL1 and ACSL4 cells compared to levels in No ORF control cells. Experiments were performed in 
triplicates (n = 3). Results represent the mean ± SD (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 2. Bioenergetic characterization of ACSL1 and ACSL4 isoforms. (A) Glycolytic profile of No ORF, 
ACSL1 and ACSL4 cells. Cells were starved 1 h and a half and Extracellular Acidification Rate (ECAR) levels 
were measured using a Seahorse extracellular flux analyser. Addition of 10 µM glucose was used for the 
measurement of glycolysis rate. Maximal ECAR was measured upon 0.5 µM Oligomycin treatment. 50 mM 
2-DG inhibits all glycolysis showing non-glycolytic acidification. Right panel shows the quantification of 
Glycolysis (measurement of glycolytic process rate), Glycolytic Capacity (Maximum response to glycolytic 
demand from stress) and Glycolytic Reserve (Reserve capacity available to utilize glycolysis beyond the 
basal rate). (B) Average quantification of glycolytic parameters in 3 independent experiments (n = 3) with 
12 replicates each. (C) Oxygen consumption rate (OCR) of No ORF, ACSL1 and ACSL4 cells. Bioenergetics 
parameters were obtained by adding 2 µM Oligomycin to block ATP-linked OCR, 0.2 µM FCCP to uncouple 
mitochondria for maximal OCR and 0.5 µM Rotenone/Antimycin A (Rot/AA) to shut down mitochondrial 
respiration. Right panel reflects the quantification of basal respiration (oxygen consumption used to meet 
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In spite of belonging to the same family that ACSL1 and the possibility to perform equivalent reactions, 
lower levels of polyunsaturated fatty acids (PUFA) were the most remarkable feature of ACSL4 cells (Fig. 3D, 
Supplementary File 1). Not surprisingly, among the significantly downregulated PUFA we can find all preferred 
ACSL4 substrates, such as arachidonate, docohexanoate and eicosapentaenoate. ACSL1 cells presented down-
regulated PUFA levels as well, even though it was not so marked as in ACSL4 cells, suggesting certain function 
overlapping.
As expected, several monounsaturated fatty acids (MUFA) were elevated relative to control in the SCD overex-
pressing cells, while their corresponding saturated substrate fatty acids were not (Fig. 3E, Supplementary File 1). 
Palmitoleate, one of the main products of SCD was clearly upregulated in these cells. Even though we did not find 
an elevation of the enzyme main product, oleate (18:1n9), this can be explained by conversion into eicosenoate 
(20:1n9) and erucate (22:1n9) upon elongase action.
The most striking results were found for the x3 cells. Figure 4 shows the main metabolic pathways enriched 
upon ACSL1, ACSL4 and SCD simultaneous overexpression, mainly involved in fatty acid, carbohydrate, nucle-
otides and energy metabolism. As a first distinctive feature, x3 cells showed higher levels of many phospholipids 
in the phosphatidylcholine, phosphatidylethanolamine and phosphatidylinositol classes (Fig. 5A, Supplementary 
File 1). Phospholipids make up the largest lipid component of cell membranes, crucial for cell proliferation and 
cancer signalling. x3 cells also displayed elevated choline and choline phosphate levels (Fig. 5A) that could be a 
result of phospholipid degradation, but lysolipids are generally down in the SCD and x3 cells, consistent with a 
decrease in phospholipid turnover (Supplementary File 1). In addition, many monoacylglycerols were up in x3 as 
well as in SCD relative to No ORF cells (Fig. 5A, Supplementary File 1). Other lipids varied in an opposite sense, 
such as sphinganine whose levels drop precipitously in x3 cells while, accordingly, products downstream of sphin-
ganine were elevated, such as phosphoethanolamine, the ceramide N-palmitoyl-sphingosine and sphingomyelin 
(Supplementary Figure 2 and Supplementary File 1).
The second distinctive feature of ACSL/SCD axis was the elevation of some urea cycle derived metabolites 
(Fig. 5B). The highly-elevated polyamines spermine and spermidine derive from the urea cycle metabolite 
ornithine and other urea cycle metabolites such as arginine, ornithine and urea were also elevated (Fig. 5C). 
Elevated polyamine levels have been associated with increased cell proliferation and other malignant features43,44. 
Moreover, creatine and creatine phosphate were also elevated in x3 cells, potentially indicating a more favourable 
energy status in those cells relative to the other clones (Fig. 5C).
The glycolysis pathway was also altered in x3 cells. The intermediates dihydroxyacetone phosphate, 
3-phosphoglycerate and phosphoenolpyruvate (PEP) were strongly elevated in x3 cells (Supplementary Figure 3 
and Supplementary File 1). PEP levels elevation could be due to a decline in pyruvate kinase (PK), or an increase 
in phosphofructosekinase-1 (PFK-1) activities. Despite the much higher PEP levels, pyruvate levels were not sig-
nificantly changed. PK activity can be down-regulated by increases in Acetyl-CoA levels, coincident with higher 
Acetyl-CoA in x3 cells. PFK-1 increased activity is also supported by decreased levels of the PFK-1 substrate, 
fructose-6-phosphate and elevation of its product, fructose 1,6-bisphosphate, up in x3 cells (Supplementary 
Figure 3 and Supplementary File 1).
Increases in the amount of phospholipids, sphingomyelins and ceramides and polyamines, have been reported 
to stimulate proliferation23,44. Thus, the more aggressive characteristics of x3 cells could be due to an increased cell 
proliferation. We have previously reported that the simultaneous overexpression of ACSL/SCD was not accom-
panied of increased proliferation19. Figure 1A shows how ACSL1/ACSL4/SCD simultaneous overexpression (x3 
cells) not only does not increase cell proliferation but also causes the opposite effect, presenting the lowest prolif-
eration rate among all the cell lines. Thus, x3 cells altered metabolic profile should be fuelling malignant charac-
teristics other than proliferation, as invasiveness or a favoured energetic balance. In this sense, more invasive and 
metastatic CRC cell lines presented increased creatine levels compared with less invasive and primary tumour 
derived cells (Fig. 6). Hence, upregulated creatine pathway (Figs 4, 5C and 6) could reflect a more favourable 
energy status that could be crucial for processes other than cell proliferation such as cell invasion.
ACSL/SCD overexpression phenocopies metabolic features of metastatic cells. This improved 
energetic status was further studied by analysing OCR in x3 cells. This invasive cell line presented a decreased 
basal OCR when compared with non-invasive No ORF cells (Fig. 7A), that, consequently, derived in a decreased 
OCR consumption under stressed conditions (FCCP addition). However, differences were not so patent when 
glycolysis was assayed, since extracellular acidification rate (ECAR) was mostly similar (or slightly less) to con-
trol cells (Fig. 7B). When both parameters of cell metabolism were analysed in a combined way, without main 
differences in glycolysis, the core dissimilarity was a lesser basal rely of oxidative metabolism in mitochondria 
(Fig. 7C). This attenuated basal oxidative metabolism is in accordance with less oxidative stress in x3 cells, as is 
reflected by increased reduced glutathione (GSH) levels in x3 cells (Fig. 7D) and upregulated general glutathione 
metabolism (Fig. 4 and Supplementary File 1).
We wondered if these metabolic differences identified in ACSL/SCD overexpressing cells were a common 
feature of other invasive cells. For this purpose, we comparatively studied metabolic differences among primary 
tumour SW480 cells and SW620 cells, derived from a metastasis of the same patient. Interestingly, the metastatic 
cellular ATP demand, calculated by subtracting non-mitochondrial OCR obtained upon Rot/AA addition) and 
spare respiratory capacity (capability to respond to an energetic demand, calculated as the difference between 
maximal and basal OCR). (D) OCR measurements over time for cells stably expressing shRNAs for ACSL1 
(shACSL1), ACSL4 (shACSL4) or scramble (shCtrl) and respiratory parameters quantification (right panel). A, 
C and D show representative experiments of 3 or 4 experiments (n = 3).
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Figure 3. Individual overexpression of ACSL1, ACSL4 or SCD associates to changes in specific sets of 
metabolites. (A) Metabolomic analysis statistical summary of colon cancer cells overexpressing ACSL1, ACSL4 
and SCD. Table indicates the number of biochemicals with statistical significance (p ≤ 0.05) or with approaching 
significance (0.05 < p < 0.10) from dataset analysis with a total 494 named biochemicals detected. Black numbers 
indicate upregulated metabolites as grey colour indicates the downregulated ones. Welch’s two-sample t-test was 
used to identify biochemicals that differed significantly between experimental groups. (B) Principal component 
analysis (PCA) segregation of DLD-1 expression-subtypes based on differences in metabolic signature. (C) 
Acylcarnitines are elevated most dramatically in DLD-1 cells expressing ACSL1. Box plots show the scaled 
intensity (Y axis) for each chemical. Mean, median and maximum and minimum values of the distribution are 
represented in the plots. (D) DLD-1 cells expressing ACSL4 present lower PUFA levels. Box plots for the levels of 
representative polyunsaturated fatty acids are shown. (E) Monounsaturated fatty acids are elevated in DLD-1 cells 
expressing SCD. Levels of the unsaturated fatty acids palmitoleate, oleate, eicosenoate and erucate are represented.
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cell line presented a lower basal respiration (Fig. 7E) compared to the parental SW480 cell line, equivalent to the 
difference found among respiratory behaviour of x3 cells when compared with their non-invasive control No ORF 
cells. Similarly, there were no substantial differences in glycolytic performance between SW480 and SW620 cells 
(Fig. 7F), and again, we can conclude that the major difference among primary tumour and metastatic CRC cells 
was that they can maintain their energetic homeostasis with a lower basal rate of mitochondrial oxidation without 
glycolytic changes (Fig. 7G). Likewise, increased levels of GSH were also found for metastatic SW620 cells, very 
likely indicating a lower oxidative stress (Fig. 7H).
Figure 4. Pathway enrichment of cells simultaneously overexpressing ACSL1, ACSL4 and SCD. Plot shows the 
main metabolic pathways differentially regulated upon ACSL1, ACSL4 and SCD overexpression (x3).
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Discussion
In this work, we have analysed the metabolic characteristics defining ACSL/SCD action on CRC cells and 
their connection with the protumorigenic features intrinsic to each enzyme network integrant, highlighting 
Figure 5. Increased phospholipids levels and urea cycle metabolites characterize x3 cells. (A) Higher 
phospholipid levels in DLD-1 cells expressing ACSL1, ACSL4 and SCD along with increased levels of choline, 
choline phosphate and monoacylglycerols. GPC = Glycerophosphocholine, GPI = glycosylphosphatidylinositol. 
(B) Schematic view of urea cycle and derived routes. (C) Urea Cycle-derived metabolites are highly elevated 
in x3 cells. The upregulated levels in x3 cells of the polyamines spermine and spermidine, the urea cycle 
intermediates ornithine and arginine, as well as the ones for creatine and creatine phosphate are presented. Box 
plots show the scaled intensity (Y axis) for each metabolite. Mean, median, and maximum and minimum values 
of the distribution are represented.
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the functional dissimilarities among the ACSL members that demanded further attention. ACSL1 and ACSL4 
showed an association between high expression of each isoform and poorer clinical outcome of stage-II CRC 
patients that resulted in a stronger and more potent association with patient relapse in the context of the ACSL/
SCD network19. Besides, systematic analysis of ACSLs expression and clinical outcomes in several human cancers 
points towards ACSL1 upregulation in CRC and breast cancer and downregulation in lung cancer. Similarly, 
ACSL4 has been found upregulated in CRC, but in contrast predicted better prognosis in breast, brain and lung 
tumours. Therefore, ACSLs member’s role in the development of different types of tumours can be diverse, find-
ing even ACSLs with a tumour suppressor profile such as ACSL5 and ACSL645.
Our results show that ACSL4 preferentially stimulates proliferation in CRC cells (Fig. 1A) and this is associ-
ated to a more glycolytic phenotype compared to control or ACSL1 cells, without major changes in mitochon-
drial performance (Fig. 2A, 2B and 2C). In contrast, ACSL1 is characterized by minor effects in proliferation or 
glycolytic performance (Figs 1A and 2A), though presents an inclination to invasive capabilities accompanied 
by a decreased basal OCR (Figs 1D,E and 2C) as found for the invasive x3 cells. This was further validated when 
opposite results were found upon the use of specific shRNAs (Figs 1B and 2D). In similar fashion, metabolic 
profiles were substantially different for both ACSL isoforms, highlighting the functional differences among them.
ACSL1 overexpression was mostly characterized by the elevation of acylcarnitines probably owed to increased 
CPT activity upon augmented acyl-CoA levels caused by ACSL1 overexpression (Fig. 3C). For instance, elevated 
oleoylcarnitine agrees with the fact that oleate is one of the ACSL1 preferred substrates. Upregulated acylcarni-
tines could be also associated with a fatty acid oxidation (FAO) reduction in the mitochondria that should be 
accompanied by decreased Acetyl-CoA, down slightly in ACSL1, but up significantly in x3 cells (Supplementary 
Figure 3). This could be connected to the lower basal OCR registered for ACSL1 cells (Fig. 2C) but not for the 
lower basal OCR in x3 (Fig. 7A). Nevertheless, acylcarnitines might be mediating invasive capabilities important 
for cancer progression since these FAO intermediates levels have been found dramatically upregulated in several 
malignancies46–49.
Lower PUFA were the defining feature of ACSL4 cells. This may reflect greater PUFA utilization to synthesize 
complex lipids, such as the phospholipids required for membrane biogenesis, crucial for cancer cells. Though 
elevated phospholipids were not characteristic of ACSL4 cells (Supplementary File 1), this could be the key con-
tribution of ACSL4 to the ACSL/SCD network phenotype as demonstrated by elevated phospholipids levels in x3 
cells (Fig. 5A). In line with this, it has been described in other cell contexts ACSL4-mediated PUFA incorporation 
into complex lipids50,51. Not surprisingly, SCD desaturase overexpression was accompanied by a clear MUFA 
upregulation, its natural products. Curiously, most of these MUFAs were lower in x3, which may again reflect 
greater incorporation into complex lipids. In general, SCD cells metabolic profile is the most similar to x3 cells 
and they present similar proliferation tendencies as ACSL/SCD cells though with a mild effect (Fig. 1A,B and 
Supplementary File 1). This is in agreement with previous findings in which SCD overexpression induced Erk and 
Akt activation, as was also the case with x3 cells19. Nonetheless, a complete EMT and invasive phenotype is only 
found in the case of the full ACSL/SCD axis overexpression, though it has been described a SCD knock-down 
impairment of EMT-like behaviour in other tumours52. Together with ACSL1 fuelling the mitochondria and 
its pro-invasive actions, and ACSL4 PUFA managing for complex lipid formation, SCD could help providing 
an appropriate MUFA/PUFA ratio that could stimulate further invasive signalling mediated by increased levels 
of phospholipids and ceramides in ACSL/SCD cells. In this sense, unsaturated fatty acids seem to be crucial for 
ACSL/SCD phenotype.
Interestingly, x3 cells metabolic landscape cannot be explained as the sum of ACSL1, ACSL4 and SCD 
individual profiles. Unexpectedly, x3 cells displayed upregulated complex lipids such as phospholipids and 
sphinganine-derived ceramides and sphingolypids (Figs 4 and 5A and Supplementary Figure 2) which through 
lipid signalling may alter key regulatory pathways21–23 such as Akt, activated in x3 cells19. Furthermore, affected 
pathways not directly associated with lipid metabolism, such as urea cycle and glycolysis were found (Fig. 5B,C 
Figure 6. The more invasive and metastatic CRC cells display increased creatine levels. Correlation of Creatine 
levels with invasiveness in different CRC cell lines. Non-invasive cell lines: DLD-1 NoORF, HCT116, HT29, 
CaCo2, LS174T and SW480. Invasive or metastatic cell lines: DLD-1 x3, SW620, Colo205, LoVo and T84.
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Figure 7. Bioenergetic profile of cells overexpressing ACSL1, ACSL4 and SCD resembles those from metastatic 
cells. (A) Seahorse assay of oxygen consumption rate for No ORF and x3 cells before and after 1 µM Oligomycin, 
0.2 µM FCCP and 0.5 µM Rotenone/Antimycin A (Rot/AA) addition. Basal respiration and spare respiratory 
capacity quantification (right panel). (B) No ORF and x3 cells glycolytic profile. Cells were starved 1 h and a half 
and ECAR levels were measured before and after addition of 10 µM glucose, 0.5 µM Oligomycin and 50 mM 
2-DG. Right panel shows the quantification of Glycolysis, Glycolytic Capacity and Glycolytic Reserve for each 
DLD-1 clone. (C) Metabolic phenotype plot depicting the relative metabolic state of cells under baseline and 
stressed conditions. Baseline Phenotype: OCR and ECAR of cells at starting assay conditions (empty circle 
and empty triangle). Stressed Phenotype: OCR and ECAR of cells under an induced energy demand, here 
achieved upon FCCP treatment (full circle and full triangle). (D) Levels of reduced glutathione for DLD-1 No 
ORF and x3 cells. (E) Seahorse assay of oxygen consumption rate for SW480 and SW620 cells before and after 
1 µM Oligomycin, 0.6 µM FCCP and 0.5 µM Rot/AA addition. Quantification of basal respiration and spare 
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and Supplementary Figure 3). The urea cycle stimulation could be derived from the increased Acetyl-CoA levels 
that x3 cells present (Supplementary Figure 3). Polyamines have been extensively related to cell proliferation and 
growth43,44. Recently, they have been involved as crucial for protein translation, key to cancer invasion and metas-
tasis53,54. Inhibition of polyamine synthesis also decreased the amount of metastasis in several cancer models44. 
Polyamines could be distinctive oncometabolites of metastatic cells, since metastatic SW620 cell present higher 
levels of polyamines than their corresponding primary tumour cells, SW480 as well as higher activity of the key 
regulatory enzymes of polyamine biosynthesis55. Creatine and phosphocreatine were also clearly upregulated 
in x3 cells (Figs 4 and 5C) indicating a more advantageous energetic status that could be essential for invasive 
features development. In this sense, phosphocreatine, has been reported to directly fuel tumour growth and liver 
metastasis in CRC56, and both creatine and creatinine downregulate toll-like receptors (TLRs) expression in mac-
rophages57, which could be used by tumour cells as an immunosuppressive strategy to favour metastasis. This is 
in accordance with our results showing increased creatine levels in the more invasive and metastatic CRC cells 
(Fig. 6). Regarding glycolytic perturbations (Supplementary Figure 3), increased PEP levels and normal pyruvate 
could be a reflect of less demand of TCA feeding from pyruvate (from carbohydrates) explaining lower basal 
OCR consumption since a more energetic status is achieved through other alternative supplies, such as FAO, that 
could be fed by ACSL1 overexpression. Nevertheless, FAO inhibitor etomoxir is not sufficient to revert the EMT 
phenotype of ACSL/SCD cells that, conversely, can be achieved upon a more drastic energetic restriction caused 
by AMPK signalling reactivation upon metformin treatment19 (Supplementary Figure 4). Thus, it seems that x3 
cells present a better overall energetic status that even though it is not due to observable differences in ATP con-
tent (data not shown), is reflected by lower basal OCR and elevated creatine pathway that could be partly fed by 
ACSL1-drived increased FAO and sustained through other levels dependent on further phospholipid signalling 
supported by ACSL4 and SCD increased activities as PUFA and MUFA suppliers, respectively.
Importantly, x3 cells metabolic capacities were reproduced in a model of primary and metastatic CRC cell 
lines, SW480 and SW620. More invasive or metastatic cells, performed mitochondrial oxidation at a lower rate 
without glycolytic changes, pointing to an overall energetic advantage in invasive cells that could derive from 
increased energetic efficiency or from an augmented utilization of alternative fuels. Furthermore, both invasive x3 
and metastatic SW620 cells presented increased GSH compared to their corresponding non-invasive control cells 
(Fig. 7D,H). This lower oxidative stress is further supported by increased gammaglutamyl-aminoacids in x3 cells 
(Supplementary File 1), as markers of glutathione regeneration and decreased levels of NADPH (Supplementary 
File 1), which could be explained by greater use for GSH generation, since pentose phosphate pathway pre-
sented no downregulation (Supplementary File 1). Furthermore, the other core reducing agent, NADH presented 
upregulated levels in x3 cells. Although oxidative stress role in tumour progression has been controversial, new 
studies indicate that cancer cells must increase their capacity to withstand oxidative stress to produce distant 
metastasis58–60.
Methods
Cell culture, stable cell lines generation and reagents. Cell lines, obtained from ATCC (ATCC, 
Manassas, VA, USA) were cultured in DMEM 10% FBS and maintained under standard conditions. Etomoxir 
and Metformin were purchased form Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO, USA). Images were cap-
tured using a Leica DM IL microscope (Leica Microsystems, Wetzlar, Germany), with a 10X Plan Fluotar objec-
tive and registered using Leica Application Suite (LAS). DLD-1 cells stably overexpressing ACSL1, ACSL4, SCD 
and ACSL1/ACSL4/SCD (x3) were generated with specific lentivirus or an equivalent control vector which does 
not express any ORF (No ORF cell line) as described19. For shACSL1, shACSL4 and shSCD cells generation, 
HEK 293T cells were transfected with Mission specific lentiviral vectors (TRCN0000045518, TRCN0000045541, 
TRCN0000312672) or a shControl pLKO.1 empty vector (Sigma-Aldrich, St. Louis, MO, USA) along with pack-
aging plasmids (Addgene, Cambridge MA, USA). Supernatant produced upon 48 h transfection in HEK293T 
cells was used to infect DLD-1 cells followed by puromycin selection (2 µg/ml) during 1 week.
Quantitative real-time PCR. RNA (400 ng) was reverse-transcribed using the High Capacity 
RNA-to-cDNA Master Mix system (Life Technologies, Carlsbad CA, USA). qPCR was performed using 
VeriQuest SYBR Green qPCR Master Mix (Affymetrix, Santa Clara, CA, USA) in the 7900HT Real-Time PCR 
System (Life Technologies). Gene specific primers for ACSL1 (Fw: 5′-ACATTATGTTCCTGGGCCCA-3′ 
and Rv: 5′-AGTCAGAAGGCCATTGTCGA-3′), ACSL4 (Fw: 5′-GGCACAACAGAAAGGGGTAG-3′ 
and Rv: 5′-GGTTCCTCAGCTCCTTCCTT-3′), SCD (Fw: 5′-TGCCCACCACAAGTTTTCAG-3′ and Rv: 
5′-CATCAGCAAGCCAGGTTTGT-3′), CDH2 (N-cadherin) (Fw: 5′-CGGTTTCATTTGAGGGCACA-3′ 
and Rv: 5′-TTGGAGCCTGAGACACGATT-3′) and SNAI2 (Slug) (Fw: 5′-CGTTTTCCAGACCCTGGTT-3′ 
and  Rv :  5 ′ -CTGCAGATGAGC C CTCAGA-3 ′ )  were  us e d  and  GAPDH  express ion  (Fw : 
respiratory capacity (right panel). (F) Glycolytic profile of SW480 and SW620 cells. Cells were starved 1 h and 
a half and ECAR levels were measured before and after addition of 10 µM glucose, 0.5 µM Oligomycin and 
50 mM 2-DG. Right panel shows the quantification of Glycolysis, Glycolytic Capacity and Glycolytic Reserve for 
each cell type. (G) Metabolic phenotype plot depicting the relative metabolic state of cells under baseline and 
stressed conditions. Baseline Phenotype: OCR and ECAR of cells at starting assay conditions (empty circle and 
empty triangle). Stressed Phenotype: OCR and ECAR of cells under an induced energy demand, such as FCCP 
treatment (full circle and full triangle). (H) Levels of reduced glutathione for SW480 and metastatic SW620 
cells. (A,B,C,E,F and G) show representative experiments of 3 or more experiments (n = 3). Results in (D and 
H) represent the mean ± SD of 3 experiments (n = 3). *p < 0.05.
87
www.nature.com/scientificreports/
Scientific  RepoRts | 7: 11143  | DOI:10.1038/s41598-017-11612-3
5′-TGGTATCGTGGAAGGACTCATGAC-3′ and Rv: 5′-ATGCCAGTGAGCTTCCCGTTCAGC-3′) used for 
normalization. Relative gene expression was calculated using the 2−∆∆Ct method.
Western Blot and antibodies. Cells were lysed in Laemmli buffer and boiled at 95 °C for 10 min. Proteins 
were separated by SDS–polyacrylamide gel electrophoresis and transferred onto a nitrocellulose membrane 
(Bio-Rad Laboratories, Hercules, CA, USA). The membranes were blocked using 5% non-fat dry milk in TBS 
0.05% Tween-20, and incubated with primary antibodies overnight at 4 °C. After incubation with secondary 
antibodies, Clarity Western ECL Substrate (Bio-Rad Laboratories) was used for signal detection and Vinculin 
determination or unspecific band were used as loading controls. Anti-human ACSL4 was generously provided 
by Dr. Stephen Prescott, University of Utah, Salt Lake, USA and Dr. Diana Stafforini, Huntsman Cancer Institute, 
University of Utah, USA, and used as indicated61. Antibody against SCD62 was a kind gift from Dr. Jean-Baptiste 
Demoulin, Université Catholique de Louvain, Brussels, Belgium. anti ACSL1 (4047) was obtained from Cell 
Signaling (Cell Signaling Technology Inc., Beverly, MA, USA) and anti-Vinculin (V9131) and β-Actin (A1978) 
were from Sigma.
Proliferation assays. Proliferation was analysed in real-time using the xCELLigence™ system (ACEA 
Biosciences, San Diego, CA). Real-time monitoring of cell proliferation, xCELLigence™ system measurements 
were performed by spreading 10000 cells over a FN-coated gold electrode sensor plate. Cellular impedance 
recordings converted to a cell index (CI) allow for the assessment of attached cells. Real-time monitoring of pro-
liferation was performed for 8 days in 15 min intervals.
Wound healing. A density of 40000 cells per reservoir was plated using IBIDI-Inserts (IBIDI GmbH, 
München, Germany) and incubated until confluence was reached. Upon inserts removal, migration was moni-
tored and registered every 12 h using a 10X Plan Fluotar objective (Leica).
Invasion assays. BD MatrigelTM invasion chambers (BD Biosciences) were seeded with 50000 cells in 
serum-free DMEM. After 48 h, using DMEM 10% FBS as a chemoattractant, inserts were fixed and stained with 
crystal violet. Once non-migrated cells were removed with cotton swaps, pictures were taken using an Olympus 
CKX41 microscope (Olympus, Tokyo, Japan), with a 20X LCAch objective and registered using analysis getIT 
software (Olympus).
Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR). OCR and 
ECAR were monitored as indicators of mitochondrial respiration and glycolytic function study with an XF96 
Extracellular Flux Analyzer using XF Cell Mito Stress Test kit and XF Glycolysis Stress kit according to man-
ufacturer instructions (Seahorse Biosciences, North Billerica, MA, USA). Cell seeding number was optimized 
(50000 cells/well for DLD-1 and SW480 cells and 90000 cells/well for SW620 cells. For mitochondrial stress 
test, cells were plated into XF96 plates and regular culture media was replaced at 24 hours with 2 mM pyruvate, 
2 mM glutamine and 10mMglucose supplemented Base media (Seahorse Bioscience) upon several washes. Cells 
were placed in a non-CO2 37 °C incubator for 1 hour, prior to assay. Upon basal rate measurements were taken, 
mitochondrial respiratory chain drugs were added, following Mito Stress kit specifications. 2 µM Oligomycin 
was used to block ATP-linked oxygen consumption, 0.2 µM FCCP (0.6 µM for SW480 and SW620 cells) as an 
uncoupling agent to obtain maximal respiration and 0.5 µM Rotenone/Antimycin A to inhibit complex I and III, 
stopping all mitochondrial respiration. For glycolysis analysis, 2 mM pyruvate and 2 mM glutamine supplemented 
Base media was used and cells were incubated without CO2 for 1 hour and a half. Following Glycolysis Stress kit 
specifications, 10 µM glucose was injected to stimulate glycolysis, 0.5 µM Oligomycin to obtain maximal glycolytic 
capacity upon oxygen consumption inhibition and 50 mM 2-Deoxy-D-glucose (2-DG) to shut down all glycoly-
sis. OCR and ECAR were measured 3 times following injection of each drug, and normalized to protein content. 
At least 6 replicates per condition were done for each experiment.
Statistical analysis. Significance between groups was determined by t-test. All reported p values were 
two-sided. Statistical significance was defined as p < 0.05. The statistical analyses were performed using the R 
statistical software version 3.1.1 (www.r-project.org).
Global metabolomic profiling. Eleven million of cells from each DLD-1 cell clone were collected, rinsed 
with PBS, and the snap-frozen cell pellets were submitted to Metabolon Inc for global metabolomic analy-
sis. Each condition included four replicates. A combination of GC-MS and LC-MS methods were used, and 
each metabolite amount was normalized to total protein amount of the individual cell pellets. Briefly, proteins 
were precipitated with methanol under vigorous shaking for 2 min (Glen Mills GenoGrinder 2000) followed 
by centrifugation to recover chemically diverse metabolites. The UPLC-MS/MS portion was based on a Waters 
ACQUITY ultra-performance liquid chromatography (UPLC) and a Thermo Scientific Q-Exactive high resolu-
tion/accurate mass spectrometer interfaced with a heated electrospray ionization (HESI-II) source and Orbitrap 
mass analyser operated at 35,000 mass resolution. The sample extract was dried then reconstituted in acidic or 
basic LC-compatible solvents, each of which contained 8 or more injection standards at fixed concentrations 
to ensure injection and chromatographic consistency. One aliquot was analysed using acidic positive ion opti-
mized conditions and the other using basic negative ion optimized conditions in two independent injections 
using separate dedicated columns (Waters UPLC BEH C18–2.1 × 100 mm, 1.7 µm). Extracts reconstituted in 
acidic conditions were gradient eluted from a C18 column using water and methanol containing 0.1% for-
mic acid. The basic extracts were similarly eluted from C18 using methanol and water, however with 6.5 mM 
Ammonium Bicarbonate. The third aliquot was analysed via negative ionization following elution from a HILIC 
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column (Waters UPLC BEH Amide 2.1 × 150 mm, 1.7 µm) using a gradient consisting of water and acetoni-
trile with 10 mM Ammonium Formate. The MS analysis alternated between MS and data-dependent MS2 
scans using dynamic exclusion, and the scan range was from 80–1000 m/z. The samples destined for analysis 
by GC-MS were dried under vacuum for a minimum of 18 h prior to being derivatized under dried nitrogen 
using bistrimethyl-silyltrifluoroacetamide. Derivatized samples were separated on a 5% diphenyl / 95% dimethyl 
polysiloxane fused silica column (20 m × 0.18 mm ID; 0.18 um film thickness) with helium as carrier gas and a 
temperature ramp from 60° to 340 °C in a 17.5 min period. Samples were analysed on a Thermo-Finnigan Trace 
DSQ fast-scanning single-quadrupole mass spectrometer using electron impact ionization (EI) and operated at 
unit mass resolving power. The scan range was from 50–750 m/z. Raw data was extracted, peak-identified and QC 
processed using Metabolon’s hardware and software. Compounds were identified by comparison to library entries 
of purified standards or recurrent unknown entities.
Principal Components Analysis (PCA). Principal components analysis is an unsupervised analysis that 
reduces the dimension of the data. Each principal component is a linear combination of every metabolite and the 
principal components are uncorrelated. The number of principal components is equal to the number of obser-
vations. The first principal component is computed by determining the coefficients of the metabolites that max-
imizes the variance of the linear combination. The second component finds the coefficients that maximize the 
variance with the condition that the second component is orthogonal to the first. The third component is orthog-
onal to the first two components and so on. The total variance is defined as the sum of the variances of the pre-
dicted values of each component (the variance is the square of the standard deviation), and for each component, 
the proportion of the total variance is computed.
Creatine determination. CRC cells were seeded into 6-well plates in appropriate growth medium. Upon 
subconfluence, cells were collected, homogenized and proteins removed using 10 kDa MWCO spin filters. 
Relative creatine content was assayed using Creatine Assay Kit (Sigma) according to the manufacturer’s instruc-
tions and fluorescence intensity measured with a GloMax®-Multi Detection System (Promega, Madison, WI, 
USA). Values were normalized to total protein content.
Reduced glutathione measurement. Cells were seeded at a density of 20000 cells per well (30000 in 
the case of SW620 cells) in a 96-well plate. At 24 hours, medium was removed, cells lysed, and the relative lev-
els of reduced glutathione (GSH) were determined using GSH-GSSG-GloTM Glutathione Assay (Promega). 
Luminescence intensity of the samples was measured with a GloMax®-Multi Detection System (Promega).
Data availability. All data generated or analysed during this study are included in this published article (and 
its Supplementary Information files).
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Complementary ACSL isoforms contribute to a non-Warburg advantageous energetic 
status characterizing invasive colon cancer cells  
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Ramírez de Molina1* 
1Molecular Oncology and Nutritional Genomics of Cancer Group, IMDEA Food Institute, CEI UAM + 
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Figure S1. ACSL1, ACSL4 and SCD knock-down by shRNA means. Related to Figure 1,2 and 6.  
A. Cell lines stably expressing shRNAs for ACSL1 (shACSL1), ACSL4 (shACSL4), SCD (shSCD) or 
scramble (shCtrl) were generated using lentiviral transduction and knock-down of every gene was 
measured by RT-QPCR. B. Protein expression levels of ACSL1 (upper band), ACSL4 and SCD for each 
cell line were detected by Western Blot with specific antibodies. Vinculin or an unspecific band detection 
were used as a loading control. Experiments in B were performed in triplicates (n = 3). Results represent 
the mean ±SD (n = 3). *, p < 0.05, **, p < 0.01, ***, p < 0.001. 
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Figure S2. Sphinganine levels are strongly reduced in x3 cells. Related to Figure 5. 
A. Schematic representation of sphinganine metabolism. B. Sphinganine and sphingosine levels are 
reduced in DLD-1 cells expressing ACSL1, ACSL4 and SCD. Accordingly, derived complex lipids such 
as phosphoethanolamine, the ceramide N-palmitoyl-sphingosine and sphingomyelin are augmented. Box 
plots show the scaled intensity (Y axis) for each metabolite. Mean, median and maximum and minimum 
values of the distribution are represented. 
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Figure S3. Perturbations in glycolysis pathway in X3 cells. Related to Figure 4 and 5.  
A. Schematic representation of glycolysis (DHAP: dihydroxyacetone phosphate; PEP:  
phosphoenolpyruvate; PFK-1: phosphofructokinase 1; PK: pyruvate kinase). B. Box plots show the scaled 
intensity (Y axis) for several glycolytic metabolites in the different DLD-1 expression-subtypes. Mean, 
median and maximum and minimum values of the distribution are represented in the plots. 
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Figure S4. Etomoxir treatment is not able to reverse x3 cells EMT phenotype while metformin 
treatment rescues normal DLD-1 epithelial phenotype. Related to Discussion. 
Representative phase contrast pictures of No ORF and x3 cells treated either with 5 mM metformin, 
40mM Etomoxir, 100mM Etomoxir or vehicle (water) for 48 hours. Scale bars, 100 μm. 
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PUBLICATION III SUMMARY  
 
Targeting the lipid metabolic axis ACSL/SCD in colorectal cancer progression by therapeutic 
miRNAs: miR-19b-1 role 
 
In this work we aimed to analyze the role of miRNAs as regulators of the ACSL/SCD axis. miRNAs 
are potent epigenetic modulators of several cell processes including tumorigenesis and may 
represent a therapeutic opportunity for targeting the network. 
We first performed a bioinformatics prediction of common miRNAs regulating ACSL1/ACSL4/SCD 
pro-tumorigenic axis obtaining 31 putative miRNAs. We developed an interaction scoring 
method based on RT-QPCR data able to reflect the potency of the miRNA candidates in targeting 
the axis components mRNAs, to select stronger miRNA-ACSL/SCD axis genes interactions. The 
lower the scores are, the higher the targets depletion is, which selected miR-544a, miR-142 and 
miR-19b-1 as the most promising candidates for axis negative regulators. Then, confirmation of 
miRNAs action on their targets (ACSL1, ACSL4 and SCD) was analyzed by WB. Furthermore, dual-
luciferase assays were performed to show the direct interaction of candidate miRNAs to their 
targets reflected by their binding on the corresponding 3’ UTRs. 
In order to confirm these miRNAs prognosis value, their expression levels were evaluated in CRC 
patients (CRC stage II patients n=80; 17,50% of recurrence; CRC stage III patients n=46; 39.13% 
of recurrence) showing a clear correlation between disease-free survival (DFS) in stage II patients 
and the expression levels of miR19b-1-5p or miR19-b-3p (mature isoforms). Furthermore, miR-
19b-3p prognostic value was also observed in stage III CRC patients. Finally, to evaluate whether 
miR-19b-1 isoforms might constitute independent prognostic classifiers, clinical and 
histopathological data were included in both univariate and multivariate Cox regression analyses 
revealing that both miR-19b-1 forms were DFS independent prognostic biomarkers in stage II 
CRC patients. Again, only miR-19b-3p constituted a DFS independent prognostic biomarker in 
stage III CRC patients. Hence, miR-19b-1 can be considered as a potential miRNA involved in the 
inhibition of the ACSL/SCD network, with a predictive value of good prognosis in CRC patients.  
We performed an in silico functional analysis, elucidating putative miRNA biological effects by 
Genecodis 3 and TarBase database. MiR-19b-1 was putatively involved in focal adhesions and 
actin cytoskeleton regulation, both related to invasion and migration. In line with this, Matrigel-
based invasion assays showed a clear decrease in the number of invasive cells when miR-19b-1 
was electroporated in CRC cell lines. Hence, mir-19b-1 blocks CRC cells invasion, in agreement 
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with the opposite effect exerted by its targets ACSL1, ACSL4 and SCD, reported in publication I. 
We finally analyzed miR-19b-1 link to lipid metabolism accordingly to the condition of lipid 
metabolism enzymes of its targets. By TG and neutral lipids intracellular content analysis we 
showed the minus accumulation of lipid droplets upon miR-19b-1 transfection; corresponding to 
ACSLs/SCD targeting and therefore the inhibition of the previous steps to TG synthesis. Besides, 
by respiratory analysis using Seahorse bioanalyzer we observed that upon miR-19b-1 
transfection, the respiratory capacity of cells was compromised, leading to an even a more 
dramatic effect upon FA oxidation inhibition. 
 
PUBLICATION III CONCLUSIONS 
 
 A screen of miRNAs simultaneously targeting ACSL1, ACSL4 and SCD evidences miR-142, 
miR-544a and miR-19b-1 as regulators of the ACSL/SCD protumorigenic network 
involved in invasiveness and poor prognosis of CRC. 
 miR-19b-1 expression correlates with a better prognosis in stage II and III CRC patients, 
arising as a promising therapeutic miRNA in CRC.   
 mir-19b-1 inhibits cancer cells invasion, counteracting the opposite effect exerted by its 
targets from the ACSL/SCD axis. 
 The possibility to detect miRNAs in body fluids designates miR-19b-1 as a potential 
noninvasive biomarker in CRC. 
 
My personal contribution to these results was to conduct the design of the experiments and their 
experimental development, as well as the manuscript preparation and revision. My supervisors 
raised this project and guide me during the whole process.  
 
This article was selected by the American Society for Biochemistry and Molecular Biology 
(ASBMB) to make a review on its informative magazine entitled “miRNAs take the wrecking ball 
to colorectal cancer” (ASBMB Today, Vol.17, No.3, March 2018). 
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individual score (IS); final Score (FS); Quantitative reverse transcription polymerase chain 
reaction (RT-QPCR); Hazard ratios (HR); corrected hypergeometric test (Hyp c). 
Abstract 
 
Abnormal acyl-CoA synthetase/ stearoyl-CoA desaturase (ACSL/SCD) lipid network 
fuels colon cancer progression endowing cells with invasive and migratory properties. 
Therapies against this metabolic network may be useful to improve clinical outcomes. 
Since miRNAs (miRNAs/miR) are important epigenetic regulators, we investigated novel 
miRNAs targeting this pro-tumorigenic axis; and hence to be used both as therapeutic or 
prognostic miRNAs. Thirty one putative common miRNAs were predicted to target 
simultaneously the three enzymes comprising ACSL/SCD network. Target validation by 
RT-QPCR, Western blotting and luciferase assays showed miR-544a, miR-142 and miR-
19b-1 as major regulators of the metabolic axis ACSL/SCD. Importantly, lower miR-19b-
1 expression associates with a decreased survival rate in CRC patients, accordingly with 
ACSL/SCD involvement in patient relapse. Finally, miR-19b-1 regulates the pro-
tumorigenic axis ACSL/SCD being able to inhibit invasion in colon cancer cells. Since its 
expression correlates with an increased survival rate in CRC patients, we propose miR-
19b-1 as a potential noninvasive biomarker of disease-free survival (DFS) and a 
promising therapeutic miRNA in CRC. 
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Graphical abstract 
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biology, Lipid and lipoprotein metabolism, Fatty Acid/Metabolism, Clinical Studies. 
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1. Introduction 
CRC, one of the most commonly diagnosed cancers, has one of the highest prevalence and 
mortality rates among malignant tumors (1). Energetic metabolism reprogramming is one of the 
emerging hallmarks of cancer. Adjustments of energy metabolism are triggered to fuel the 
uncontrolled growth of cancer cells. Lipid metabolism is altered in cancer, among other metabolic 
pathways (2, 3), and it represents an important source of energy and structural and biosynthetic 
resources fundamental for carcinogenic processes (3, 4).  
Our group identified a cooperative lipid metabolism related genes involved in CRC (5): two 
members of the acyl-CoA synthetase (ACSL) family: ACSL1 and ACSL4; and the stearoyl 
desaturase (SCD). ACSL1 and ACSL4 catalyze the conversion of long chain fatty acids to acyl-
CoA (6) and have been related to carcinogenesis (4, 7). SCD, the rate-limiting enzyme converting 
saturated into monounsaturated fatty acids, is also related to malignant transformation, 
proliferation or survival (8–10). ACSL/SCD lipid network fuels migratory and invasive properties 
through EMT induction and it is associated with an increased risk of relapse in CRC patients (5). 
 
miRNAs are endogenous non-coding small RNAs that have recently emerged as potent epigenetic 
modulators, which specifically bind to complementary regions within messenger RNAs to 
promote their degradation and/or to inhibit translation (11, 12). miRNAs regulate cellular 
homeostasis and development and also several processes involved in tumorigenesis (12–14). The 
reported crosstalk between miRNAs and several lipid metabolism processes like lipogenesis, 
lipolysis or lipophagy (13) could contribute to their action as tumor suppressors or as 
oncomiRNAs.  
Here, we characterize novel regulators of the whole ASCL/SCD network through miRNAs 
screening. Firstly, using bioinformatics approaches, then testing the effect of the strongest 
miRNAs candidates on ACSL/SCD axis and validating their specificity through the action on their 
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3’UTR. Finally, we evaluated the expression of the most remarkable regulator in stage II and III 
CRC patients.  
2. Materials and methods  
 
2.1.  Cell culture and reagents 
SW620, DLD-1, LoVo and HEK-293T cell lines were obtained from ATCC, maintained under 
standard conditions, Mycoplasma tested every two weeks and 3-4 passages (2-3 weeks) for each 
cell line were used for experiments between collection and thawing.  Commercial antibodies used 
are listed in Supplementary Table 3. Antibody against SCD (15) was a gentle contribution from 
Dr. Jean-Baptiste Demoulin, Université Catholique de Louvain, Brussels, Belgium. Anti-human 
ACSL4 was generously granted by Dr. Stephen Prescott, University of Utah, Salt Lake, USA and 
Dr. Diana Stafforini, Huntsman Cancer Institute, University of Utah, USA, and used as indicated 
(16). 
 
2.2.  Bioinformatics tools  
Four different algorithms were used simultaneously in order to identify miRNA-genes 
interactions: miRanda, PITA, TargetScan and PicTar5.  miRanda (17) and TargetScan (18) use 
the degree of sequence complementarity as primary key parameters to identify miRNA-mRNA 
interactions. PITA (19) utilize thermodynamics as the main criterion and miRanda has also 
included this feature. PicTar5 (20) or the mirSVR scoring model (21) collect different types of 
features derived from the latest in vivo and in-vitro assays and utilize machine learning techniques 
to find the feature patterns shared by true miRNA-target interactions. A prediction was considered 
valid whenever co-occurs in at least 2 algorithms. For miRNAs functional analysis, Genecodis 3 
(22) determined overrepresented biological processes from gene Ontology or overrepresented 
pathways from Panther database.  
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To provide a miRNA-mRNA interaction scoring schema we used the miRanda / mirSVR scoring 
schema. miRanda algorithm provides alignment, thermodynamic, and conservation scores and 
mirSVR algorithm uses the machine-learning based score (http://www.microrna.org/). Alignment 
and conservation scores reflect level of complementarity between sequences and conservation of 
the target site among vertebrates, respectively. The seed category represents the number of 
nucleotides interacting at the seed level. An 8 seed-category or 8mer site (8 monomer site), means 
an interaction between all nucleotides from 2-9, and 7mer site from 2-8, and an 6mer site between 
all nucleotides from 2-7. However, 0 represents a mismatch somewhere along the nucleotides 2-
7 within the seed, so 5 or fewer nucleotides interact.  mirSVR score (21) detects experimentally 
verified non-canonical miRNA-mRNA interactions. The higher the probability of 
downregulation, the lower the mirSVR score is. Cutoff was set at -0.5, since 15% of all the 
predicted targets have a score lower than 0.5, and at such score the expected probability of 
observing a minimal log expression change of -0.1 is approximately 50%.  
 
2.3.  Quantitative real-time PCR and interaction score method generation 
Mimic miRNAs (30 nM) were transfected into HEK-293T cells (Lipofectamine® 2000, Thermo 
Fisher Scientific). Total RNA was extracted 48 hours post transfection using Tri Reagent (Sigma) 
and reverse-transcribed using the High Capacity RNA-to-cDNA Master Mix system (Life 
Technologies). RT-QPCR was performed using VeriQuest SYBR Green qPCR Master Mix 
(Affymetrix, Santa Clara, CA, USA) and gene specific primers listed in Supplementary Table 1. 
miRNAs expression in patients was monitored using TaqMan® MicroRNA Reverse 
Transcription Kit (ThermoFisher Scientific), and Taq-man miRNA probes for RT-QPCR 
(Supplementary Table 2). The 2
-∆∆Ct 
method was applied to calculate the relative gene or miRNA 
expression. 
Regarding the interaction scoring method, individual score (IS) was obtained by subtracting the 
replicas mean (2-∆∆Ct) for each miRNA-gene interaction by the global mean (2-∆∆Ct average 
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among the 31 miRNAs for each gene). In this way, we select only the best interactions for each 
gene. Consequently, final Score (FS) represents the average of the 3 individual scores of each 
miRNA for the 3 target genes ACSL1, ACSL4 and SCD. FS gets lower as the probability of 
downregulation increases. Individual 2-∆∆Ct data (fold change), replicas mean, global mean and IS 
and FS are listed in Supplementary Table 5 for each miRNA-gene interaction. 
 
2.4.  Western Blot  
Mimic miRNAs (60 nM) were transfected into HEK-293T cells (Lipofectamine® 2000, Thermo 
Fisher Scientific). Cell lysates were separated on SDS-PAGE, transferred onto nitrocellulose 
membranes, blocked with 5 % nonfat dry milk and probed with the antibodies listed in 
Supplementary Table 3. Signal detection was performed using the Clarity Western ECL Substrate 
(Bio-Rad). Vinculin determination was used as loading control.  
 
2.5.  Dual-luciferase assays (cloning and co-transfection) 
Sequences for ACSL1 (ENST00000281455), ACSL4 (ENST00000348502) and SCD 
(ENST00000370355) were cloned into psiCheck2 by DNA 2.0. 50.000 HEK-293T cells were 
transfected using Lipofectamine2000 (Invitrogen) according to the manufacturer’s 
recommendations. Each co-transfection reaction contained 100 ng of either psiCheck2-3´-UTR-
ACSL1, psiCheck2-3´UTR-ACSL4 or psiCheck2-3´-UTR-SCD, and 30 nM of each mimic 
miRNA. The relative luciferase activity (Renilla luminescence/ firefly luminescence) was 
determined after transfection using the Dual-Luciferase Reporter Assay System (Promega) 
representing the translational repression of ACSL1, ACSL4 and SCD upon binding to their 3′UTR 
of candidate miRNAs. 
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2.6.  Patients and samples  
80 CRC stage II and 46 CRC stage III patients from La Paz University Hospital were enrolled in 
the study. Formalin-Fixed, Paraffin-Embedded (FFPE) samples were obtained with the patient's 
authorization and with the approval of the human research Ethics review Committee of La Paz 
University Hospital (HULP-PI-1452). Clinico-histopathological data of patients were 
prospectively collected on clinical history and were confirmed by oncologists of the hospitals 
implicated in this study (Supplementary Table 4).  
 
2.7. Invasion assays 
SW620 or LoVo cells were nucleotransfected (Neon® Transfection System, ThermoFisher) with 
30 nM mimic miR-19b-1 (miR-19b-1) or a control miRNA (miR-Ctrl). For rescue experiments 
miRNAs were co-transfected with 300 ng of vectors expressing the coding sequence of ACSL1, 
ACSL4, SCD (DNA 2.0, Menlo Park CA, USA). Cells were seeded in 0.1% FBS- DMEM using 
Matrigel Invasion Chambers (Corning). DMEM 10% FBS is used as chemoattractant. After 
fixation and staining, images were captured (Olympus CKX41) and registered (getIT software, 
Olympus). 
2.8.  Neutral lipid content distribution 
DLD-1 cells were transfected with Lipofectamine2000 with mimic miRNAs (30 nM) for 48h. 
Oleic acid conjugated with BSA (0,5mM ) was added the day before the analysis to increase the 
lipid content. Fatty acid free BSA was used as vehicle for the control group. 
Triglycerides (TG) analysis: Cell lipids were extracted with chloroform-methanol (23) and 
analyzed enzymatically using commercial kits (from Spinreact, Sant Esteve de Bas, Spain). Lipids 
were expressed as µg TG/mg of protein. 
Bodipy staining for microscopy: Cells were treated with 2 μM BODIPY staining solution 
(BODIPY™ 493/503, Invitrogen) in PBS for 15 min at 37 °C and fixed with 4% 
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paraformaldehyde. Images were captured using a Leica DM IL microscope, with a 40X Plan 
Fluotar objective and registered using Leica Application Suite (LAS). 
2.9. Oxygen consumption rate (OCR)  
OCR was monitored as an indicator of mitochondrial respiration with an XF96 Extracellular Flux 
Analyzer using XF Cell Mito Stress Test kit according to manufacturer instructions (Seahorse 
Biosciences, North Billerica, MA, USA). Cells were seeded into XF96 plates with DMEM 10% 
FBS at a density of 90000 cells/well for SW620 cells, as described in (24), and transfected the 
following day with mimic miRNAs (30 nM) using Lipofectamine2000. Upon several washes, 
media was replaced for 1 hour prior to assay with Krebs Henseleit Buffer (KHB; 111mM NaCl, 
4.7mM KCl, 1.25mM CaCl2, 2mM MgSO4, 1.2mM NaH2PO4) supplemented with 2.5mM 
Glucose, 0.5mM Carnitine and 5mM Hepes, as FAO (fatty acid oxidation) media. Etomoxir 
(Sigma), a CPT-1 (carnitine palmitoyl transferase-1) inhibitor and therefore a fatty acid oxidation 
inhibitor, was added to the media 15 min prior to assay. Once basal rate measurements were taken, 
mitochondrial respiratory chain drugs were added, following Mito Stress kit specifications. 2 µM 
Oligomycin was used to block ATP-linked oxygen consumption, 0.6 µM FCCP as an uncoupling 
agent to obtain maximal respiration and 0.5 µM Rotenone/Antimycin A to inhibit complex I and 
III, stopping all mitochondrial respiration. OCR was measured 3 times following injection of each 
drug, and normalized to total protein content. At least 6 replicates per condition were done for 
each experiment. 
 
2.10.  Statistical analysis 
Time to relapse was obtained for the analysis of 3-year DFS, defined from the time of surgical 
procedure. The Kaplan-Meier method was used to estimate DFS. Log-rank test for Univariate 
Cox regression analysis was performed to test association between DFS and individual miRNA 
expression. Hazard ratios (HR) and 95% CI were calculated from the adjusted Cox regression 
model (vascular invasion, lymphatic invasion, perineural invasion, together with age > 70). All 
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reported P-values were two-sided. Statistical significance was defined as p<0·05. Statistical 
analyses were done by R statistical software v3.1 (www.r-project.org).   
 
 
3. Results 
 
3.1.  Bioinformatics prediction of common miRNAs regulating ACSL1/ACSL4/SCD 
pro-tumorigenic axis 
MiRanda, PITA, TargetScan and PICTAR5 were run in order to identify miRNA-genes 
interactions. Considering a valid prediction whenever it co-occurred in at least 2 algorithms, we 
identified 31 putative miRNAs (Figure 1.A) capable to target simultaneously ACSL1, ACSL4 and 
SCD. A more restrictive prediction based on the co-occurrence of at least 3 algorithms was also 
performed. Venn diagram shows the intersection of predictions for 28 common miRNAs of 
ACSL1/ACSL4/SCD (Figure 1.B). Since the number did not vary significantly, we thus considered 
the initial 31 candidate miRNAs for further in vitro validation. 
 
3.2.  Screening of the predicted miRNAs evidences miR-544a, miR-142 and miR-
19b-1 as regulators of the ACSL1/ACSL4/SCD network  
Since in vitro screening and validation are essential to avoid false predictions, HEK-293T cells 
were transfected with miRNA mimics and measured the ACSL1/ACSL4/SCD protein expression 
levels. We next developed an interaction scoring method based on RT-QPCR data to select 
stronger miRNA-gene interactions based on better mRNA depletions. Table (Figure 2.A) shows 
individual scores (IS) and final scores (FS) from miRNA-gene interactions. The lower the scores 
are, the higher the targets depletion is. We defined a FS cutoff of -0.35 which selects miR-544a 
(FS= -0.474), miR-142 (FS= -0.416) and miR-19b-1 (FS= -0.354) as best candidates.  
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We further confirmed their action on their targets by WB (Figure 2.B). The FS (-0.474) for miR-
544a is in accordance with a reduction of the targets protein expression (52%, 80% and 26% of 
protein downregulation of ACSL1, ACSL4 and SCD, respectively). miR-142 obtained a FS of -
0.416 (-0.421/-0.25/-0.577 as IS for ACSL1/ACSL4/SCD, respectively), which is in agreement 
with a 70%, 57% and 49% of protein downregulation of ACSL1, ACSL4 and SCD, respectively. 
Finally, miR-19b-1 (FS=-0.354) showed 38%, 89% and 77% of protein downregulation of 
ACSL1, ACSL4 and SCD, respectively; also in agreement with previous IS (-0.298/-0.295/-0.468 
for ACSL1/ACSL4/SCD, respectively). Additionally, two miRNAs not pre-selected, miR-578 
and miR-199b, with higher FS and therefore less predicted capacity to downregulate the targets, 
were also able to downregulate the three target proteins in the case of miR-199b (44%, 54% and 
75% of protein downregulation of ACSL1, ACSL4 and SCD, respectively); and ACSL4 and SCD 
proteins in the case of miR-578 (0%, 48% and 33% of protein downregulation of ACSL1, ACSL4 
and SCD, respectively). We also analyzed miR-205, whose prognostic value in CRC has been 
described (14) and miR-106, characterized as a biomarker in CRC (25, 26). Although miR-205 
and miR-106-a were good candidates globally (FS –0.205 and -0.282, respectively), only miR-
205 presented significant protein downregulations (45%, 92% and 67% of ACSL1, ACSL4 and 
SCD protein downregulation, respectively).  
Even though miR-205 and miR-199b presented significant downregulation capacity at the protein 
level; we decided to further continue studying miR-544a, miR-142 and miR-19b-1, as the most 
robust candidates downregulating both RNA and protein levels of the ACSL/SCD pro-
tumorigenic axis. 
To complement WB results, those mRNA-miRNA interactions were quantified based on the 
miRanda/mirSVR scoring schema. Regarding ACSL1 (Figure 2.C upper table), selected miRNAs 
alignment scores were quite low, since 120 is the minimum score for a target to be considered as 
valid. It is remarkable that 4 out of 5 interactions were canonical at the seed level. MirSVR scores, 
which get lower as downregulation probability increases, were better for 7mer sites. Curiously, 
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miR-544a had a high probability to downregulate ACSL1, stated by a mirSVR score of -1.0027, 
demonstrating this score ability to detect non-canonical miRNA-mRNA interactions. Thus, miR-
142-3p, which has a canonical 7mer interaction site together with good alignment, energy and 
conservation scores, and miR-544a, which it is not a canonical interaction but presents a 
significantly low mirSVR score, may be among the best candidates. Regarding miR-19b-1 mature 
forms: miR-19b-1-5p (MIMAT0004491) and miR-19b-3p (MIMAT0000074); further in vitro 
assessment is needed since they present the minimal alignment score to be considered as valid 
candidates and the mirSVR does not reflect a high downregulation probability.  In the case of 
ACSL4 (Figure 2.C middle table), the highest alignment scores correspond to 7mer canonical 
sites, which in addition have acceptable mirSVR scores based on our cutoff. The miR-19b-1-5p 
interaction does not account for a canonical site type, and the mirSVR score does not reflect a 
potential non-canonical interaction. Regarding SCD (Figure 2.C lower table), the alignment and 
energy scores were strong and all the interaction sites were canonical with a 7 nucleotides 
interaction along the seed with the exception of miR-19b-1-5p whose interaction is not potent 
enough to overcome the detection threshold. This was also the case for the ACSL4-miR-142-5p 
interaction. Considering the above-mentioned results, we reaffirm the decision to consider miR-
544a, miR-142, and miR-19b-1 as the best candidates to regulate the ACSL1/ACSL4/SCD pro-
tumorigenic axis for more detailed analysis. 
 
3.3.  MiR-142, miR-544a and miR-19b-1 target the 3´UTR of ACSL1, ACSL4 and 
SCD 
To validate the direct interaction of these miRNAs to their targets we performed dual-luciferase 
assays (Figure 2D). In agreement with previous results, miR-544a, miR-142 and miR-19b-1 
downregulated the activity of the three reporter constructions reflecting their binding on the 
corresponding 3’ UTRs. Hence, we assumed miR-544a, miR-142, and miR-19b-1 as validated 
miRNAs regulating the ACSL/SCD pro-tumorigenic axis. 
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3.4.  Low expression of miR-19b-1 correlates with a poorer prognosis in CRC stage 
II and stage III patients 
 
In order to confirm these miRNAs potency as regulators of ACSL/SCD axis involved in CRC 
prognosis, their expression levels were evaluated in CRC patients. For both mature forms of miR-
142 [miR-142-3p (MIMAT0000434); miR-142-5p (MIMAT0000433)] and for miR-544a, 
significant correlation with DFS was not found (data not shown). However, both miR-19b mature 
forms significantly predict DFS in CRC stage II patients. MiR-19b-5p displayed a HR (95% 
CI):0.27(0.09-0.78), log-rank p=0.0097 (Figure 3A) and miR-19b-3p a HR (95% CI):0.27 (0.09-
0.77), log-rank p=0.0087 (Figure 3B). Furthermore, miR-19b-3p prognostic value was also 
observed in III CRC patients DFS [HR (95% CI):0.37(0.14-0.97), log-rank p=0.034] (Figure 3C 
and D). Finally, to evaluate whether miR-19b-1 might constitute independent prognostic 
classifiers, clinical and histopathological data were included in both univariate and multivariate 
Cox regression analyses (Figure 3E) revealing that both miR-19b-1 forms were DFS independent 
prognostic biomarkers in stage II CRC patients: miR-19b-1-5p: HR(95% CI):0.22(0.07-0.74), 
p=0.0111; and miR-19b-3p: HR(95% CI):0.25(0.08-0.78), p=0.0173 (Figure 3E). Again, only 
miR-19b-3p [HR (95% CI):0.37(0.14-0.98), p= 0.041] constituted a DFS independent prognostic 
biomarkers in stage III CRC patients (Figure 3E). Hence, miR-19b-1 could be considered as a 
potential miRNA with predictive value related with good prognosis in CRC patients through the 
inhibition of the ACSL/SCD network activation. 
3.5. MiR-19b-1 blocks cell invasion and regulates lipid metabolism in CRC cells 
 
To further validate miR-19b-1 interference with CRC cell invasiveness mediated by ACSL/SCD 
axis, we performed an in silico functional analysis, elucidating putative miRNA biological effects. 
Figure 4A shows biological processes ordered according to the increasing number of genes 
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involved in each statistically significant process (Hyp_c < 0,05); while in Figure 4B are ordered 
by corrected hypergeometric test (Hyp c). Interestingly, focal adhesions (Hyp_c =0,001) and actin 
cytoskeleton regulation (Hyp_c =0,011), both related with invasion and migration (27, 28) are 
putatively elicited by miR-19b-1; in accordance with the reported ACSL/SCD effect promoting 
invasion and migration (5). To confirm the miR-19b-1 implication in these processes we 
performed a matrigel-based invasion assay in two well-known invasive CRC cell lines: SW620 
and LoVo (Figure 4C). Remarkably, in both cases, a clear decrease in the number of invasive 
cells was observed upon miR-19b-1 electroporation. Therefore, miR-19b-1 blocks CRC cells 
invasion, which is in agreement with the opposite effect exerted by its targets ACSL1, ACSL4 and 
SCD (5). To demonstrate whether the effect of miR-19b-1 in CRC cells invasion is regulated 
directly by the suppression of ACSL1, ACSL4 and SCD we performed rescue experiments by 
reintroducing ACSL1, ACSL4 and SCD in miR-19b-1 transfected cells. As shown in Figure 4D, 
the invasive phenotype of CRC cells is significantly recovered when miR-19b-1 transfection is 
combined with ACSL/SCD expression vectors lacking the 3’ UTR and thus not affected by miR-
19b-1 regulation. This demonstrates that re-expression of the ACSL/SCD axis is able to recover 
the lost invasion upon miR-19b-1 treatment of SW620 cells, and therefore, it evidences the 
specific role of miR-19b-1/ACSL/SCD regulatory axis in controlling CRC invasion.  
To further assess the impact of our miRNA candidate in lipid metabolism we measured the 
triglyceride levels in miR-19b-1 transfected cells, as shown in Figure 4E. Since CRC cells are not 
normally storing substantial amounts of neutral lipids, cells were exposed to oleic acid (OA) to 
favor lipids storage. Under these conditions, cells transfected with miR-19b-1 presented a clear 
reduction in the cellular triglyceride (TG) content indicating that miR-19b-1 diminishes neutral 
lipids accumulation in the cells. As a complementary analysis, we also used the Bodipy 
fluorophore, a specific dye for cellular neutral lipid droplets. Figure 4F shows again that cells 
transfected with miR-19b-1 are less prone to neutral lipid droplets accumulation upon oleic acid 
supplementation (OA-BSA), compared to the vehicle control alone (BSA).  
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To get further insight into miR-19b-1 metabolic role on CRC cells, we performed bioenergetics 
experiments using the Seahorse XF bioanalyzer. Figure 4G shows that miR-19b-1 does not only 
trigger an overall effect on lipid droplets maintenance or mobilization; but also at the bioenergetic 
level.  Upon treatment with a β-oxidation inhibitor (Etomoxir), which inhibits FA transport to 
mitochondria and therefore respiration dependent on FA, miR-19b-1 transfected cells present a 
lower maximal oxygen consumption rate compared to miR control cells. As a consequence of 
this, the spare capacity (measured as the difference between maximal respiration and the 
correspondent basal respiration) is null in cells transfected with miR-19b-1, differently from cell 
transfected with miR control. This spare respiratory capacity indicates the presence of a reserve 
that is accessible for the cells in case of a bioenergetic demand or a stressful situation. These 
results suggest that miR-19b-1 compromises respiratory capacity of cells, leading to even a more 
dramatic effect upon FA oxidation inhibition, eliminating the spare respiratory capacity of cells. 
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4. Discussion 
 
ACSL/SCD network is a clear example of how cancer cells reprogram their metabolism to 
promote cell invasion and poorer disease prognosis (5). Hence, it is crucial to unveil this network 
regulating mechanisms in order to design effective cancer therapies. In this sense, regulatory 
miRNAs emerge as promising therapeutic tools and non-invasive biomarkers since they can be 
detected in body fluids.  
Combined bioinformatics tools led us to a 31 candidates miRNAs library (Figure 1), that were 
screened by analyzing their effect on their targets ACSL1/ACSL4/SCD expression using a novel 
interaction scoring method (Figure 2A). WB, miRanda/mirSVR scoring schema and dual-
luciferase assays (Figure 2) validated miR-544a, miR-142, and miR-19b-1 as ACSL/SCD 
regulators. Importantly, miR-19b-1 lower expression correlates with a poorer prognosis in stage 
II and III CRC patients (Figure 3) suggesting a protective role for this miRNA in CRC, very likely 
through its involvement in cell invasion and lipid metabolism regulation (Figure 4).  
Here we have used novel scoring approaches for a more convenient managing and screening of 
bioinformatics data. For instance, the interaction scoring method enables us to select the best 
miRNA candidates for a combination of targets. Furthermore, the combination of two important 
bioinformatic tools in the defined miRanda/mirSVR scoring schema allow us to detect canonical 
and non-canonical interaction sites which are often filtered out during the prediction process by 
most algorithms such as miRanda, making hard to detect experimentally verified non-canonical 
interactions. This was the case for miR-544a-ACSL1 interaction, whose mirSVR score of -1.0027 
represented a high downregulation probability, which was further validated despite not having a 
canonical interaction (17).  
 miR-19b-1, is a member of the miR-17-92 cluster frequently recognized as an oncomiR (29). 
This cluster has been associated to CRC (30) among other cancers (31). However, recent studies 
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describe miR-19 to be decreased in gastric cancer (32, 33) suggesting that miR-17-92 cluster role 
needs to be further investigated. Probably these miRNAs roles and expression may be tissue and 
tumor stage dependent (34). This study opens a new avenue for miR-17-92 cluster involvement 
in CRC regulation; particularly, miR-19b-1, since its potential role as a tumor suppressor is here 
described. 
An important finding is miR-19b-1 ability to inhibit CRC cells invasion. In silico analysis 
indicates this miRNA implication in processes like focal adhesions and regulation of actin 
cytoskeleton. Focal adhesions, which regulate cellular behaviors such as cell proliferation, 
migration, and invasion (35), also connect ECM and thus, tumor microenvironment to actin 
cytoskeleton also involved in cancer cell migration and invasion (28). The fact that miR-19b-1 
may be able to inhibit these processes is in agreement with previous findings describing 
ACSL/SCD metabolic signature to promote invasion and migration (5).  
In this vein, miR-19b-1 implication on lipid metabolism agrees with the condition of lipid 
metabolism enzymes of its targets ACSL1, ACSL4 and SCD. The use of two different tracers of 
lipid trafficking points towards the role of this miRNA in the maintenance of lipid droplets, either 
causing a decreased intake, an impaired incorporation of the fatty acids into neutral lipids, or an 
increased mobilization. miR-19b-1 could act by inhibiting de novo lipogenesis by targeting fatty 
acid (FA) activating enzymes (ACSLs and SCD), and therefore the previous steps to TG 
synthesis, leading to less accumulation of lipid droplets. Furthermore, Seahorse analysis suggest 
that miR-19b-1 compromises the respiratory capacity of cells potentiating the effect of the β-
oxidation inhibitor Etomoxir. Again, by inhibiting ACSL-mediated FA activation, miR-19b-1 
would lead to a diminished β-oxidation, and to a limited maximal mitochondrial respiration and 
impaired spare capacity.  Nevertheless, further studies will help to elucidate the mechanisms 
underlying the miRNAs fine-tuning control of lipid metabolism fueling cancer energy. 
Considering miR-19b-1 interacting together with the other selected candidates, miR-142 and 
miR-544a, a Panther analysis designates Wnt route as the most represented biological pathway 
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common to these 3 miRNAs (Supplementary Figure 1). Wnt activation requires avoiding β-
Catenin degradation upon GSK3β inhibitory phosphorylation leading to invasion genes 
transcription (36). ACSL/SCD increases GSK3β phosphorylation, activating Wnt signaling and 
EMT (5), therefore the downregulation elicited by these miRNAs over this network suggests a 
role for them in Wnt regulation. Although with an opposite role, miR-544a has been involved in 
Wnt pathway actions in gastric and lung cancer (37, 38). MiR-142-3p has been reported to target 
cancer stem cell markers such as the Wnt target LGR5 in CRC cells (39), in agreement with its 
action on ACSL/SCD network; also involved in cancer stem cell features generation (5). 
Furthermore, reported miR-142-3p downregulation in CRC patients (40) supports our 
bioinformatics analysis.  All this data come up with the idea of miRNA networks controlling 
functional gene interactions such as ACSL/SCD. 
Finally, we propose miR-19b-1 as a potential noninvasive biomarker given its strong association 
with a better prognosis in CRC patients and as promising therapeutic miRNA inhibiting CRC 
cells invasion. miR-19b-1 could be used as a biomarker of CRC prognosis, which could be done 
either by directly evaluating its expression in biopsy tissues as described here, or its circulating 
levels in serum as previously described for other types of cancer (33). From a therapeutic point 
of view, miRNA replacement therapy could be an alternative to increase the expression of this 
particular miRNA in colorectal tissue, as exemplified by the use of miR-34 for other types of 
human neoplasias (41). Other alternatives such as dietary modulation of the miRNA could also 
be possible, since it has been recently showed miR-19b-1 induction by low protein diet in piglets 
(42). However, more in vivo research to test efficacy and safety issues is needed before we could 
benefit from therapeutic approaches to increase miRNA levels in humans.  
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Figure 1: Bioinformatics prediction of common miRNAs regulating ACSL1, ACSL4 and 
SCD 
A) MiRanda, PITA, TargetScan and PICTAR5 algorithms were run to predict 31 common 
miRNAs putatively regulating ACSL1, ACSL4 and SCD. A prediction was considered valid 
whenever co-occurring in at least 2 algorithms. MiRbase ID for all the candidates is also shown. 
B) Venn diagram showing the intersection of predictions for ACSL1, ACSL4 and SCD based on 
the co-occurrence of at least 3 predicting algorithms  
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Figure 2. Validation of the predicted miRNAs evidences 3 selected miRNAs: miR-142, 
miR-544a and miR-19b-1 
A) Interaction scoring method: Individual scores (IS) and final scores (FS) from miRNA-gene 
interactions upon performing RT-QPCR. IS was obtained by subtracting the RT-QPCR replicas 
mean (2-∆∆Ct) for each interaction by the global mean (2-∆∆Ct average among the 31 miRNAs 
for each gene). FS represents the average of the 3 individual scores. B) Western blotting showing 
ACSL1, ACSL4 and SCD protein depletion upon treatment with mimic miRNAs for selected 
candidates from previous RT-QPCR experiments: miR-578, miR-199-b, miR-205, miR-106a, 
miR-142, miR-544a and miR-19b-1. A negative mimic miRNA control without any known target 
was used as a control. RI: Relative intensity of protein bands compared to controls. C) 
MiRanda/mirSVR scoring schema of mRNA-miRNA interactions: ACSL1, ACSL4 and SCD and 
the selected miRNAs [miR-544a, miR-142 (miR-142-3p and miR-142-5p) and miR-19b-1 (miR-
19b-1-5p and miR-19b-3p)], based on three different scores generated by miRanda (alignment, 
thermodynamic, and conservation scores) and the mirSVR machine-learning based score. D) 
Relative luciferase activity of ACSL1 (left graph), ACSL4 (middle graph) or SCD (right graph) 
3’UTR psiCHECK™-2 vectors upon treatment with the selected miRNAs (miR-142, miR-544a 
and miR-19b-1). The relative luciferase activity (Renilla luminescence/ firefly luminescence) was 
determined 48 hours after transfection representing the translational repression of the proteins 
upon binding to their 3′UTR of candidate miRNAs.  A miRNA with no predictive target was used 
as a negative control.  Results represent the fold-change mean ±SD (n= 3).  
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Figure 3. Prognostic value of miR-19b-1 in CRC stage II patients 
Kaplan-Meier survival curves for colorectal cancer (CRC) patients showing correlation between 
disease free survival (DFS) in stage II patients and the expression levels of miR19b-1-5p  (A) or 
miR19-b-3p (B); or in stage III patients and the expression levels of miR19b-1-5p  (C) or miR19-
b-3p (D).  E) Univariate and multivariate Cox regression analyses. (CRC stage II patients n=80; 
17,50% of recurrence: CRC stage III patients n=46; 39.13% of recurrence). 
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Figure 4. MiR-19b-1 implication in cell invasion and lipid metabolism 
 
A) Biological processes elicited by miR-19b-1 obtained from Genecodis 3 [29]. The chart 
is ordered according to the increasing number of genes involved in each process (Hyp_c 
<0,05). The corrected hypergeometric test (Hyp c), P-value obtained from the 
hypergeometric test, determines the significance of the biological process. For miRNA 
hsa-miR-19b-1, due to its promiscuity, targets were limited to the ones experimentally 
validated and were retrieved from TarBase database. B) Genes involved in each biological 
predicted process elicited by miR-19-b1 and ordered by corrected hypergeometric test 
(Hyp c). C) Boyden chamber transwell assay of invasion through matrigel. miR-19b-1 or 
a control miRNA with no predicting binding site in the 3′UTR of ACSL1, ACSL4 or SCD 
were electroporated into SW620 or LoVo cells. D) Boyden chamber transwell assay for 
invasion through matrigel. As a rescue experiment, vectors expressing ACSL1, ACSL4, 
and SCD were transfected together with mimic miR-19b-1 (miR-19b-1) or a control 
miRNA (miR-Ctrl) in SW620 cells. The positive invasion controls miR-Ctrl alone and 
(1/4/S) were also included. In both cases (C, D), after 72h with chemoattractant 
(10%FBS), inserts were fixed and stained with crystal violet. Non-migrated cells were 
removed using cotton swabs and images were captured using an Olympus CKX41 
microscope (Olympus, Tokyo, Japan) with a 20X LCAch objective and registered using 
analysis getIT software (Olympus). Scale bars, 50µm. Results represent the number of 
migrated cells found in six random microscope fields in two independent inserts in three 
independent experiments ± standard error of the mean (SEM) (n= 3).  *, p<0.05, **, 
p<0.01, ***, p<0.001, ****, p<0.0001. E) TG analysis content in DLD-1 cells transfected 
with mimic miR-19b-1 or a mimic miRNA control upon a 0,5mM Oleic acid-BSA or 
Fatty acid free BSA (vehicle control) input. Lipids content was expressed as µg TG/mg 
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of protein in two independent experiments ± standard error of the mean (SEM) (n= 2).  *, 
p<0.05. F) Representative immunofluorescence images of the fluorophore Bodipy 
distribution in DLD-1 cells transfected with mimic miR-19b-1 or a mimic miRNA 
control, upon a 0,5mM Oleic acid-BSA or Fatty acid free BSA (vehicle control) input. 
Images were captured using a Leica DM IL microscope from a representative experiment, 
with a 40X Plan Fluotar objective and registered using Leica Application Suite (LAS) 
(n=2). G) Bioenergetic profile (oxygen consumption rate) of cells transfected with miR-
19b-1 or a mimic miRNA control with or without Etomoxir addition. Injection schema 
(oligomycin, FCCP, Antimycin A/Rotenone) and key parameters assayed (basal 
respiration, maximal respiration and spare capacity) are also indicated. H) Basal 
respiration and spare respiratory capacity quantification of cells transfected with miR-
19b-1 or a mimic miRNA control with or without Etomoxir addition. Both results show 
a representative experiment of two independent experiments with at least 6 replicates per 
condition ± standard error of the replicates mean (SEM) (n= 2). 
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Figure S1. Biological processes predictably elicited by selected miRNAs: 142-3p, 544a, 19b-
1  
A) Panther pathways analysis showing biological processes predictably elicited by 142-3p, 544a, 
19-b1 miRNAs jointly. The chart is ordered according to the increasing number of genes involved 
in each process (Hyp_c <0,001). B) Table showing predicted genes involved in each biological 
predicted process elicited by 142-3p, 544a, 19b-1 miRNAs jointly and ordered by corrected 
hypergeometric test (Hyp c), the corrected P-value obtained from the hypergeometric test.  
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Supplementary Table 1: Primers used for quantitative real-time PCR 
 
 
 
 
 
 
 
 
 
Supplementary Table 2: Probes from TaqMan® MicroRNA Assays (ThermoFisher) used for 
quantitative real-time PCR 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 3: Commercial antibodies used in this study  
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Supplementary Table 4: Detailed clinical and histopathological characteristics of patients 
included in the study. 
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Supplementary Table 5: Detailed data from RT-QPCR experiment for miRNA-gene 
interaction 
Left panel shows 2-∆∆Ct data (fold change) from 2 independent experiments for each miRNA-
gene interaction as well as the mean of both replicas with their corresponding downregulation 
percentages and the global mean of the 31 miRNAs interactions for each gene (overall mean value 
of the whole interactions panel). Negative downregulation percentages mean overexpression 
instead of downregulation. Right panel shows the replicas mean of each interaction subtracted by 
the global mean (IS) ensuring only the best interactions within each gene. Final score (FS) is 
defined as the average of the 3 individual scores. 
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PUBLICATION IV SUMMARY  
 
A more physiological approach to lipid metabolism alterations in cancer: CRC-like organoids 
assessment  
(submitted for publication) 
Organoids represent excellent physiological tools for the development of new CRC personalized 
treatments. In this way, we decided to get a more in vivo approach for the analysis of the lipid 
metabolism-related axis ACSL/SCD, by employing genetically engineered intestinal mouse models. 
These organoids have the relevant mutations acquired throughout the different CRC stages (APCfl/fl, 
KRASG12D/WT, P53R172H/WT and Smad4fl/fl ; corresponding to stages I to IV) named CRC-like organoids.  
To check the status of the axis in CRC-like organoids, we measured the mRNA levels of the ACSL/SCD 
network integrants. ACSL4 mRNA levels clearly augmented throughout the organoid stages, 
correlating with increased aggressiveness of the organoid. Conversely, ACSL1 levels were stable over 
the series, and SCD levels increased from the third stage henceforth. 
In the case of miRNAs, miR-19b-1-3p expression was decreased in a stage-dependent manner, 
maintaining its good prognosis role. The rest of the candidate miRNAs were also measured though no 
statistically significant differences were found in its expression. Therefore, miR-19b-1-3p preserved 
its protective role, reflecting ACSL/SCD axis involvement on CRC progression. 
Since Metformin, an AMPK activator used as antidiabetic treatment that has been associated to 
increased survival of cancer patients, was able to rescue the epithelial phenotype from the 
mesenchymal process caused by the overexpression of ACSL/SCD in CRC cells; we wondered what 
this drug effect would be through the different stages in tumor progression. Using MTT assays, a 
colorimetric assay to assess viability, we compared Metformin action with the current 
chemotherapeutic drugs 5-FU upon 48h treatment. Metformin was able to decrease CRC-like 
organoids viability of all stages at the same rate as 5-FU, without affecting wild-type (WT) organoids 
viability.  
To further check the treatments scope, we analyzed not only the effect but also the potential 
reversibility of the treatment. We assessed the organoids recovery capacity after 48h treatment plus 
the subsequent recovery of 72 additional hours in their growing media. Metformin treatment 
organoids recovery was significantly lower compared to 5-FU in first stages organoids, but a greater 
recovery was observed in WT organoids; suggesting Metformin potential use as a chemotherapy drug 
in the first tumor phases. Along the rest of the stages, 5-FU performed a major effect, with lower 
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recovery rates. Furthermore, we proved that Metformin was able to downregulate the crypt stem 
cell biomarker LGR5 and the Wnt target genes expression in all CRC-like organoid stages, reaffirming 
its potential use in intestinal cancers. Metformin action was also stronger on ACSL4 and SCD-
overexpressing first stages organoids, diminishing these axis components mRNA levels. This is in 
accordance with Metformin greater action on this first stage. Finally, we observed that Metformin 
action in CRC organoids was not related to a Warburg-effect impairment, since L-lactate levels were 
even higher in Metformin treated CRC-like organoids despite its antitumor progression effect. This 
increase was especially higher in stage I organoids, coincident with the higher sensitivity to the drug 
in this stage of CRC-like organoids. 
PUBLICATION IV CONCLUSIONS 
 
1. ACSL4 is progressively overexpressed throughout CRC-like organoids stages; while miR-
19b-1-3p preserves its protective role, reflecting the role of ACSL/SCD axis action on CRC 
progression. Besides, Metformin action is stronger on ACSL4 and SCD-overexpressing 
first stages organoids, agreeing with Metformin greater action on this stage. 
Metformin treatment is further proved as an efficient drug in CRC: 
2. It is able to decrease CRC-like organoids viability at the same rate as current 
chemotherapy (5-FU) but that it does not affect to WT organoids.  
3. Metformin treatment recovery is significantly inferior compared to 5-FU in first stages 
organoids, but with a greater recovery in WT organoids; becoming an appealing 
chemotherapy drug in first tumor phases. 
4. Metformin downregulates the stem cell biomarker LGR5 and Wnt target genes 
expression in all CRC-like organoid stages, reaffirming its potential use in intestinal 
cancers. 
5. Metformin action in CRC organoids is not related to a Warburg-effect impairment, 
presuming that other metabolisms rather than Warburg should be targeted to complete 
the cancer progression obstruction 
 
My personal contribution to this project was complete. I first enjoyed a research stage in Germany 
under Dr. Stange supervision, where I learned organoids technology and further implement in our lab. 
I performed the majority of the experiments and the project approach, always under my supervisors 
guide. 
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ABSTRACT  
 
Precision medicine might be the response to the recent questioning of the use of metformin as an 
anticancer drug in colorectal cancer (CRC). Thus, in order to establish properly its benefits, its 
application need to be assayed on the different progression stages of CRC. In this way, organoids 
imply a more physiological tool, representing a new therapeutic opportunity for CRC 
personalized treatment to assay tumor stage-dependent drugs effects. Since the lipid metabolism-
related axis, ACSL/SCD, stimulates colon cancer progression and Metformin is able to rescuing 
the invasive and migratory phenotype conferred to cancer cells upon this axis overexpression; we 
checked ACSL/SCD status, its regulatory miRNAs and the effect of Metformin treatment in 
organoids as a model for specific and personalized treatment. Despite ACSL4 expression is 
upregulated in CRC-like organoids, Metformin is able to downregulate it, especially in the first 
stages. Besides, organoids are clearly more sensitive in this first stage (Apc mutated) to 
Metformin than current chemotherapeutic drugs such as fluorouracil (5-FU). Metformin performs 
an independent “Warburg effect” blockade to cancer progression and is able to reduce crypt stem 
cell markers expression such as Lgr5+. These results suggest a putative increased efficiency of 
the use of Metformin in the first stages of CRC than in advanced disease. 
Keywords: CRC-like organoids, colorectal cancer, ACSL/SCD axis, lipid metabolism, acyl-CoA 
synthetases, Stearoyl-CoA desaturase, Metformin, LGR5+, non-Warburg metabolism, 
personalized medicine.  
Abbreviations: ACSL1: Acyl-CoA synthetase 1; ACSL4: Acyl-CoA synthetase 4; CRC: 
Colorectal cancer; EMT: Epithelial-mesenchymal transition; 5-FU: Fluorouracil; MiRNAs/ miR: 
MicroRNAs; MTT: 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide; OAA: 
Oxaloacetate; SCD: Stearoyl-CoA desaturase; TCA: Tricarboxylic Acid cycle; 2D: 2-
dimensional; 3D: 3-dimensional. 
  
144
Introduction 
 
Colorectal cancer (CRC) is the third most common cancer in men (10% of the total), after lung 
and prostate cancer, and the second in women (9.2% of the total), after breast cancer (1). Most of 
the CRC cases are sporadic (70-80%), which consists of the acquisition of somatic mutations and 
in which there is no family history or genetic predisposition. The remaining cases (20-30%) are 
those among close relatives, which are divided into inherited or familial CRC, (2). Genetically, 
sporadic CRC development is due to the abnormalities accumulation in tumor suppressor genes 
and oncogenes (3). Previous research postulated the adenoma-carcinoma transition theory, in 
which specific somatic mutations promoting tumorigenesis are acquired; proposed by Fearon and 
Vogelstein (Vogelgram). The Vogelgram proposes that the adenoma-carcinoma sequence model 
would start with loss of the APC gene, followed by mutations in KRAS or BRAF genes, mutations 
or loss of TP53 gene and of SMAD family member 4 (SMAD4) (4).  
Over the last decade, the interest in metabolic research with respect to cancer has been 
expansively increased. The first and most characterized tumor metabolism event to be described 
is the exacerbated glucose uptake and glycolysis utilization; which even in normoxic condition, 
are not used for maximal ATP generation via mitochondrial respiration. This phenomenon is 
denoted as the “Warburg effect”. 
Even though lipid-associated pathways are functionally dependent on glucose and glutamine 
catabolic pathways, are now a well-recognized and frequently described cancer metabolic feature 
with a key role in their tumorigenesis. This is the case for the ACSL/SCD axis (5), a lipid 
metabolism-related network described to promote tumorigenesis through an epithelial-
mesenchymal transition (EMT) program that promotes migration and invasion of colon cancer 
cells. The mesenchymal phenotype produced upon overexpression of these enzymes is reverted 
through reactivation of AMPK signaling performed by the well-known anti-diabetic drug, 
Metformin. Though its mechanism of action is not fully understood, Metformin has shown a 
robust anti-proliferative effect on several types of cancer such as colon, pancreatic, breast, 
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ovarian, prostate and lung cancer cells (6). Furthermore, Metformin has been recently associated 
with improved survival of cancer patients, including CRC, though its use as an antitumoral agent 
has not been established yet (7) 
The ACSL/SCD axis pro-tumorigenic activity has been also described to be post-transcriptionally 
regulated by miRNAs. miR-544a, miR-142, and miR-19b-1 has been proposed as major 
regulators of the ACSL/SCD network and the miR-19b-1-3p isoform decreased expression 
associated with a poorer survival rate in CRC patients, consistently with ACSL/SCD involvement 
in patients relapse (8). 
To get insight into the metabolic implication on CRC progression with a special focus on the 
ACSL/SCD axis and the effect of metformin in each case, more personalized and physiological 
tools are needed since most of the available data rely on traditional studies using cancer cell lines 
cultures. In this way, the organoid culture system opens a new methodological door for ex vivo 
studies. 
Adult tissue-derived epithelial organoids, also called “mini guts” (9) are stereotypic tissue-like 
structures derived from digestive healthy tissues or tumors which mimics in vitro the tissue 
composition and morphology of their in vivo counterparts (10). This methodology was first 
established in long-term primary culture from mouse small intestinal crypts to generate epithelial 
organoids with crypt- and villus-like epithelial domains representing both progenitor and 
differentiated cells (11). 
The organoids technology takes advantage of the intestinal epithelium self-renewing capacity. 
Organoids starts from LGR5+ gut epithelial stem cells forming symmetric cyst structures, which 
finally will form budding structures resembling intestinal crypts. These budding structures are 
formed by these LGR5+ stem cells flanked by differentiated daughter cells (9). 
Organoids are currently employed in colorectal cancer studies and chemotherapy assessment (12, 
13). Along with intestinal organoids, similar epithelial organoids culture conditions for other 
146
mouse and human digestive epithelial tissues have been also adapted (14–17) including tumor-
derived organoids from cancer patients. Importantly, organoids grow as pure epithelial cultures 
without any contamination of vessels, immune cells or non-transformed mesenchymal which 
leads to an accurate sequencing or expression profiling (10). 
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Materials and Methods 
CRC-like organoids: culture and maintenance 
Mice:  Mutant intestinal murine organoids were obtained from the Universitätsklinikum Carl 
Gustav Carus, Dresden. All procedures involving animals were conducted strictly in accordance 
with FELASA regulations and approved by the animal welfare committees of the Technische 
Universität Dresden and the Landesdirektion Sachsen prior to initiation of the experiments. 
Mice with conditional mutations in Apc, Kras, Tp53 and Smad4 were obtained from the NCI 
Mouse Repository (Apc, Kras Tp53) or the Jackson Laboratory (Smad4) and interbred to obtain 
compound mutant mice. The CRC-like organoid model represents the adenoma-carcinoma 
sequence with the most common acquired mutations in a sporadic CRC: APCfl/fl, KRASG12D/WT, 
P53R172H/WT and Smad4fl/fl (corresponding to stages I to IV) (Table 1).  The parental mouse lines 
were described in Table 2. 
 Murine organoids mutagenesis is conditioned by the Cre/loxP system. Adenoviral infections 
were performed as explained in (18)to provide active mutations. 
 
Crypt isolation and organoid culture: Crypts were isolated from the murine small  intestine by 
incubation for 30 min at 4°C in PBS containing 2 mM EDTA as previously reported (11, 19). 
Isolated crypts were seeded in Matrigel (Corning® Matrigel® Matrix). The basic culture medium 
(Advanced Dulbecco’s modified Eagle Medium DMEM/F12 complemented with 
penicillin/streptomycin, 10 mmol/L HEPES, 1x Glutamax [Gibco], named ADF +++) was 
supplemented with: 100 ng/ml Noggin (Peprotech), R-spondin (conditioned medium, 10% final 
volume), 1x B27 (Invitrogen), 1x N2 (Invitrogen), 1,25 mM N-acetylcysteine (Sigma-Aldrich), 
100 μg/mL Primocin TM (InvivoGen) and 50 ng/mL mEGF (Thermofisher). The complete media 
is named supplemented ADF +++ media. For passaging, organoids were removed from Matrigel 
and mechanically dissociated with a glass pipette, pelleted and then transferred to fresh Matrigel 
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(11, 14, 20). Splitting was performed twice a week in a 1:3 split ratio. Cultures were kept at 37 °C, 
5% CO2 in humidity.  
Drugs treatment - viability assays 
Cell viability was determined by counting and seeding 1000 crypts in 60% of Matrigel in 48-well 
plates. After 2 days of culture, organoids were exposed 48 hours to 10 µM Metformin (Sigma) or 
10, 100 or 150 µM 5-FU (Sigma) in supplemented ADF +++ media, as indicated in the figures. 
At this point, organoids were collected, split and reseeded for recovery experiments over 72 hours 
in supplemented ADF +++ media. 
Upon treatments (48h) or recovery assays (post-72h), organoids were incubated 3 hours with 3-
(4,5-dimethyl-thyazol-2-yl)-2,5-diphenyl-tetrazolium (MTT, Sigma). After discarding the media, 
20 μl of 2% SDS (Sigma) solution in H2O was added to solubilize Matrigel (2 h, 37 °C).  The 
resultant formazan was dissolved in 100 μl of DMSO for 1 h (37 °C). The absorbance was 
measured on the microplate reader (Asys UVM 340, Isogen life science) at 562 nm.  
Untreated organoids were defined as 100% viable. Data were expressed as the fold change of 
viable cells from treated organoids compared to the non-treated organoids. 
 
RNA isolation and RT-QPCR 
For RNA isolation, organoids were released from Matrigel (Corning) with cold Dispase (Corning) 
and pelleted by centrifugation. The supernatant was removed and pelleted organoids were 
carefully resuspended in Trizol (Qiagen), and storage at -80ºC. RNA was isolated according to 
the supplier’s protocol (Invitrogen) and the concentration and purity (A260/A280 ratio) were 
determined by spectrophotometric analysis (NanoDrop 2000 Spectrophotometer 
ThermoScientific). 20 ng/μl RNA was reverse-transcribed using the High Capacity RNA-to-
cDNA kit (ThermoFisher), according to manufacturer’s instructions. Relative gene expression 
was measured using VeriQuest Fast SYBR Green qPCR Master Mix (2X) (Isogen). Primers used 
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are listed in Supplemental Table S1. Regarding miRNAs, their expression was monitored using 
TaqMan® MicroRNA Reverse Transcription Kit (ThermoFisher Scientific) and Taq-man 
miRNA probes for RT-qPCR (Supplemental Table S2). RT-QPCRs were performed on the 
QuantStudio 12K Flex (Applied Biosystems) and the 2-ΔΔCt method was applied to calculate the 
relative gene or miRNA expression.  
L-Lactate quantification  
Organoids were seeded at a density of 1000 crypts per well in a 48-well plate. After 48 hours, the 
medium was changed to PBS, 10 mM of Metformin or 10 µM 5-FU in supplemented ADF +++ 
media overnight at 37°C before quantification. Using Cayman’s Glycolysis cell-based assay 
(Cayman, Ann Arbor, MI, USA, 600450) extracellular L-Lactate was measured by determining 
absorbance at 490 nm. L-Lactate measurements (mM) were normalized to total protein 
concentration (mg) x100. 
 
Statistical analysis 
All statistical analyses were performed using the Graph Pad Prism software (Ver. 7.03) (GraphPad 
Software, San Diego, CA, USA). Significance between groups was determined by t-test analyses 
(unpaired Student's t-tests). Data with P < 0.05 were considered statistically significant (ns, P > 
0.05; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001). All reported p values were 
two-sided. All values are reported as mean ± S.D. 
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Results 
ACSL4 is overexpressed throughout CRC-like organoids stages  
ACSL4 has been previously reported to be overexpressed in malignant tumors, and together with 
ACSL1 and SCD form an axis involved in CRC progression. ACSL1, ACSL4, and SCD mRNA 
expression was measured in CRC-like organoids. ACSL4 mRNA was very significantly 
augmented in more aggressive stages compared to WT (Figure 1A). It is shown an intermediate 
expression pattern in Apc-mutated organoids, with a significantly differential expression (p-
value: **) compared to the following second stage (Apc, Kras mutated stage) henceforth. 
Conversely, ACSL1 and SCD levels were maintained or increased from the third stage henceforth, 
respectively (Supplemental Figure S1). 
Interestingly, organoids in more advanced stages (III and IV) presented a genetic misbalance in 
ACSL4 expression (Figure 1A) with huge differences in their fold inductions ranges in the same 
stage, though with a similar tendency.  
MiR-19b-1-3p keeps its protective role in CRC-like organoids 
MiRNAs expression was assayed in 3 different RNA extractions over time. Previous results from 
our group pointed toward a correlation between miR-19b-1-3p lower expression and a poorer 
prognosis in CRC patients (which might have a putative high clinical interest due to its potential 
to be assed in plasma as a non-invasive biomarker); very likely through its involvement in cell 
invasion and lipid metabolism regulation (8). In the case of CRC-like organoids, this tendency 
was maintained and miR-19b-1-3p expression was decreased in a stage-dependent manner 
(Figure 1B). 
Together with miR-19b-1-3p, miR-142 (3p and 5p isoforms) and miR-544a (without murine 
isoform) were also involved on targeting ACSL/SCD axis (8). Hence, the previous mentioned 
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miRs plus miR-19b-1-5p isoform was measured though no statistically significant differences 
were found in its expression (Supplemental Figure S2)   
Metformin decreases CRC-like organoids viability to the same extent as current 
chemotherapy without significant effects on WT organoids 
Since Metformin treatment, an AMPK activator used as antidiabetic treatment that has been 
recently associated to increased survival of cancer patients, was able to rescue the epithelial 
phenotype from the EMT process caused by the overexpression of ACSL/SCD in CRC cells (5); 
we wondered what this drug effect would be through the different stages in tumor progression. 
CRC-like organoids were treated with PBS, 10 µM of Metformin or with the commonly used 
chemotherapeutic agent 5-FU; and the organoids viability was examined by MTT assays 48 hours 
upon treatment. None of the drugs affected significantly the viability of WT organoids (Figure 
2A), while they were able to cause a decrease of about 50% in the viability of mutated organoids 
corresponding to the most aggressive phenotypes (Figure 2B-E). 5-FU higher concentrations (100 
µM and 150 µM) showed the same effects than the lower concentration (10 µM) in mutated 
organoids, while they had stronger effects on WT ones (Supplemental Figure S3A-E). 
Metformin treatment recovery is significantly lower compared to 5FU in first stages 
organoids while WT organoids present an opposite behavior 
To further check the treatments scope, and analyzing not only the effect but also the potential 
reversibility of the treatment in normal and tumoral cells in different stages, organoids viability 
was assayed upon 48 hours treatment (PBS, Metformin or 5-FU) plus the subsequent recovery of 
72 additional hours in their growing media. In this case, WT organoids showed differential 
recovery sensitivity to the treatment. Metformin treated and recovered WT organoids presented 
almost similar measurements than only treated organoids. Nonetheless, 5FU treated WT 
organoids recoveries are noteworthy more sensitive and upon 72h recovery time their viability 
was quite significant reduced (p-value: ***) (Figure 3A). In Apc mutated organoids the recovery 
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is very significantly lower upon Metformin treatment (p-value: ****) than 5-FU (p-value: *), 
compared to PBS recovery control; making these Apc mutated organoids the most responsive to 
the Metformin treatment compared to 5-FU (Figure 3B). Regarding organoids corresponding to 
stages II-III (Figures 3C-D), both treatments presented almost similar recovery effects, while in 
stage IV organoids, 5-FU presented a stronger effect shown by the lower recovery of these 5-FU 
treated organoids (Figures 3E). Again 5-FU higher concentrations (100 µM and 150 µM) had 
nearly the same recovery effects than the lower concentration (10 µM) (Supplemental Figure 
S4A-E). 
Since WT organoids require more time to achieve their size and their crypt-like phenotype (Figure 
3F), the recovery measures are lesser than the mutated organoids. On the other hand, WT 
organoids recovered upon Metformin treatment presented a higher size than the ones treated with 
5-FU (Figure 3F). On the contrary, stage I (Apc mutated) organoids recovered upon Met treatment 
showed an evident reduced size compared with the control and the 5-FU treated ones. In 
accordance with viability assays results, this effect is lost in further stages; where Metformin is 
less effective and Metformin treated recovered organoids presented a bigger size than the ones 
treated with 5-FU. 
By way of clarification, all mutated organoids presented Apc mutated since is the first gene in the 
adenocarcinoma sequence. Apc completed deletion provokes a hyperactive Wnt signaling. This 
aberration makes an organoids phenotype switch, losing their crypt-like structure and adopting a 
cystic morphology (17, 21) 
Metformin action is stronger on ACSL4 and SCD overexpressing first stages organoids 
Since stage I organoids seemed to present a differential sensitivity to metformin compared to 
other stages, together with a differential expression of ACSL4, we aimed to analyze the possible 
link between Metformin and ACSL/SCD axis in intestinal organoids. 
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To this aim, ACSL4 expression was measured, as well as the other enzymes of the ACSL/SCD 
metabolic network (ACSL1 and SCD) upon 10 µM Metformin treatment. ACSL4 mRNA 
expression was strongly reduced by this drug compared to their non-treated controls in stage I and 
II organoids.  By contrast, stage III and IV presented no significance in their reduction or a slight 
significance, respectively. WT organoids also presented a slight reduction of ACSL4 mRNA upon 
Metformin treatment (Figure 4B). In addition, SCD expression levels were clearly decreased by 
Metformin in WT and stage I organoids, while a less marked tendency was found for stage III 
and IV organoids (Figure 4C). ACSL1 mRNA analysis showed less significant results (Figure 
4A) upon Metformin treatment.  
The expression of these enzymes was also measured upon 10 µM 5-FU treatment. This drug was 
able to significantly downregulate ACSL4 and SCD mRNA in most of the stages, though no 
differences were showed between the effects in initial and later stages such as the case for 
Metformin treatment (Supplemental Figures S5A-C). 
Metformin, but not 5-FU, downregulates stem cell biomarker LGR5 and Wnt target genes 
expression in all organoid stages  
To further assay whether Metformin treatment was targeting the organoids crypts stem cell 
marker, LGR5; we analyzed its expression together with two other Wnt target genes, Axin2 and 
Ctnnb-1. Importantly, LGR5 expression was significantly diminished in the whole CRC-like 
organoids series upon Metformin treatment (Figure 4C) as well as Axin-2 (Figure 4D) and Ctnnb-
1 (Figure 4E) mRNAs. Surprisingly, this pattern was not maintained when organoids were treated 
with 10 µM 5-FU (Supplemental Figures S5D-F).  
Metformin action in CRC-like organoids is not related to a Warburg-effect impairement 
The avidity to perform glycolysis even in the presence of oxygen, known as the Warburg effect, 
is one of the hallmarks of tumors. For this reason, we measured the levels of L-lactate, the end 
product of glycolysis. CRC-like organoids presented increased glycolysis compared to WT 
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organoids, reflecting an increasing Warburg effect throughout the stages, as expected. Even 
though 5-FU treatment caused a slight decrease in the glycolytic performance of the mutant 
organoids (Figure 5), Metformin treatment caused an opposite effect, increasing the glycolytic 
capacity in all stages, especially in stage I, the most sensitive to the drug. Thus, it seems that 
Metformin effect on CRC-like organoids viability relies in mechanisms other than preventing pro-
tumorigenic Warburg effect, likely through the regulation of lipid metabolism. 
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 Discussion 
Organoids seem to represent a good tool to study lipid metabolism (22) and previous studies 
employing intestinal organoids have linked the critical role of fatty acid metabolism to the 
intestinal epithelial integrity in vivo (23). Therefore, we propose this system to get insight into 
cancer progression mechanisms in regards to fatty acid metabolism and therefore, to assay 
ACSL/SCD protumorigenic axis action in CRC. 
We showed that ACSL4 augmented while miR-19b-1-3p diminished its expression, both 
progressively, in murine CRC-like organoids. Metformin action compared to the 
chemotherapeutic agent 5-FU, in terms of viability reduction, was similar; although no significant 
reduction was found in WT organoids viability with any treatment. Stage I organoids were the 
most susceptible to Metformin action compared to 5-FU; while further stages presented similar 
or stronger sensitivity to 5-FU, including WT organoids. Besides, Metformin was able to reduce 
the intestinal crypt stem cell marker LGR5 in all the stages, together with two other Wnt 
downstream targets, Ctnnb-1 and Axin-2. Finally, we showed that even though the CRC-
organoids series present a growing Warburg effect through the stages consistent with increased 
L-lactate levels; Metformin action on CRC organoids viability was not related to an ablation of 
Warburg effect. 
The individual role of ACSL isoform 1 (24, 25) and 4 (24, 26) as well as SCD (27–31) in CRC 
has been extensively reported. Surprisingly, while ACSL4 mRNA levels are clearly increased 
through the stages in this organoids model, this was not the case for ACSL1, and SCD was only 
overexpressed in advanced stages. These results differ from previous ones using human CRC cells 
which can be due to differential expression in murine tissues compared to human 2D cultures (5) 
(8). Nevertheless, the use of murine organoids allows their genetic engineering and to accurately 
control the mutations for a better mechanistic characterization, rather than patient tumor-derived 
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biopsies with the high variability that each tumor represent. Thus, our CRC model mimics a 
sporadic colorectal tumor with the common mutations acquired during the progression of this 
cancer. Due to the organoids results, the overexpression of the three enzymes could be only 
present in some punctual tumors. However, the overexpression of ACSL4 is preserved in murine 
organoids with the acquired CRC most common mutations (Figure 1A), indicating a predominant 
role of this ACSL/SCD component in these cancer progression aspects. The ACSL4 mRNA huge 
range of expression considering the most mutated stages (Figure 1A) could be explained since 
stages III and IV in real tumors present an uncontrolled genetic variability with the accumulation 
of other undetermined mutations. Organoids would be mimicking these uncontrolled stages, 
compared to the homogeneity presented in 2D cultures. Conversely, ACSL1 static role 
(Supplemental Figure S1A) could be due to a lesser implication in tumor development in this 
system which can be also explained by the fact that the rodent protein is one residue longer (699 
amino acids) than the human protein (698 amino acids), making it necessary to study the extent 
of this dissimilarity. For its part, SCD overexpression has been mainly reported in mesenchymal 
tissues, rather than epithelial ones, which are the only scaffold for organoids (32, 33) giving a 
reason for the distinctive results found in these epithelial systems among the first stages 
(Supplemental Figure S1B). 
Regarding miRs expression, miR-19b-1-3p kept its tumor-suppressor role in murine CRC-like 
organoids, also reported as a good prognosis miRNA, able to target the axis (8). The immature 
isoform of miR-19b-1-3p, miR-19b, and other members of the miR-17-92 cluster, where this 
miRNA is involved, regulate the self-renewal ability of gastric cancer stem cells (34). The miR-
17-92 cluster role is controversial and dependent on the cancer type (35, 36). However, it is 
interesting the reported role of this miRNA in digestive cancer stem cells, and its role in CRC 
stem cells may be a potential line of research henceforth. In line with our results, miR-19b was 
also reported to downregulate suppressor of cytokine signaling 3 (SOC3), modulating chemokine 
production in intestinal epithelial cells and thereby avoiding intestinal inflammation in Crohn’s 
disease, which may ultimately prevent the derived disease, CRC (37). 
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Since Metformin was able to revert the ACSL/SCD EMT phenotype, we tried to gain insight on 
this process using organoid cultures resembling the different stages of a CRC progression. 
Metformin treatment seems to be more efficient than 5-FU only during first tumor stages, making 
organoids recovery harder compared to the ones treated with 5-FU. We propose that Metformin 
therapies could be an appealing alternative in those cases when the tumor is detected in very early 
stages rather than 5-FU treatments. However, some studies of Metformin treatment in CRC 
patients points to stage III to be the most likeable to present an effect (38). Since CRC is very 
improbable to detect on its very early stages, known as one of the most silent and deadly cancer; 
we wonder whether these studies with a low number of candidates in stage I are enough 
representative. 
As well, Metformin therapies has been proposed alone or in combination with other drugs, in 
CRC. For example, Metformin has been recently combined with aspirin to treat middle stages in 
non-diabetic CRC patients.( II and III stages) (39). Furthermore, it exists a Phase 2 Trial for the 
study of Metformin and 5-Fluorouracil combination in metastatic CRC (40) ,concluded with a 
longstanding cancer control. An older report also claimed the benefits of this combination, but 
they also reported that Metformin alone has antineoplastic activity per se in colon cancer cells, 
and enhanced the activity of 5-FU, oxaliplatin and irinotecan in cells previously treated (41). 
Previous reports hypothesized that the inhibition of mitochondrial complex I was the main 
mechanism of action for Metformin. However, recent studies suggest that cancer progression is 
compromised upon Metformin treatment, by decreasing the TCA cycle´s anaplerosis. Metformin 
decreases the flow of glucose- and glutamine-derived metabolic intermediates into the TCA cycle, 
decreasing the citrate output of the mitochondria and leading to a reduction of acetyl-CoA (Ac-
CoA) and oxaloacetate (OAA) in the cytoplasm and therefore a reduction in de novo FA synthesis 
(42). This way, Metformin could be targeting lipid metabolism through ACSL/SCD axis. ACSL4 
downregulation in the presence of Metformin is clearly evident and the results are larger 
significant in first stages (I, II) (Figure 4A). Maybe, the reduced overexpression of ACSL4 in the 
first stages (Figure 1A) increases the sensitivity to Metformin action (Figure 4A); while in more 
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advanced stages, the overexpression is so high that Metformin action could appear to be less 
effective. This would not be the case for SCD, which showed no overexpression in the first stages 
and enhanced overexpression in III and IV stages, though it is significantly reduced upon 
Metformin exposure again in the first stages (Figure 4B). On the other hand, it has been reported 
that variations in the types and amounts of fatty acids, are able to modify intracellular ACSLs 
expression (43), thus, this conditions could be also affecting ACSL/SCD components expression 
besides that the network connection between those enzymes could make them present coordinated 
effects upon Metformin treatment, reducing its expression due to the lack of their substrate. 
Metformin was also previously reported to downregulate ACSL expression, lowering fatty acid 
synthesis and normalizing lipid profile in diabetic rats (44); as well as limiting its products, 18-
carbon chain length fatty acids, in skeletal muscle insulin resistant rats (45), suggesting in this 
case that metformin is increasing FAs mitochondrial channeling due to the reduction of CPT1 
inhibition by malonyl-CoA and therefore decreasing 18-carbon acyl-chain-derived bioactive 
lipids in the cytoplasm (45), This action of Metformin could be additional to the aforementioned, 
detoxifying ACSLs probable over activity.  
Metformin seems also to target  cancer stem cells of different cancer types (46). However, we 
have described for the first time the LGR5 downregulation in CRC-like organoids upon 
Metformin treatment; consistent with previous reports using 2D CRC cultures (47). LGR5 was 
diminished in the whole CRC-like organoids series to minimum levels, an indicative that 
Metformin action is affecting the stem cells of the crypt, responsible for the progression of the 
organoids lineage. Curiously, Metformin treated organoids do not present apoptosis or even 
necrosis, but they kept at a minimum size compared to other treatments, where the organoids layer 
disappeared and the cells appeared apoptotic in the lumen (Supplemental Figure S6), showing 
that cell membrane biogenesis is somehow blocked, mostly built by de novo lipogenesis routes. 
 
Finally, Metformin treated CRC organoids exhibit a greater compensatory increase in aerobic 
glycolysis. Since ATP levels are diminished due to complex I inhibition, the metabolic sensor 
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AMPK is activated, inhibiting mTOR and proliferative events; and promoting glycolysis as an 
alternative ATP source (48). We found that even though the CRC-organoids serie presented an 
increasing glycolysis with the stages, (Figure 5); Metformin was able to increase more this 
glycolytic phenotype, especially in stage I organoids, coincident with the higher sensitivity to the 
drug in this organoids. These results point towards Metformin targeting different metabolic routes 
other that Warburg effect to perform its effect on CRC organoids viability. 
Even though the Warburg effect is a priority for current drugs, each day the evidence grows that 
other metabolic pathways should be targeted for cancer progression ablation. CRC is a leading 
cause of death in the developed world, though yet simplistic preclinical models that mimic the 
usual stages of CRC progression are lacking (13). In this way, organoids further analysis need to 
be included as the tool of choice for stage-dependent drugs screening. 
Conclusions 
General conclusion 
1. Organoids display a precise platform to assay tumor stage-dependent drugs being 
suitable for personalized medicine, constituting an invaluable tool due to their relatively 
low costs, animal saving suffering and their ease and legibility to genetically manipulate. 
Metformin-related conclusions 
2. Metformin treatment is further proved as an efficient drug in CRC: 
 
-It is able to decrease CRC-like organoids viability at the same rate as current 
chemotherapy (5-FU) but it does not affect to WT organoids.  
 
-Metformin treatment recovery is significantly inferior compared to 5-FU in first stages 
organoids, but with a greater recovery in WT organoids; becoming an appealing 
chemotherapy drug in first tumor phases. 
 
-Metformin downregulates the stem cell biomarker LGR5 and Wnt target genes 
expression in all CRC-like organoid stages, reaffirming its potential use in intestinal 
cancers. 
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 -Metformin action in CRC organoids is not related to a Warburg-effect impairment, 
presuming that other metabolisms rather than Warburg should be targeted to complete 
the cancer progression obstruction 
  
ACSL/SCD-related conclusions 
3. ACSL4 is progressively overexpressed throughout CRC-like organoids stages; while 
miR-19b-1-3p preserves its protective role, reflecting the role of ACSL/SCD axis action 
on CRC progression. Besides, Metformin action is stronger on ACSL4 and SCD-
overexpressing first stages organoids, agreeing with Metformin greater action on this 
stage. 
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Figures 
 
Figure 1: ACSL4 is overexpressed throughout CRC-like organoids stages while miR-19b-1-
3p preserves its protective role.  
A) RT-QPCR analysis showing ACSL4 mRNA expression levels throughout CRC-like 
organoids stages. B) RT-QPCR analysis showing miR-19b-1-3p mRNA expression levels 
throughout CRC-like organoids stages. Results represent the fold-change mean ±SD (n = 
4) in plots A, (n = 3) in plots B. (ns, P > 0.05; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; 
****, P ≤ 0.0001) 
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 Figure 2: Metformin decreases CRC-like organoids viability to the same extent as current 
chemotherapy without significant effects on WT organoids 
MTT cell viability assays upon 48 hours treatments with Metformin or 5-FU in the different CRC-
like organoids representative stages (A) WT organoids; (B) APCfl/fl  organoids resembling stage 
I; (C) APCfl/fl , KRASG12D/WT organoids resembling stage II; (D) APCfl/fl , KRASG12D/WT ,P53R172H/WT 
organoids resembling stage III; (E) APCfl/fl , KRASG12D/WT ,P53R172H/WT ,Smad4fl/fl organoids 
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resembling stage IV. Data are represented by the fold-change mean ±SD (n = 3) in all the plots 
except A: (n=2). (ns, P > 0.05; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001).  
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Figure 3: Metformin treatment recovery is significantly lower compared to 5FU in first 
stages organoids while WT organoids present an opposite behavior 
MTT cell viability assays upon 48 hours treatments (black bars) and upon extra 72h post-
treatment recovery with PBS (light grey bars) Metformin (yellow bars) or 5-FU (dark grey bars) 
in the different CRC-like organoids representative stages (A) WT organoids; (B) APCfl/fl  
organoids resembling stage I; (C) APCfl/fl , KRASG12D/WT organoids resembling stage II; (D) APCfl/fl 
, KRASG12D/WT ,P53R172H/WT organoids resembling stage III; (E) APCfl/fl , KRASG12D/WT ,P53R172H/WT 
,Smad4fl/fl organoids resembling stage IV. Data are represented by the fold-change mean ±SD (n 
= 3) in all the plots. (ns, P> 0.05; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001). 
(F) Organoids pictures with PBS, Metformin or 5-FU, upon 48 hours treatments and upon extra 
72h post-treatment recovery as indicated. Pictures were captured using the × 10 objective, in 
bright field. Leica microscope (Leica microsystems). 
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 Figure 4: Metformin action is stronger on ACSL4 and SCD overexpressing first stages 
organoids and downregulates stem cell biomarker LGR5 and Wnt target genes expression 
in all organoid stages. 
mRNA expression levels of enzymes related to the ACSL/SCD axis, ACSL4 (A), SCD (B), by 
RT-QPCR; and expression levels of different stem cell markers, Lgr5 (C), Axin-2 (D) and Ctnnb-
1 (E) by RT-QPCR upon PBS (black bars) and 10 uM Metformin (yellow bars). Data are 
represented by the fold-change mean to each PBS control ±SD (n = 3). (ns, P> 0.05; *, P ≤ 0.05; 
**, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001).  
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 Figure 5: Metformin action in CRC organoids is not related to a Warburg-effect 
impairement 
Bars represent the extracellular L-lactate production upon overnight PBS treatment (black bars), 
Metformin treatment (yellow bars) and 5-FU treatment (grey bars) using the Cayman’s Glycolysis 
cell-based assay. L-lactate production measurement is normalized by total protein content (x100). 
Data are represented by the fold-change mean ±SD (n = 3) in all the plots. (ns, P> 0.05; *, P ≤ 
0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001).   
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Tables 
 
Table 1: CRC-like organoids with the acquired mutations related to the stage. 
Organoid mutation CRC-like stage  
WT - 
APCfl/fl I 
APCfl/fl , KRASG12D/WT  II 
APCfl/fl , KRASG12D/WT ,P53fl/R172H III 
APCfl/fl , KRASG12D/WT ,P53fl/R172H ,Smad4fl/fl IV 
 
Table 2: Parental cell lines and publication´s PMID of the mutations in the organoids 
Mutation Parental mouse line PMID 
APC C57BL/6 males 17002498 
KRAS G12D C57BL/6 males 11323676 
P53 floxed C57BL/6 males 11694875 
P53 R172H C57BL/6 males 15607980 
Smad4 floxed C57BL/6 males 11857783 
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A
Supplemental Figure S1
B
Supplemental Figure S1: ACSL1 and SCD mRNA expression throughout CRC-like organoids
stages;
RT-QPCR analysis showing ACSL1 (A) and SCD (B) mRNA expression levels throughout CRC-
like organoids stages. Results represent the fold-change mean ±SD (n = 3) (ns, P > 0.05; *, P ≤
0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001)
Supplemental Figures and Tables
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Supplemental Figure S2
A
B
C
Supplemental Figure S2: ACSL/SCD regulatory miRNAs expression in CRC-like organoids
RT-QPCR analysis showing mRNA expression levels throughout CRC-like organoids stages of
different ACSL/SCD regulatory miRNAS: miR-19b-1-5p (A), miR-142-3p (B), miR-142-5p (C).
Results represent the fold-change mean±SD (n = 3). (ns, P> 0.05; *, P ≤ 0.05; **, P ≤ 0.01; ***,
P ≤ 0.001; ****, P ≤ 0.0001).
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Supplemental Figure S3
A
B C
D E
Supplemental Figure S3: Metformin and 5-FU effect in CRC-like organoids.
MTT cell viability assays upon 48 hours treatments with PBS (black bars), 10 uM Metformin (yellow
bars) or 10, 100 and 150 uM 5-FU (grey bars) in the different CRC-like organoids representative
stages: WT organoids (A); APCfl/fl organoids resembling stage I (B); APCfl/fl , KRASG12D/WT
organoids resembling stage II (C); APCfl/fl , KRASG12D/WT ,P53R172H/WT organoids resembling stage III
(D); APCfl/fl , KRASG12D/WT ,P53R172H/WT ,Smad4fl/fl organoids resembling stage IV (E). Data are
represented by the fold-change mean±SD (n = 3) in all the plots. (ns, P > 0.05; *, P ≤ 0.05; **, P ≤
0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001).
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Supplemental Figure S4A
B C
D E
Supplemental Figure S4: Metformin and 5-FU recovery effect in CRC-like organoids.
MTT cell viability assays upon 48 hours treatments (black bars) and upon extra 72h post-treatment
recovery with PBS (light grey bars), 10 uM Metformin (yellow bars) or 10, 100 and 150 uM 5-FU
(dark grey bars) in the different CRC-like organoids representative stages:: WT organoids (A); APCfl/fl
organoids resembling stage I (B); APCfl/fl , KRASG12D/WT organoids resembling stage II (C); APCfl/fl ,
KRASG12D/WT ,P53fl/R172H organoids resembling stage III (D); APCfl/fl , KRASG12D/WT ,P53fl/R172H
,Smad4fl/fl organoids resembling stage IV (E). Data are represented by the fold-change mean±SD (n =
3) in all the plots. (ns, P > 0.05; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001).
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Supplemental Figure S5
A B
C D
E F
Supplemental Figure S5: ACSL/SCD axis and stem cell markers expression (Lgr5, Axin-2 and 
Ctnnb-1) upon Metformin and 5-FU treatment 
Expression leveles of enzymes related to the ACSL/SCD axis, ACSL1 (A), ACSL4 (B) and SCD 
(C) by RT-QPCR; and expression levels of different stem cell markers, Lgr5 (D), Axin-2 (E) and 
Ctnnb-1 (F) by RT-QPCR; upon PBS (black bars), 10 uM Metformin (yellow bars) or 10, 100 and 
150 uM 5-FU (grey bars). Data are represented by the fold-change mean ±SD (n = 3). (ns, P> 
0.05; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001). 
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Supplemental Figure S6
Met 10 uMPBS Other drugs
Stage I 
organoids
Stage III 
organoids
Supplemental Figure S6: Comparative organoids morphology between Metformin and
other oncologic treatments.
Organoids (stage I and III) representative pictures with DMSO, Metformin and other metabolic
drugs against CRC progression, upon 48 hours treatments plus upon extra 72h post-treatment
recovery. Pictures were captured using the × 10 objective, in bright field. Leica microscope
(Leica microsystems).
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ACSL1 TGACCTCTCCATGCAGTCAG/ AGCCTATGCACTCAGCCAGT
ACSL4 CACCATTGCCATTTTCTGTG/ GCCTTCAGTTTGCTTTCCAG
SCD TTCTTACACGACCACCACCA/ GCAGGAGGGAACCAGTATGA
CTNNB1 TAACTATCAGGATGACGCGG/ TTAACTACCACCTGGTCCTC
AXIN-2 GGACTGGGGAGCCTAAAGGT/ 
AAGGAGGGACTCCATCTACGC
LGR5 GGACCAGATGCGATACCGC/ CAGAGGCGATGTAGGAGACTG
B2M AGACTGATACATACGCCTGC/ ATCACATGTCTCGATCCCAG
Supplemental Table S1: Primers´ sequences (Invivogen) used for quantitative real-time PCR.
miRBase ID Cat No
mmu-miR-19b-3p 4427975
mmu-miR-19b-1-5p 4427975
mmu-miR-142a-3p 4427975
mmu-miR-142a-5p 4427975
U6 snRNA 4427975
Supplemental Table S2: Probes from TaqMan® MicroRNA Assays (ThermoFisher) used for 
quantitative real-time PCR.
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Discussion 
Considering the axis ACSL/SCD as a work team 
The research reported in this Doctoral Thesis contribute to elucidate the role in cancer 
progression of the joint overexpression of three enzymes involved in FA metabolism: ACSL1, 
ACSL4 and SCD. We propose this metabolic switch in FA metabolism as an example of metabolic 
reprogramming that can be used by malignant cells to increase their tumorigenicity, and 
therefore an appealing and hot point to target. Here we describe how their overexpression 
stimulates cell plasticity accompanied with increased migratory and invasive properties but not 
proliferation, in CRC cells. Therefore, the axis would be producing other altered metabolisms 
rather than the Warburg effect, characterized by pro-proliferative events and aerobic glycolysis. 
In fact, ACSL/SCD cells show a decrease in lactate production. Other metabolic enzymes 
overexpression have been linked to cancer migration and invasion before; such as a 
monoacylglycerol lipase 88 or ACLY, involved in metastasis 221. ACSL/SCD overexpressed cells 
present also an upgraded energetic status characterized by elevated creatine and 
phosphocreatine levels together with lower basal respiration levels and decreased OCR. Besides, 
the number of differential metabolites are incremented in ACSL/SCD cells compared to their 
individual overexpressions. Indeed, they show same metabolic features than other well-known 
metastatic cells. CRC patients which present elevated levels of ACSL1, ACSL4 and SCD 
simultaneously show an increased risk of relapse compared to other CRC patients in the same 
clinical stage. All the facts above mentioned evidence the aggressive phenotype provoked 
exclusively upon the three metabolic enzymes overexpression. 
The abnormal metabolism performed by ACSL/SCD is driven by an impaired AMPK signaling 
since the original epithelial phenotype is recovered through Metformin, an AMPK activator. 
AMPK could be regulating EMT via Akt-MDM2-Foxo3 signaling axis, linked to EMT suppression 
222. Although this fact is in agreement with the increased Akt signaling observed in x3 cells; an 
Akt inhibitor fails to revert the mesenchymal features, suggesting that additional pathways 
affected by AMPK are also needed for a complete rescue. Accordingly, SCD downregulation was 
reported to activate AMPK 163,223 and since free FA are able to activate AMPK 224, ACSL 
overexpression could prevent this activation through the conversion of fatty acids into Acyl-
CoAs. Regarding Akt signaling, inhibition of SCD decreases the synthesis of PIP3, crucial for 
Pi3K/Akt signaling; and SCD’s main product, oleic acid, activates Akt 223. In addition, AA, ACSL4 
preferred substrate, is one of the most common fatty acids of PIP3 129, evidencing the 
contribution of the axis enzymes to this pathway, highly linked to cell cycle progression and 
survival, key to cancer progression 225.  
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Discussion 
Even though the complete phenotype is achieved upon x3 overexpression; either of the enzymes 
show a specific and partial function to the whole axis contribution. ACSL1 seems to be the 
initiator of mesenchymal-promoting genes stimulation and acquisition of invasion capabilities 
accompanied by a decreased in basal OCR. In ACSL1 overexpressed cells, acylcarnitines were 
showed elevated. Upregulated acylcarnitines could be also associated with a fatty acid oxidation 
(FAO) reduction in the mitochondria, accompanied by decreased Acetyl-CoA. This could be 
connected to the lower basal OCR 226. In line with this, the ACSL1 deficiency was reported to 
promote β-oxidation and the synthesis of PL species in hepatic cells 227. Besides, acylcarnitines 
could be mediating the invasive capabilities important for cancer progression since FAO 
intermediates levels have been found dramatically upregulated in several malignancies 228–230.  
ACSL4 display the most epithelial-like behavior, probably taking part in the reversion of the 
epithelial phenotype in the metastasis establishment 231. As well, ACSL4 overexpressed cells 
present a tendency to induce proliferation; together with a more glycolytic phenotype compared 
to control or ACSL1 cells. ACSL4 also presents reduced PUFA levels corresponding to a greater 
utilization to synthesize complex lipids, such as the phospholipids required for membrane 
biogenesis, crucial for cancer cells 232. Although not directly involved in invasion or migration, we 
wonder whether ACSL4 substrate preference for AA is contributing to prostaglandin production 
and inflammatory mediators for EMT action 233,234. ACSL4 has been previously reported to 
promote AA conversion into PE, PI, and TG; metabolic building blocks and energy storage for the 
cell as well as lipooxygenated and cyclooxygenated metabolites, inflammatory mediators, known 
to trigger tumor aggressiveness in several cancers, including CRC 121,129,130. Besides, intestinal 
organoids technology, a new platform bridging in vitro and patient results, keep the poor 
prognosis potential of ACSL4 overexpression along the organoids staging increase; despite its 
murine origin. The axis status results differ from previous ones using human CRC cells in ACSL1 
static expression, which can be due to differential expression in murine tissues compared to 
human 2D cultures but also by the fact that the rodent protein is one residue longer (699 amino 
acids) than the human protein (698 amino acids), making it necessary to study the extent of this 
dissimilarity 
Several shreds of evidence makes ACSLs family of enzymes a productive network for the 
progression of cancer. ACSL1 catalyzes and activates FAs from 16:0-20:0 carbons; and also 
unsaturated FAs from 16:1-22:6 carbons. For its part, ACSL4 catalyzes preferentially FAs of 20:4 
and 20:5 carbons 235. With both enzymes overexpressed most of the FAs activation needed for 
the tumor progression is covered. On the other hand, each isoform is located in different cell 
compartments covering again a wide physical space, though they can share some subcellular 
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locations 122. ACSL1 is mainly found in mitochondria and lipid droplets. However, ACSL4 is a 
peripheral protein which moves from ER to peroxisomes 235, where it is probably the only ACSL 
isoform located 123. Covering the majority of the subcellular locations, the overexpression of 
these two enzymes allows the tumor to take control over FAs different fates: storage, β-
oxidation… 
SCD might maintain the network through different signaling pathways activation such as Erk and 
Akt, allowing GSK3β inactivation, β-catenin degradation impairment and allowing EMT signaling 
as a consequence, reported also by Ha, G.H. et al. 236. Accordingly, SCD knock-down has been 
described to cause EMT in breast cancer cells 237. Naturally, SCD overexpression implies MUFA 
levels upregulation, which is not the case for x3 cells, with lower MUFA levels reflecting its 
incorporation in complex lipids. Low proliferation tendencies are presented by SCD and x3, in 
agreement with Erk and Akt activation of both cells. Globally, SCD could help to provide an 
appropriate MUFA/PUFA ratio, essential for the membrane integrity. Regarding organoids 
results, SCD augments significantly its expression but only in higher stages (III and IV). We 
postulate if this late overexpression is due to the lipotoxic accumulation regarding ACSL4 
overexpression from first stages. 
As previously mentioned, the complete aggressive phenotype is only achieved upon x3 
overexpression though is not the sum of individual enzymes effects. These cells are also depicted 
by upregulated complex lipids such as phospholipids and sphinganine-derived ceramides and 
sphingolipids, reported to alter signaling pathways like Akt 238–240, over-activated in x3 cells. 
Curiously, other non-lipid metabolism related pathways were altered in x3 cells such us urea 
cycle and glycolysis. Urea metabolites upregulation, such as polyamines, probably mediated by 
increased Acetyl-CoA levels, have been previously reported in cancer malignancies, 219,220,241,242. 
Interestingly, polyamines could suppose a metastatic biomarker since we have also reported 
elevated levels in a CRC metastatic line compared to its primary tumor. The elevated levels of 
creatine and phosphocreatine found in x3 cells, represent an advantageous energetic status to 
the aim of invasion, as reported in liver metastasis upon phosphocreatine elevation 243. The 
lower basal respiration levels and decreased OCR is also part of the energetically efficient status 
of ACSL/SCD cells 
These features characterized as well metastatic CRC cells when compared to their parental cell 
line. We hypothesize that x3 cells lower basal OCR together with elevated creatine that could be 
partly fed by ACSL1-drived increased FAO and maintained by further phospholipid signaling 
supported by ACSL4 and SCD increased PUFA and MUFA products, respectively. 
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Although other reports point toward the simultaneous overexpression of ACSL and SCD, this is 
the first time reporting their joint action. For example, in a previous study from melanoma 
patients genes involved in the synthesis of FAs (SCD) and complex lipids (ACSL3) among other 16 
genes involved in the FAs metabolism have been found to be upregulated 244 in these tumors. 
ACSL1 and ACSL4, together with ACSL5 were previously reported overexpressed in a breast 
cancer type, the estrogen receptor-negative type 245. 
All in all, an increased FA synthesis caused by ACSL overexpression, together with an enriched 
MUFA content and lipotoxicity detoxification upon SCD upregulation, an improved energetic 
capacity and invasive and migratory properties could generate the perfect context for the 
progression of cancer and might represent a new therapeutic opportunity for CRC treatment. 
 
Therapies and prognosis of the axis 
The ACSL/SCD metabolic axis could be highly considered from a therapeutic point of view. First 
for being involved in the last steps of FA activation and therefore the previous critical 
intermediates crucial for other routes could follow its fate, avoiding undesirable side effects. ACS 
enzymes are also involved in the first step when considering the uptake of extracellular FAs. 
Thus ACS inhibition leads to the blockade of FAs entrance to the routes. ACS is also considered 
the first enzyme in TG synthesis 246. Lipid droplets, composed by TG, could also play a role in 
cancer as described in the introduction section. The activation by ACS and the following FAs 
desaturation by SCD suppose a key point in the partition of FAs into different routes. For those 
reasons, we consider this axis an interesting strategic point in terms of therapeutics.  
The combination of two specific ACSL/SCD inhibitors, Triacsin C and A939572 synergistically 
decreases CRC cells viability without affecting colon normal cells. Both drugs, A939572 159 and 
Triacsin C 247 separately have significantly delayed CRC tumor growth in previous reports. 
Additionally, this is also effective in CRC cells resistant to conventional chemotherapy (5-FU). In 
fact, it has been reported also that Triacsin C is able to increase 5-FU activity in CRC cell lines, 
despite cell-death resistance provoked by LD accumulation 248.  Therefore, the combination of 
ACSL and SCD inhibitors might represent a new way for targeting tumor metabolism. 
Remarkable antitumorigenic results were also obtained upon Metformin, initially used as an 
antidiabetic treatment. Metformin, able to revert the ACSL/SCD invasive phenotype, greatly 
decreases the viability of first stages CRC-like organoids compared to current chemotherapeutic 
drugs (5-FU), without affecting WT organoids. Metformin is also proved to reduce ACSL/SCD 
expression levels in organoids, as well as stem cells markers (LGR5). Despite we found that CRC-
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organoids show increased glycolysis throughout the stages; upon Metformin treatment 
glycolysis experimented an increase in this glycolytic phenotype, especially in stage I organoids, 
coincident with the higher sensitivity to the drug in this organoids. Hence, Metformin could be 
targeting different metabolic routes other than Warburg effect to perform its effect on CRC 
organoids viability, such as ACSL/SCD axis impairment. Considering that it has been proved as a 
drug for CRC in previous studies 249, Metformin based therapies could also be an appealing 
alternative in those cases when the tumor is detected in very early stages rather than 5-FU 
treatments.  Our results using Metformin are very promising and extend the list of the increasing 
studies over its use in CRC 249. However, some reports point to CRC stage III patients to be the 
most likeable stage to present a greater Metformin response 250, though with a low number of 
candidates in stage I, not enough representative. As well, further studies with combination doses 
of Metformin with 5-FU in different stages would be of great interest. Remarkably, it exists a 
Phase 2 Trial for the study of Metformin and 5-FU combination in metastatic CRC 251, concluded 
with a longstanding cancer control. Metformin therapies in combination with other drugs are 
also an appealing approach such as Metformin combined with aspirin to treat middle stages in 
non-diabetic CRC patients (stages II and III) 252.  
CRC patient’s great difficulty lies on the absence of symptoms until the tumor is in advanced 
stages, leading to a reduction of the treatments efficacy. Early diagnosis pursuit might be an 
appealing focus in the clinics. In this way, ACSL/SCD axis could be considered a prognostic value 
in stage II-CRC patients since the joint overexpression of ACSL1/ACSL4/SCD show a poorer 
outcome and higher risk of relapse when compared to the upregulation of the individual genes. 
This suggests an augmented aggressiveness of tumors displaying ACSL/SCD network 
overexpression. Together with this potential clinical biomarker, we consider the possibility of 
non-invasive biomarkers such as miRNAs. In this way, miR-19b-1 lower expression in stage II and 
III CRC patients correspond with a poorer prognosis suggesting also a protective role for this 
miRNA in CRC. Both prognostic values could comprise a tandem of clinical biomarkers.  
MiRs comprehend a vast group of inter regulations among genes and they sometimes are 
encountered in polycistronic miRNA “clusters”, where a single primary transcript generates 
multiple miRNA genes. Contradictorily, miR-19b-1, a member of the miR-17-92 cluster is 
frequently accepted as an oncomiR 253 associated to CRC 254 among other cancers 255. However, it 
exists a wide controversy among this cluster with several studies suggesting the anti-tumorigenic 
role of some of its members 256,257; evidencing that miR-17-92 cluster role needs to be further 
investigated. Probably these miRNAs roles and expression may be tissue and tumor stage 
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dependent 258. As a noninvasive biomarker, it could be interesting to further study its circulating 
levels in serum, plasma or urine as previously described for other types of cancer 257.  
Apart from the prognostic value of this miRNA, studying miRNAs regulating mechanisms over the 
axis supposes a great strategy to propose effective cancer therapies. Here we propose novel 
interaction scoring approaches for a more convenient bioinformatics screening, selecting best 
miRNA candidates for a combination of targets. We also proved the combination of two 
important bioinformatic tools (miRanda/mirSVR) to detect canonical and non-canonical 
interaction sites, often filtered out by most algorithms. Through these screening tools we get the 
best candidates simultaneously targeting ACSL1, ACSL4 and SCD; which are miR-142, miR-544a 
and miR-19b-1. We finally proved miR-19b-1, the best prognosis candidate, involvement in cell 
invasion and lipid metabolism regulation. In accordance with previous findings describing the 
ACSL/SCD to promote invasion and migration, miR-19b-1 was able to inhibit CRC cells invasion. 
In silico analysis were an effective method to discover this miRNA implication in processes like 
focal adhesions and regulation of actin cytoskeleton, which regulate cellular behaviors such as 
cell proliferation, migration, and invasion 259,260. MiR-19b-1 was further related to lipid 
metabolism accordingly to the condition of lipid metabolism enzymes of its targets. We 
postulate that miR-19b-1 could act by inhibiting de novo lipogenesis by targeting fatty acid (FA) 
activating enzymes (ACSLs and SCD), and therefore the previous steps to TG synthesis, leading to 
less accumulation of lipid droplets. Furthermore, respiratory analysis suggested that miR-19b-1 
compromises the respiratory capacity of cells. Inhibiting ACSL-mediated FA activation by miR-
19b-1 would lead to a reduced β-oxidation, limiting maximal mitochondrial respiration and 
impaired spare capacity. 
Wnt route was the most represented biological pathway common to the 3 candidate miRNAs 
designated by Panther analysis. Wnt pathway was demonstrated to be activated by ACSL/SCD 
mediated GSK3β phosphorylation 261. Therefore, it would be interesting to study these miRNAs 
role over this network through Wnt regulation. Previous reports linked Wnt routes with our 
candidate miRNAs: miR-544a in gastric and lung cancer 262,263 or miR-142-3p in CRC 264. Wnt over 
active route is also present in all Apc mutated organoids from stage I to stage IV, since Apc is the 
first gene in the adenocarcinoma sequence. Apc completed deletion provokes a hyperactive Wnt 
signaling 208,265. Remarkably, the best candidate, miR-19b-1, preserves its protective role again in 
murine CRC-like organoids showing a steady decline throughout the increasing aggressive 
stages. A deeper study of the effect of this miRNA over Wnt pathway in CRC-like organoids 
would be of great interest. As well, it is interesting the reported role of miR-19b-1  in digestive 
cancer stem cells, and also its role in CRC stem cells may be a prospective line of research 266. 
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miR-19b-1 was also reported to modulate chemokine production avoiding intestinal 
inflammation in Crohn’s disease, which may ultimately prevent the derived disease, CRC 267, in 
line with our results. Regarding the other miRNA candidates, no statistically significant results 
were obtained in organoids. However, miR-142-3p was reported to target cancer stem cell 
markers such as the Wnt target, LGR5, in CRC cells 264.  Targeting LGR5 could be the main 
mechanism of action for miR-142-3p since ACSL/SCD are positively enriched in this stem cell 
marker, among others.  
Regarding the previous discussion, miR-19b-1 could be considered not only a good prognosis 
marker but a promising therapeutic miRNA inhibiting CRC cells invasion. miRNA replacement 
therapy, as exemplified by the use of miR-34 for other types of human neoplasias 268 or miRNA 
dietary modulation as described for miR-19b-1 low protein diet in piglets 269 are examples of 
succesful miRNAs therapies.  
Organoids bounties 
Organoids were previously reported to represent a useful tool to study lipid metabolism 270 and 
previous studies have linked the critical role of FA metabolism to the intestinal epithelial 
integrity in vivo employing intestinal organoids 271. We suggest organoids as a great platform to 
get insight into fatty acid metabolic anomalies in cancer progression and therefore, to assay 
ACSL/SCD protumorigenic axis action in CRC.  
In this work we decided to employ murine organoids, which allow their genetic engineering and 
accurate control of the mutations for a better mechanistic characterization. Using patient tumor-
derived biopsies would lead with the management of high variability that each tumor 
represents. Thus, our next step is to stablish paired organoids (tumor biopsies and its normal 
counterparts), where we will be able to assess ACSL/SCD status as well as doing drug testing, 
evidencing personalized medicine as a great tool to give an accurate prognosis and therapy. 
We suggest the use of organoids as great platforms to study drug screening in controlled stages, 
as it was done in stages of prostate cancer looking for different Vitamin E effects 272. Apart from 
the above-mentioned boundaries to use organoids as a precise platform to assay tumor stage-
dependent drugs being suitable for personalized medicine, they also constitute an invaluable 
tool due to their relatively low costs. On one hand, because we can save in animal facilities costs 
but also to test High-Priced Drugs before administering it to a patient 273. Moreover, from an 
ethical point of view, animal saving suffering could be reduced to minimal levels, once the 
pertinent analysis are fine tuned to minimal variables in organoids.  
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GENERAL CONCLUSIONS 
 
1. ACSL/SCD network is a relevant metabolic axis for colon cancer progression able to confer 
cancer stem cells properties, increase cellular migration and invasion, stimulate several 
survival pathways and to present an upgraded energetic status and differential 
metabolomic phenotype that cannot be explained by additive functions of each enzyme 
separately. 
 
 
2. ACSL/SCD network is susceptible to be targeted by different inhibitors.  
-Specific ACSLs/SCD pharmacological inhibitors, A939572 and Triacsin C, affect cancer cell 
viability in a synergistic manner without showing an effect in normal colonocytes.  
-Metformin becomes an appealing chemotherapy drug in first tumor phases, where it 
present a stronger downregulation on ACSL and SCD levels.  
-MiR-19b-1 inhibits cancer cells invasion, counteracting the opposite effect exerted by 
its targets from the ACSL/SCD axis. 
 
3. ACSL/SCD simultaneous overexpression represents an increased aggressiveness in a CRC 
tumor with an increased risk of relapse and disfavored outcomes in patients; while miR-
19b-1 is postulated as a protective miRNA correlating with a better prognosis in CRC 
patients, evidencing a possible tandem of clinical biomarkers. 
 
4. Organoids display a precise platform to assay tumor stage-dependent drugs being 
suitable for personalized medicine.  
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CONCLUSIONES GENERALES  
 
1. La red ACSL/SCD se postula como un eje metabólico relevante para la progresión del 
cáncer de colon confiriendo propiedades de células madre del cáncer, a la vez que 
aumenta la invasión y la migración celular, estimula varias vías de supervivencia, 
presenta un estado energético mejorado y un fenotipo metabólico diferencial que no se 
puede explicar por las  funciones aditivas de cada enzima por separado.  
 
2.  La red ACSL / SCD es susceptible de ser regulada por diferentes inhibidores: 
 
- La combinación de dos inhibidores farmacológicos específicos de ACSL/SCD, 
denominados A939572 y Triacsin C, afectan a la viabilidad de las células cancerosas de 
manera sinérgica sin mostrar un efecto en los colonocitos normales. 
-La Metformina se convierte en un fármaco antitumoral favorable en las primeras fases 
del tumor, donde presenta una regulación negativa sobre los niveles de ACSL y SCD. 
-MiR-19b-1 inhibe la invasión de células cancerosas, contrarrestando el efecto opuesto 
ejercido por sus dianas ACSL/SCD. 
 
3. La sobreexpresión simultánea de ACSL/SCD en un tumor de CCR supone un aumento de 
la agresividad con un mayor riesgo de recaída y un pronóstico desfavorable en los 
pacientes; mientras que el miR-19b-1 se postula como un miRNA protector cuya 
sobreexpresión se correlaciona con un mejor pronóstico en pacientes con CCR, lo que 
evidencia un posible tándem de biomarcadores clínicos. 
 
4. 4. Los organoides suponen una plataforma de precisión para el análisis de fármacos 
dependientes de la etapa del tumor como medio para una medicina más personalizada.  
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